US8119608B2 - Method and medicament for inhibiting the expression of a given gene - Google Patents

Method and medicament for inhibiting the expression of a given gene Download PDF

Info

Publication number: US8119608B2
Authority: US; United States
Prior art keywords: dsrna; rna; target gene; strands; complementary
Prior art date: 1999-01-30
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Expired - Fee Related

Application number

US10/383,099

Other languages

English (en)

Other versions

US20040102408A1 (en

Inventor

Roland Kreutzer

Stefan Limmer

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Alnylam Pharmaceuticals Inc

Original Assignee

Alnylam Pharmaceuticals Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1999-01-30

Filing date

2003-03-06

Publication date

2012-02-21

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26051592&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=US8119608(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2003-03-06 Application filed by Alnylam Pharmaceuticals Inc filed Critical Alnylam Pharmaceuticals Inc

2003-03-06 Priority to US10/383,099 priority Critical patent/US8119608B2/en

2003-10-27 Assigned to RIBOPHARMA AG reassignment RIBOPHARMA AG ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: LIMMER, STEFAN, KREUTZER, ROLAND

2004-05-27 Publication of US20040102408A1 publication Critical patent/US20040102408A1/en

2004-06-22 Assigned to ALNYLAM EUROPE AG reassignment ALNYLAM EUROPE AG CHANGE OF NAME (SEE DOCUMENT FOR DETAILS). Assignors: RIBOPHARMA AG

2004-08-30 Assigned to RIBOPHARMA AG reassignment RIBOPHARMA AG CORRECTIVE ASSIGNMENT TO CORRECT RECEIVING PARTY ADDRESS, PREVIOUSLY RECORDED AT REEL 014621, FRAME 0958. Assignors: LIMMER, STEFAN, KREUTZER, ROLAND

2009-08-07 Assigned to ALNYLAM PHARMACEUTICALS, INC. reassignment ALNYLAM PHARMACEUTICALS, INC. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: ALNYLAM EUROPE AG

2012-02-21 Application granted granted Critical

2012-02-21 Publication of US8119608B2 publication Critical patent/US8119608B2/en

2020-01-29 Anticipated expiration legal-status Critical

Status Expired - Fee Related legal-status Critical Current

Images

Classifications

- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/713—Double-stranded nucleic acids or oligonucleotides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/111—General methods applicable to biologically active non-coding nucleic acids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
- C12N2310/111—Antisense spanning the whole gene, or a large part of it
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/50—Physical structure
- C12N2310/53—Physical structure partially self-complementary or closed
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2330/00—Production
- C12N2330/30—Production chemically synthesised
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Definitions

the present invention is in the field of gene expression inhibition using double stranded ribonucleotides.
the antisense RNA takes the form of an RNA molecule which is complementary to regions of the mRNA. Inhibition of the gene expression is caused by binding to these regions. This inhibition can be employed in particular for the diagnosis and/or therapy of diseases, for example tumor diseases or viral infections.
the disadvantage is that the antisense RNA must be introduced into the cell in an amount which is at least as high as the amount of the mRNA.
the known antisense methods are not particularly effective.
U.S. Pat. No. 5,712,257 discloses a medicament comprising mismatched double-stranded RNA (dsRNA) and bioactive mismatched fragments of dsRNA in the form of a ternary complex together with a surfactant.
dsRNA mismatched double-stranded RNA
the dsRNA used for this purpose consists of synthetic nucleic acid single strands without defined base sequence. The single strands undergo irregular base pairing, also known as “non-Watson-Crick” base pairing, giving rise to mismatched double strands.
the known dsRNA is used to inhibit the amplification of retroviruses such as HIV. Amplification of the virus can be inhibited when non-sequence-specific dsRNA is introduced into the cells. This leads to the induction of interferon, which is intended to inhibit viral amplification. The inhibitory effect, or the activity, of this method is poor.
dsRNA whose one strand is complementary in segments to a nematode gene to be inhibited inhibits the expression of this gene highly efficiently. It is believed that the particular activity of the dsRNA used in nematode cells is not due to the antisense principle but possibly on catalytic properties of the dsRNA, or enzymes induced by it. None is mentioned in this paper on the activity of specific dsRNA with regard to inhibiting the gene expression, in particular in mammalian and human cells.
the present invention provides methods and compositions for inhibiting gene expression using double stranded RNA molecule's as well as double stranded RNA molecules containing modified bases.
FIG. 1 shows the schematic representation of aplasmid for the in vitro transcription with T7- and SP6-polymerase.
FIG. 2 shows RNA following electrophoresis on an 8% polyacrylamide gel and staining with ethidium bromide.
FIG. 3 shows a representation of radioactive RNA transcripts following electrophoresis on an 8% polyacrylamide gel with 7M urea by means of an instant imager.
FIG. 4 a - e shows Texas Red and YFP fluorescence in murine fibroblasts.
the object of the present invention is to do away with the disadvantages of the prior art.
it is intended to provide as effective as possible a method, medicament or use for the preparation of a medicament, which method, medicament or use is capable of causing particularly effective inhibition of the expression of a given target gene.
the region I which is complementary to the target gene exhibits not more than 49 successive nucleotide pairs.
an oligoribonucleotide or a vector encoding therefor are provided in accordance with the invention. At least segments of the oligoribonucleotide exhibit a defined nucleotide sequence. The defined segment may be limited to the complementary region I. However, it is also possible that all of the double-stranded oligoribonucleotide exhibits a defined nucleotide sequence.
dsRNA with a length of over 50 nucleotide pairs induces certain cellular mechanisms, for example the dsRNA-dependent protein kinase or the 2-5A system, in mammalian and human cells.
protein biosynthesis in the cell is blocked.
the present invention overcomes this disadvantage in particular.
dsRNA with short chain lengths into the cell or into the nucleus is facilitated markedly over longer-chain dsRNAs.
dsRNA or the vector it has proved advantageous for the dsRNA or the vector to be present packaged into micellar structures, preferably in liposomes.
the dsRNA or the vector can likewise be enclosed in viral natural capsids or in chemically or enzymatically produced artificial capsids or structures derived therefrom.
the abovementioned features make it possible to introduce the dsRNA or the vector into given target cells.
the dsRNA has 10 to 1,000, preferably 15 to 49, base pairs.
the dsRNA can be longer than the region I, which is complementary to the target gene.
the complementary region I can be located at the terminus or inserted into the dsRNA.
Such dsRNA or a vector provided for coding the same can be produced synthetically or enzymatically by customary methods.
the gene to be inhibited is expediently expressed in eukaryotic cells.
the target gene can be selected from the following group: oncogene, cytokin gene, Id protein gene, developmental gene, prion gene. It can also be expressed in pathogenic organisms, preferably in plasmodia. It can be part of a virus or viroid which is preferably pathogenic to humans.
the method proposed makes it possible to produce compositions for the therapy of genetically determined diseases, for example cancer, viral diseases or Alzheimer's disease.
the virus or viroid can also be a virus or viroid which is pathogenic to animals or plant-pathogenic.
the method according to the invention also permits the provision of compositions for treating animal or plant diseases.
segments of the dsRNA are designed as double-stranded.
a region II which is complementary within the double-stranded structure is formed by two separate RNA single strands or by autocomplementary regions of a topologically closed RNA single strand which is preferably in circular form.
the ends of the dsRNA can be modified to counteract degradation in the cell or dissociation into the single strands. Dissociation takes place in particular when low concentrations or short chain lengths are used. To inhibit dissociation in a particularly effective fashion, the cohesion of the complementary region II, which is caused by the nucleotide pairs, can be increased by at least one, preferably two, further chemical linkage(s).
a dsRNA according to the invention whose dissociation is reduced exhibits greater stability to enzymatic and chemical degradation in the cell or in the organism.
the complementary region II can be formed by autocomplementary regions of an RNA hairpin loop, in particular when using a vector according to the invention.
the nucleotides it is expedient for the nucleotides to be chemically modified in the loop region between the double-stranded structure.
the chemical linkage is expediently formed by a covalent or ionic bond, a hydrogen bond, hydrophobic interactions, preferably van-der-Waals or stacking interactions, or by metal-ion coordination. In an especially advantageous aspect, it can be formed at at least one, preferably both, end(s) of the complementary region II.
the chemical linkage can be formed by one or more linkage groups, the linkage groups preferably being poly(oxyphosphinicooxy-1,3-propanediol) and/or polyethylene glycol chains.
the chemical linkage can also be formed by purine analogs used in place of purines in the complementary regions II. It is also advantageous for the chemical linkage to be formed by azabenzene units introduced into the complementary regions II. Moreover, it can be formed by branched nucleotide analogs used in place of nucleotides in the complementary regions II.
the chemical linkage can furthermore be formed by thiophosphoryl groups provided at the ends of the double-stranded region.
the chemical linkage at the ends of the double-stranded region is preferably formed by triple-helix bonds.
the chemical linkage can expediently be induced by ultraviolet light.
the nucleotides of the dsRNA can be modified. This counteracts the activation, in the cell, of a double-stranded-RNA-dependent protein kinase, PKR.
at least one 2′-hydroxyl group of the nucleotides of the dsRNA in the complementary region II is replaced by a chemical group, preferably a 2′-amino or a 2′-methyl group.
At least one nucleotide in at least one strand of the complementary region II can also be a locked nucleotide with a sugar ring which is chemically modified, preferably by a 2′-O, 4′-C methylene bridge.
several nucleotides are locked nucleotides.
a further especially advantageous embodiment provides that the dsRNA or the vector is bound to, associated with or surrounded by, at least one viral coat protein which originates from a virus, is derived therefrom or has been prepared synthetically.
the coat protein can be derived from polyomavirus.
the coat protein can contain the polyomavirus virus protein 1 (VP1) and/or virus protein 2 (VP2).
VP1 polyomavirus virus protein 1
VP2 virus protein 2
the use of such coat proteins is known from, for example, DE 196 18 797 A1, whose disclosure is herewith incorporated. The abovementioned features considerably facilitate the introduction of the dsRNA or of the vector into the cell.
a capsid or capsid-type structure is formed from the coat protein, one side preferably faces the interior of the capsid or capsid-type structure.
the construct formed is particularly stable.
the dsRNA can be complementary to the primary or processed RNA transcript of the target gene.
the cell can be a vertebrate cell or a human cell.
At least two dsRNAs which differ from each other or at least one vector encoding them can be introduced into the cell, where at least segments of one strand of each dsRNA are complementary to in each case one of at least two different target genes. This makes it possible simultaneously to inhibit the expression of at least two different target genes.
a double-stranded-RNA-dependent protein kinase, PKR one of the target genes is advantageously the PKR gene. This allows effective suppression of the PKR activity in the cell.
the invention furthermore provides a medicament with at least one oligoribonucleotide with double-stranded structure (dsRNA) for inhibiting the expression of a given target gene, where one strand of the dsRNA has a region I where at least segments are complementary to the target gene.
dsRNA double-stranded structure
the inhibition is already caused at concentrations which are lower by at least one order of magnitude.
the medicament according to the invention is highly effective. Lesser side effects can be expected.
the invention furthermore provides a medicament with at least one vector for coding at least one oligoribonucleotide with double-stranded structure (dsRNA) for inhibiting the expression of a given target gene, where one strand of the dsRNA has a region I where at least segments are complementary to the target gene.
dsRNA double-stranded structure
the medicament proposed exhibits the abovementioned advantages. By using a vector, in particular production costs can be reduced.
the complementary region I has not more than 49 successive nucleotide pairs. Surprisingly, it has emerged that an effective inhibition of the expression of the target gene can be achieved even when the complementary region I is not more than 49 base pairs in length. The procedure of providing such oligoribonucleotides is less complicated.
the invention furthermore provides a use of an oligoribonucleotide with double-stranded structure (dsRNA) for preparing a medicament for inhibiting the expression of a given target gene, where one strand of the dsRNA has a region I where at least segments are complementary to the target gene.
dsRNA double-stranded structure
the inhibition is already caused at concentrations which are lower by one order of magnitude when using dsRNA.
the use according to the invention thus makes possible the preparation of particularly effective medicaments.
the invention furthermore provides the use of a vector for coding at least one oligoribonucleotide with double-stranded structure (dsRNA) for preparing a medicament for inhibiting the expression of a given target gene, where one strand of the dsRNA has a region I where at least segments are complementary to this target gene.
dsRNA double-stranded structure
the inhibition of transcription was detected by means of sequence homologous dsRNA in an in vitro transcription system with a nuclear extract from human HeLa cells.
the DNA template for this experiment was plasmid pCMV1200 which had been linearized by means of BamHI.
the plasmid shown in FIG. 1 was constructed for use in the enzymatic synthesis of the dsRNA.
a polymerase chain reaction with the “positive control DNA” of the HelaScribe® Nuclear Extract in vitro transcription kit by Promega, Madison, USA, as DNA template was first carried out.
One of the primers used contained the sequence of an EcoRI cleavage site and of the T7 RNA polymerase promoter as shown in sequence listing No. 1.
the other primer contained the sequence of a BamHI cleavage site and of the SP6 RNA polymerase promoter as shown in sequence listing No. 2.
the two primers had, at the 3′ ends, regions which were identical with or complementary to the DNA template.
PCR was carried out by means of the “Taq PCR Core Kits” by Qiagen, Hilden, Germany, following the manufacturer's instructions.
1.5 mM MgCl 2 in each case 200 ⁇ M dNTP, in each case 0.5 ⁇ M primer, 2.5 U Taq DNA polymerase and approximately 100 ng of “positive control DNA” were employed as template in PCR buffer in a volume of 100 ⁇ l.
amplification was carried out in 30 cycles of denaturation for in each case 60 seconds at 94° C., annealing for 60 seconds at 5° C. below the calculated melting point of the primers and polymerization for 1.5-2 minutes at 72° C.
the length of the DNA fragment amplified thus was 400 base pairs, 340 base pairs corresponding to the “positive control DNA”.
the PCR product was purified, hydrolyzed with EcoRI and BamHI and, after repurification, employed in the ligation together with a pUC18 vector which had also been hydrolyzed by EcoRI and BamHI. E. coli XL1-blue was then transformed.
the plasmid obtained (pCMV5) carries a DNA fragment whose 5′ end is flanked by the T7 promoter and whose 3′ end is flanked by the SP6 promoter.
RNA 23 nucleotides in length was also synthesized. To this end, a DNA shown in sequence listing No. 4 was ligated with the pUC18 vector via the EcoRI and BamHI cleavage sites.
Plasmid pCMV1200 was constructed as DNA template for the in-vitro transcription with HeLa nuclear extract.
a 1 191 bp EcoRI/BamHI fragment of the positive control DNA contained in the HeLaScribe® Nuclear Extract in vitro transcription kit was amplified by means of PCR.
the amplified fragment encompasses the 828 bp “immediate early” CMV promoter and a 363 bp transcribable DNA fragment.
the PCR product was ligated to the vector pGEM-T via “T-overhang” ligation.
a BamHI cleavage site is located at the 5′ end of the fragment.
the plasmid was linearized by hydrolysis with BamHI and used as template in the run-off transcription.
pCMV5 plasmid DNA was linearized with EcoRI or BamHI. It was used as DNA template for an in-vitro transcription of the complementary RNA single strands with SP6 and T7 RNA polymerase, respectively.
the transcription reaction was made up to 300 ⁇ l with H 2 O and purified by phenol extraction.
the RNA was precipitated by addition of 150 ⁇ l of 7 M ammonium acatate [sic] and 1 125 ⁇ l of ethanol and stored at ⁇ 65° C. until used for the hybridization.
RNA For the hybridization, 500 ⁇ l of the single-stranded RNA which had been stored in ethanol and precipitated were spun down. The resulting pellet was dried and taken up in 30 ⁇ l of PIPES buffer, pH 6.4 in the presence of 80% formamide, 400 mM NaCl and 1 mM EDTA. In each case 15 ⁇ l of the complementary single strands were combined and heated for 10 minutes at 85° C. The reactions were subsequently incubated overnight at 50° C. and cooled to room temperature.
dsRNA single-stranded RNA
the reactions were treated, after hybridization, with the single-strand-specific ribonucleases bovine pancreatic RNase A and Aspergillus oryzae RNase T1.
RNase A is an endoribonuclease which is specific for pyrimidines.
RNase T1 is an endoribonuclease which preferentially cleaves at the 3′ side of guanosines.
dsRNA is no substrate for these ribonucleases.
the reactions in 300 ⁇ l of Tris, pH 7.4, 300 mM NaCl and 5 mM EDTA were treated with 1.2 ⁇ l of RNaseA at a concentration of 10 mg/ml and 2 ⁇ l of RNaseT1 at a concentration of 290 ⁇ g/ml.
the reactions were incubated for 1.5 hours at 30° C.
the RNases were denatured by addition of 5 ⁇ l of proteinase K at a concentration of 20 mg/ml and 10 ⁇ l of 20% SDS and incubation for 30 minutes at 37° C.
the dsRNA was purified by phenol extraction and precipitated with ethanol. To verify the completeness of the RNase digestion, two control reactions were treated with ssRNA analogously to the hybridization reactions.
FIG. 2 shows the RNA which had been visualized in a UV transilluminator.
the sense RNA which had been applied to lane 1 and the antisense RNA which had been applied to lane 2 showed a different migration behavior under the chosen conditions than the dsRNA of the hybridization reaction which had been applied to lane 3.
the RNase-treated dsRNA of the hybridization reaction which had been applied to lane 6 is resistant to RNase treatment.
the band which migrates faster in the native gel in comparison with the dsRNA applied to lane 3 results from dsRNA which is free from ssRNA. In addition to the dominant main band, weaker bands which migrate faster are observed after the RNase treatment.
the reactions were treated with 100 ⁇ l of phenol/chloroform/isoamyl alcohol (25:24:1 v/v/v) saturated with TE buffer, pH 5.0, and the reactions were mixed vigorously for 1 minute.
the reactions were spun for approximately 1 minute at 12 000 rpm and the top phase was transferred into a fresh reaction vessel.
Each reaction was treated with 250 ⁇ l of ethanol.
the reactions were mixed thoroughly and incubated for at least 15 minutes on dry ice/methanol.
To precipitate the RNA the reactions were spun for 20 minutes at 12 000 rpm and 40° C. The supernatant was discarded. The pellet was dried in vacuo for 15 minutes and resuspended in 10 ⁇ l of H 2 O.
RNA transcripts formed upon transcription with HeLa nuclear extract, in denaturing loading buffer were heated for 10 minutes at 90° C. and 10 ⁇ l aliquots were applied immediately to the freshly washed pockets. The electrophoresis was run at 40 mA. The amount of the radioactive ssRNA formed upon transcription was analyzed after electrophoresis with the aid of an Instant Imager.
FIG. 3 shows the radioactive RNA from a representative test, shown by means of the Instant Imager. Samples obtained from the following transcription reactions were applied:
Lane 1 without template DNA, without dsRNA
Lane 1 50 ng of template DNA, without dsRNA
Lane 3 50 ng of template DNA, 0.5 ⁇ g of dsRNA YFP;
Lane 4 50 ng of template DNA, 1.5 ⁇ g of dsRNA YFP;
Lane 5 50 ng of template DNA, 3 ⁇ g of dsRNA YFP;
Lane 6 50 ng of template DNA, 5 ⁇ g of dsRNA YFP;
Lane 7 without template DNA, 1.5 dsRNA YFP;
Lane 8 50 ng of template DNA, without dsRNA
Lane 9 50 ng of template DNA, 0.5 ⁇ g of dsRNA CMV5;
Lane 10 50 ng of template DNA, 1.5 ⁇ g of dsRNA CMV5;
Lane 11 50 ng of template DNA, 3 ⁇ g of dsRNA CMV5;
Lane 12 50 ng of template DNA, 5 ⁇ g of dsRNA CMV5;
the reduction of the transcript upon addition of sequence-specific dsRNA can therefore be ascribed unequivocally to the dsRNA itself.
the reduction of the amount of transcript of a gene in the presence of dsRNA in a human transcription system indicates an inhibition of the expression of the gene in question. This effect can be attributed to a novel mechanism caused by the dsRNA.
the test system used for these in-vivo experiments was the murine fibroblast cell line NIH3T3, ATCC CRL-1658.
the YFP gene was introduced into the nuclei with the aid of microinjection. Expression of YFP was studied under the effect of simultaneously cotransfected dsRNA with sequence homology. This dsRNA YFP shows homology with the 5′-region of the YFP gene over a length of 315 bp.
the nucleotide sequence of a strand of the dsRNA YRP is shown in sequence listing No. 5. Evaluation under the fluorescence microscope was carried out 3 hours after injection with reference to the greenish-yellow fluorescence of the YFP formed.
a plasmid was constructed following the same principle as described in use example 1 to act as template for the production of the YFP dsRNA by means of T7 and SP6 in-vitro transcription.
the desired gene fragment was amplified by PCR and used analogously to the above description for preparing the dsRNA.
the dsRNA YFP obtained is identical to the dsRNA used in use example 1 as non-sequence-specific control.
a dsRNA linked chemically at the 3′ end of the RNA as shown in sequence listing No. 8 to the 5′ end of the complementary RNA via a C18 linker group was prepared (L-dsRNA).
synthons modified by disulfide bridges were used.
the 3′-terminal synthon is bound to the solid support via the 3′ carbon with an aliphatic linker group via a disulfide bridge.
the 5′-trityl protecting group is bound via a further aliphatic linker and a disulfide bridge.
the thiol groups which form are brought into spatial vicinity.
the single strands are linked to each other by oxidation via their aliphatic linkers and a disulfide bridge. This is followed by purification with the aid of HPLC.
the cells were incubated in DMEM supplemented with 4.5 g/l glucose, 10% fetal bovine serum in culture dishes at 37° C. under a 7.5% CO 2 atmosphere and passaged before reaching confluence.
the cells were detached with trypsin/EDTA. To prepare for microinjection, the cells were transferred into Petri dishes and incubated further until microcolonies formed.
the culture dishes were removed from the incubator for approximately 10 minutes. Approximately 50 nuclei were injected singly per reaction within a marked area using the AIS microinjection system from Carl Zeiss, Göttingen, Germany. The cells were subsequently incubated for three more hours.
borosilicate glass capillaries from Hilgenberg GmbH, Malsfeld, Germany, with a diameter of less than 0.5 ⁇ m at the tip were prepared. The microinjection was carried out using a micromanipulator from Narishige Scientific Instrument Lab., Tokyo, Japan. The injection time was 0.8 seconds and the pressure was approximately 100 hPa.
the transfection was carried out using the plasmid pCDNA YFP, which contains an approximately 800 bp BamHI/EcoRI fragment with the YFP gene in vector pcDNA3.
the samples injected into the nuclei contained 0.01 ⁇ g/ ⁇ l of pCDNA-YFP and Texas Red coupled to dextran-70000 in 14 mM NaCl, 3 mM KCl, 10 mM KPO 4 [sic], ph 7.5.
RNA with a concentration of 1 ⁇ M or, in the case of the L-dsRNA, 375 ⁇ M were additionally added.
FIGS. 4 a - e show the result for NIH3T3 cells.
sense-YFP-ssRNA has been injected, in FIG. 4 b antisense-YFP-ssRNA, in FIG. 4 c dsRNA-YFP, in FIG. 4 d no RNA and in FIG. 4 e L-dsRNA.
the field on the left shows in each case the fluorescence of cells with excitation at 568 nm.
the fluorescence of the same cells at an excitation of 488 nm is seen on the right.
the Texas Red fluorescence of all the cells shown demonstrates that the injection solution had been applied successfully into the nuclei and that cells with successful hits were still alive after three hours. Dead cells no longer showed Texas Red fluorescence.
FIGS. 4 a and 4 b show that YFP expression was not visibly inhibited when the single-stranded RNA was injected into the nuclei.
the right field of FIG. 4 c shows cells whose YFP fluorescence was no longer detectable after the injection of dsRNA-YFP.
FIG. 4 d shows cells into which no RNA had been injected, as control.
the cell shown in FIG. 4 e shows YFP fluorescence which can no longer be detected owing to the injection of the L-dsRNA which shows regions with sequence homology to the YFP gene. This result demonstrates that even shorter dsRNAs can be used for specifically inhibiting gene expression in mammals when the double strands are stabilized by chemically linking the single strands.

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Engineering & Computer Science (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Biomedical Technology (AREA)
General Health & Medical Sciences (AREA)
Genetics & Genomics (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Molecular Biology (AREA)
Bioinformatics & Cheminformatics (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Biotechnology (AREA)
Zoology (AREA)
Wood Science & Technology (AREA)
General Engineering & Computer Science (AREA)
Biochemistry (AREA)
Communicable Diseases (AREA)
Oncology (AREA)
Biophysics (AREA)
Physics & Mathematics (AREA)
Plant Pathology (AREA)
Microbiology (AREA)
Virology (AREA)
Epidemiology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Hospice & Palliative Care (AREA)
Psychiatry (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicinal Preparation (AREA)
Saccharide Compounds (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)

US10/383,099 1999-01-30 2003-03-06 Method and medicament for inhibiting the expression of a given gene Expired - Fee Related US8119608B2 (en)

Priority Applications (1)

Application Number	Priority Date	Filing Date	Title
US10/383,099 US8119608B2 (en)	1999-01-30	2003-03-06	Method and medicament for inhibiting the expression of a given gene

Applications Claiming Priority (9)

Application Number	Priority Date	Filing Date	Title
DE19903713		1999-01-30
DE19903713.2		1999-01-30
DE19903713		1999-01-30
DE19956568A DE19956568A1 (de)	1999-01-30	1999-11-24	Verfahren und Medikament zur Hemmung der Expression eines vorgegebenen Gens
DE19956568		1999-11-24
DE19956568.6		1999-11-24
PCT/DE2000/000244 WO2000044895A1 (de)	1999-01-30	2000-01-29	Verfahren und medikament zur hemmung der expression eines vorgegebenen gens
US88980201A	2001-09-17	2001-09-17
US10/383,099 US8119608B2 (en)	1999-01-30	2003-03-06	Method and medicament for inhibiting the expression of a given gene

Related Parent Applications (2)

Application Number	Title	Priority Date	Filing Date
US09889802 Division		2000-01-29
PCT/DE2000/000244 Division WO2000044895A1 (de)	1999-01-30	2000-01-29	Verfahren und medikament zur hemmung der expression eines vorgegebenen gens

Publications (2)

Publication Number	Publication Date
US20040102408A1 US20040102408A1 (en)	2004-05-27
US8119608B2 true US8119608B2 (en)	2012-02-21

Family

ID=26051592

Family Applications (17)

Application Number	Title	Priority Date	Filing Date
US10/383,099 Expired - Fee Related US8119608B2 (en)	1999-01-30	2003-03-06	Method and medicament for inhibiting the expression of a given gene
US10/382,768 Expired - Fee Related US8168776B2 (en)	1999-01-30	2003-03-06	Method for making a 21 nucleotide double stranded RNA chemically linked at one end
US10/382,395 Expired - Fee Related US8101584B2 (en)	1999-01-30	2003-03-06	Method and medicament for inhibiting the expression of a given gene
US10/612,179 Expired - Fee Related US8202980B2 (en)	1999-01-30	2003-07-02	Method and medicament for inhibiting the expression of a given gene
US11/982,345 Expired - Fee Related US8729037B2 (en)	1999-01-30	2007-10-31	Method and medicament for inhibiting the expression of a given gene
US11/982,425 Expired - Fee Related US8183362B2 (en)	1999-01-30	2007-10-31	Method and medicament for inhibiting the expression of a given gene
US11/982,325 Abandoned US20080171862A1 (en)	1999-01-30	2007-10-31	Method and medicament for inhibiting the expression of a given gene
US11/982,441 Expired - Fee Related US8114981B2 (en)	1999-01-30	2007-10-31	Method and medicament for inhibiting the expression of a given gene
US11/982,305 Expired - Fee Related US8101742B2 (en)	1999-01-30	2007-10-31	Method and medicament for inhibiting the expression of a given gene
US11/982,434 Expired - Fee Related US8114851B2 (en)	1999-01-30	2007-10-31	Method and medicament for inhibiting the expression of a given gene
US13/656,513 Expired - Fee Related US8877726B2 (en)	1999-01-30	2012-10-19	Method and medicament for inhibiting the expression of a given gene
US13/656,548 Expired - Fee Related US9902954B2 (en)	1999-01-30	2012-10-19	Method and medicament for inhibiting the expression of a given gene
US13/656,540 Abandoned US20130164366A1 (en)	1999-01-30	2012-10-19	Method and medicament for inhibiting the expression of a given gene
US13/753,438 Abandoned US20130177631A1 (en)	1999-01-30	2013-01-29	Method and medicament for inhibiting the expression of a given gene
US14/218,476 Expired - Fee Related US9133454B2 (en)	1999-01-30	2014-03-18	Method and medicament for inhibiting the expression of a given gene
US14/218,489 Expired - Fee Related US9902955B2 (en)	1999-01-30	2014-03-18	Method and medicament for inhibiting the expression of a given gene
US15/870,380 Abandoned US20180179526A1 (en)	1999-01-30	2018-01-12	Method and Medicament For Inhibiting The Expression of A Given Gene

Family Applications After (16)

Application Number	Title	Priority Date	Filing Date
US10/382,768 Expired - Fee Related US8168776B2 (en)	1999-01-30	2003-03-06	Method for making a 21 nucleotide double stranded RNA chemically linked at one end
US10/382,395 Expired - Fee Related US8101584B2 (en)	1999-01-30	2003-03-06	Method and medicament for inhibiting the expression of a given gene
US10/612,179 Expired - Fee Related US8202980B2 (en)	1999-01-30	2003-07-02	Method and medicament for inhibiting the expression of a given gene
US11/982,345 Expired - Fee Related US8729037B2 (en)	1999-01-30	2007-10-31	Method and medicament for inhibiting the expression of a given gene
US11/982,425 Expired - Fee Related US8183362B2 (en)	1999-01-30	2007-10-31	Method and medicament for inhibiting the expression of a given gene
US11/982,325 Abandoned US20080171862A1 (en)	1999-01-30	2007-10-31	Method and medicament for inhibiting the expression of a given gene
US11/982,441 Expired - Fee Related US8114981B2 (en)	1999-01-30	2007-10-31	Method and medicament for inhibiting the expression of a given gene
US11/982,305 Expired - Fee Related US8101742B2 (en)	1999-01-30	2007-10-31	Method and medicament for inhibiting the expression of a given gene
US11/982,434 Expired - Fee Related US8114851B2 (en)	1999-01-30	2007-10-31	Method and medicament for inhibiting the expression of a given gene
US13/656,513 Expired - Fee Related US8877726B2 (en)	1999-01-30	2012-10-19	Method and medicament for inhibiting the expression of a given gene
US13/656,548 Expired - Fee Related US9902954B2 (en)	1999-01-30	2012-10-19	Method and medicament for inhibiting the expression of a given gene
US13/656,540 Abandoned US20130164366A1 (en)	1999-01-30	2012-10-19	Method and medicament for inhibiting the expression of a given gene
US13/753,438 Abandoned US20130177631A1 (en)	1999-01-30	2013-01-29	Method and medicament for inhibiting the expression of a given gene
US14/218,476 Expired - Fee Related US9133454B2 (en)	1999-01-30	2014-03-18	Method and medicament for inhibiting the expression of a given gene
US14/218,489 Expired - Fee Related US9902955B2 (en)	1999-01-30	2014-03-18	Method and medicament for inhibiting the expression of a given gene
US15/870,380 Abandoned US20180179526A1 (en)	1999-01-30	2018-01-12	Method and Medicament For Inhibiting The Expression of A Given Gene

Country Status (13)

Country	Link
US (17)	US8119608B2 (es)
EP (6)	EP1144623B9 (es)
JP (14)	JP2003502012A (es)
AT (3)	ATE222953T1 (es)
AU (2)	AU778474B2 (es)
CA (1)	CA2359180C (es)
CY (3)	CY1108896T1 (es)
DE (7)	DE19956568A1 (es)
DK (4)	DK1214945T4 (es)
ES (5)	ES2597953T3 (es)
PT (4)	PT1214945E (es)
WO (1)	WO2000044895A1 (es)
ZA (1)	ZA200105909B (es)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20100184039A1 (en) *	2002-06-12	2010-07-22	Life Technologies Corporation	Methods and compositions relating to labeled rna molecules that reduce gene expression
US8877726B2 (en)	1999-01-30	2014-11-04	Alnylam Pharmaceuticals, Inc.	Method and medicament for inhibiting the expression of a given gene
US9592250B2 (en)	2002-02-01	2017-03-14	Life Technologies Corporation	Double-stranded oligonucleotides
US9796978B1 (en)	2002-02-01	2017-10-24	Life Technologies Corporation	Oligonucleotide compositions with enhanced efficiency

Families Citing this family (665)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20030206887A1 (en) *	1992-05-14	2003-11-06	David Morrissey	RNA interference mediated inhibition of hepatitis B virus (HBV) using short interfering nucleic acid (siNA)
US20030216335A1 (en) *	2001-11-30	2003-11-20	Jennifer Lockridge	Method and reagent for the modulation of female reproductive diseases and conditions
US9096636B2 (en)	1996-06-06	2015-08-04	Isis Pharmaceuticals, Inc.	Chimeric oligomeric compounds and their use in gene modulation
US6506559B1 (en)	1997-12-23	2003-01-14	Carnegie Institute Of Washington	Genetic inhibition by double-stranded RNA
AU743316C (en)	1998-03-20	2005-09-15	Commonwealth Scientific And Industrial Research Organisation	Control of gene expression
AUPP249298A0 (en)	1998-03-20	1998-04-23	Ag-Gene Australia Limited	Synthetic genes and genetic constructs comprising same I
EP1147204A1 (en) *	1999-01-28	2001-10-24	Medical College Of Georgia Research Institute, Inc.	Composition and method for in vivo and in vitro attenuation of gene expression using double stranded rna
US7601494B2 (en)	1999-03-17	2009-10-13	The University Of North Carolina At Chapel Hill	Method of screening candidate compounds for susceptibility to biliary excretion
US20070021979A1 (en) *	1999-04-16	2007-01-25	Cosentino Daniel L	Multiuser wellness parameter monitoring system
JP2002542263A (ja) *	1999-04-21	2002-12-10	ワイス	ポリヌクレオチド配列の機能を阻害するための方法および組成物
US6423885B1 (en)	1999-08-13	2002-07-23	Commonwealth Scientific And Industrial Research Organization (Csiro)	Methods for obtaining modified phenotypes in plant cells
US7531718B2 (en)	1999-08-26	2009-05-12	Monsanto Technology, L.L.C.	Nucleic acid sequences and methods of use for the production of plants with modified polyunsaturated fatty acids
JP4744049B2 (ja)	1999-08-26	2011-08-10	モンサント・カンパニー	改質したポリ不飽和脂肪酸を有する植物
US7067722B2 (en)	1999-08-26	2006-06-27	Monsanto Technology Llc	Nucleic acid sequences and methods of use for the production of plants with modified polyunsaturated fatty acids
GB9925459D0 (en) *	1999-10-27	1999-12-29	Plant Bioscience Ltd	Gene silencing
GB9927444D0 (en) *	1999-11-19	2000-01-19	Cancer Res Campaign Tech	Inhibiting gene expression
DE10160151A1 (de) *	2001-01-09	2003-06-26	Ribopharma Ag	Verfahren zur Hemmung der Expression eines vorgegebenen Zielgens
US7829693B2 (en)	1999-11-24	2010-11-09	Alnylam Pharmaceuticals, Inc.	Compositions and methods for inhibiting expression of a target gene
DE10100586C1 (de) *	2001-01-09	2002-04-11	Ribopharma Ag	Verfahren zur Hemmung der Expression eines Ziegens
WO2002081628A2 (en)	2001-04-05	2002-10-17	Ribozyme Pharmaceuticals, Incorporated	Modulation of gene expression associated with inflammation proliferation and neurite outgrowth, using nucleic acid based technologies
US7833992B2 (en)	2001-05-18	2010-11-16	Merck Sharpe & Dohme	Conjugates and compositions for cellular delivery
US8273866B2 (en)	2002-02-20	2012-09-25	Merck Sharp & Dohme Corp.	RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (SINA)
WO2005041859A2 (en)	2003-04-30	2005-05-12	Sirna Therapeutics, Inc.	Conjugates and compositions for cellular delivery.
US8202979B2 (en)	2002-02-20	2012-06-19	Sirna Therapeutics, Inc.	RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid
WO2005019453A2 (en) *	2001-05-18	2005-03-03	Sirna Therapeutics, Inc.	RNA INTERFERENCE MEDIATED INHIBITION OF GENE EXPRESSION USING CHEMICALLY MODIFIED SHORT INTERFERING NUCLEIC ACID (siNA)
WO2003070918A2 (en)	2002-02-20	2003-08-28	Ribozyme Pharmaceuticals, Incorporated	Rna interference by modified short interfering nucleic acid
US7491805B2 (en)	2001-05-18	2009-02-17	Sirna Therapeutics, Inc.	Conjugates and compositions for cellular delivery
US8202846B2 (en)	2000-03-16	2012-06-19	Cold Spring Harbor Laboratory	Methods and compositions for RNA interference
EP1272630A2 (en)	2000-03-16	2003-01-08	Genetica, Inc.	Methods and compositions for rna interference
BRPI0117338B1 (pt) *	2000-03-30	2016-06-21	Massachusetts Inst Technology	método para produzir células animais nocauteadas in vitro e método para produzir uma célula nocauteada
EP1309726B2 (en)	2000-03-30	2018-10-03	Whitehead Institute For Biomedical Research	Rna sequence-specific mediators of rna interference
US20080032942A1 (en)	2000-08-30	2008-02-07	Mcswiggen James	RNA interference mediated treatment of Alzheimer's disease using short interfering nucleic acid (siNA)
US20030190635A1 (en) *	2002-02-20	2003-10-09	Mcswiggen James A.	RNA interference mediated treatment of Alzheimer's disease using short interfering RNA
AU2001297906B2 (en) *	2000-10-31	2007-07-19	Commonwealth Scientific And Industrial Research Organisation	Method and means for producing barley yellow dwarf virus resistant cereal plants
US20020173478A1 (en) *	2000-11-14	2002-11-21	The Trustees Of The University Of Pennsylvania	Post-transcriptional gene silencing by RNAi in mammalian cells
US20040259247A1 (en)	2000-12-01	2004-12-23	Thomas Tuschl	Rna interference mediating small rna molecules
US8546143B2 (en)	2001-01-09	2013-10-01	Alnylam Pharmaceuticals, Inc.	Compositions and methods for inhibiting expression of a target gene
US7423142B2 (en)	2001-01-09	2008-09-09	Alnylam Pharmaceuticals, Inc.	Compositions and methods for inhibiting expression of anti-apoptotic genes
US7767802B2 (en)	2001-01-09	2010-08-03	Alnylam Pharmaceuticals, Inc.	Compositions and methods for inhibiting expression of anti-apoptotic genes
DE10100587C1 (de) *	2001-01-09	2002-11-21	Ribopharma Ag	Verfahren zur Hemmung der Expression eines Zielgens
WO2003035869A1 (de) *	2001-10-26	2003-05-01	Ribopharma Ag	Verwendung einer doppelsträngigen ribonukleinsäure zur gezielten hemmung der expression eines vorgegebenen zielgens
DE10100588A1 (de) *	2001-01-09	2002-07-18	Ribopharma Ag	Verfahren zur Hemmung der Expression eines Zielgens
GB0104948D0 (en) *	2001-02-28	2001-04-18	Novartis Res Foundation	Novel methods
US20050288242A1 (en) *	2001-05-18	2005-12-29	Sirna Therapeutics, Inc.	RNA interference mediated inhibition of RAS gene expression using short interfering nucleic acid (siNA)
US20050159381A1 (en) *	2001-05-18	2005-07-21	Sirna Therapeutics, Inc.	RNA interference mediated inhibition of chromosome translocation gene expression using short interfering nucleic acid (siNA)
US20050256068A1 (en)	2001-05-18	2005-11-17	Sirna Therapeutics, Inc.	RNA interference mediated inhibition of stearoyl-CoA desaturase (SCD) gene expression using short interfering nucleic acid (siNA)
US20030175950A1 (en) *	2001-05-29	2003-09-18	Mcswiggen James A.	RNA interference mediated inhibition of HIV gene expression using short interfering RNA
WO2005014811A2 (en) *	2003-08-08	2005-02-17	Sirna Therapeutics, Inc.	RNA INTERFERENCE MEDIATED INHIBITION OF XIAP GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
EP2415486B1 (en)	2001-05-18	2017-02-22	Sirna Therapeutics, Inc.	Conjugates and compositions for cellular delivery
US20050159382A1 (en) *	2001-05-18	2005-07-21	Sirna Therapeutics, Inc.	RNA interference mediated inhibition of polycomb group protein EZH2 gene expression using short interfering nucleic acid (siNA)
US20050143333A1 (en) *	2001-05-18	2005-06-30	Sirna Therapeutics, Inc.	RNA interference mediated inhibition of interleukin and interleukin receptor gene expression using short interfering nucleic acid (SINA)
WO2003070887A2 (en) *	2002-02-20	2003-08-28	Sirna Therapeutics, Inc.	RNA INTERFERENCE MEDIATED INHIBITION OF POLYCOMB GROUP PROTEIN EZH2 GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
US7109165B2 (en)	2001-05-18	2006-09-19	Sirna Therapeutics, Inc.	Conjugates and compositions for cellular delivery
WO2003072705A2 (en) *	2002-02-20	2003-09-04	Sirna Therapeutics, Inc.	Rna interference mediated inhibition of cyclin d1 gene expression using short interfering nucleic acid (sina)
US20050182007A1 (en) *	2001-05-18	2005-08-18	Sirna Therapeutics, Inc.	RNA interference mediated inhibition of interleukin and interleukin receptor gene expression using short interfering nucleic acid (SINA)
US7517864B2 (en)	2001-05-18	2009-04-14	Sirna Therapeutics, Inc.	RNA interference mediated inhibition of vascular endothelial growth factor and vascular endothelial growth factor receptor gene expression using short interfering nucleic acid (siNA)
US20050014172A1 (en)	2002-02-20	2005-01-20	Ivan Richards	RNA interference mediated inhibition of muscarinic cholinergic receptor gene expression using short interfering nucleic acid (siNA)
US20050196767A1 (en) *	2001-05-18	2005-09-08	Sirna Therapeutics, Inc.	RNA interference mediated inhibition of GRB2 associated binding protein (GAB2) gene expression using short interfering nucleic acis (siNA)
WO2004097020A2 (en) *	2003-04-25	2004-11-11	Sirna Therapeutics, Inc.	Rna interference mediated inhibition of map kinase gene expression
US20050233997A1 (en) *	2001-05-18	2005-10-20	Sirna Therapeutics, Inc.	RNA interference mediated inhibition of matrix metalloproteinase 13 (MMP13) gene expression using short interfering nucleic acid (siNA)
US20040198682A1 (en) *	2001-11-30	2004-10-07	Mcswiggen James	RNA interference mediated inhibition of placental growth factor gene expression using short interfering nucleic acid (siNA)
US20050176025A1 (en) *	2001-05-18	2005-08-11	Sirna Therapeutics, Inc.	RNA interference mediated inhibition of B-cell CLL/Lymphoma-2 (BCL-2) gene expression using short interfering nucleic acid (siNA)
US20050158735A1 (en) *	2001-05-18	2005-07-21	Sirna Therapeutics, Inc.	RNA interference mediated inhibition of proliferating cell nuclear antigen (PCNA) gene expression using short interfering nucleic acid (siNA)
US20050148530A1 (en)	2002-02-20	2005-07-07	Sirna Therapeutics, Inc.	RNA interference mediated inhibition of vascular endothelial growth factor and vascular endothelial growth factor receptor gene expression using short interfering nucleic acid (siNA)
US20050203040A1 (en) *	2001-05-18	2005-09-15	Sirna Therapeutics, Inc.	RNA interference mediated inhibition of vascular cell adhesion molecule (VCAM) gene expression using short interfering nucleic acid (siNA)
US20050159378A1 (en)	2001-05-18	2005-07-21	Sirna Therapeutics, Inc.	RNA interference mediated inhibition of Myc and/or Myb gene expression using short interfering nucleic acid (siNA)
US9994853B2 (en)	2001-05-18	2018-06-12	Sirna Therapeutics, Inc.	Chemically modified multifunctional short interfering nucleic acid molecules that mediate RNA interference
WO2003102131A2 (en) *	2002-04-22	2003-12-11	Sirna Therapeutics Inc.	Nucleic acid mediated disruption of hiv fusogenic peptide interactions
US20050196765A1 (en) *	2001-05-18	2005-09-08	Sirna Therapeutics, Inc.	RNA interference mediated inhibition of checkpoint Kinase-1 (CHK-1) gene expression using short interfering nucleic acid (siNA)
US20050124566A1 (en) *	2001-05-18	2005-06-09	Sirna Therapeutics, Inc.	RNA interference mediated inhibition of myostatin gene expression using short interfering nucleic acid (siNA)
US20040019001A1 (en) *	2002-02-20	2004-01-29	Mcswiggen James A.	RNA interference mediated inhibition of protein typrosine phosphatase-1B (PTP-1B) gene expression using short interfering RNA
US8008472B2 (en)	2001-05-29	2011-08-30	Merck Sharp & Dohme Corp.	RNA interference mediated inhibition of human immunodeficiency virus (HIV) gene expression using short interfering nucleic acid (siNA)
WO2003006477A1 (en)	2001-07-12	2003-01-23	University Of Massachusetts	IN VIVO PRODUCTION OF SMALL INTERFERING RNAs THAT MEDIATE GENE SILENCING
US8022272B2 (en)	2001-07-13	2011-09-20	Sungene Gmbh & Co. Kgaa	Expression cassettes for transgenic expression of nucleic acids
WO2003008573A2 (en) *	2001-07-17	2003-01-30	Anne Josephine Milner	Silencing of gene expression by sirna
US10590418B2 (en)	2001-07-23	2020-03-17	The Board Of Trustees Of The Leland Stanford Junior University	Methods and compositions for RNAi mediated inhibition of gene expression in mammals
DK1409506T3 (da)	2001-07-23	2012-08-06	Univ Leland Stanford Junior	Fremgangsmåder og sammensætninger til RNAi-formidlet inhibering af genekspression i pattedyr
US7456335B2 (en) *	2001-09-03	2008-11-25	Basf Plant Science Gmbh	Nucleic acid sequences and their use in methods for achieving pathogen resistance in plants
DE10163098B4 (de)	2001-10-12	2005-06-02	Alnylam Europe Ag	Verfahren zur Hemmung der Replikation von Viren
US7745418B2 (en)	2001-10-12	2010-06-29	Alnylam Pharmaceuticals, Inc.	Compositions and methods for inhibiting viral replication
JP2005506087A (ja) *	2001-10-26	2005-03-03	リボファーマアーゲー	プラス鎖ｒｎａウイルスによる感染症を処置するための２本鎖リボ核酸の使用
WO2003035083A1 (de) *	2001-10-26	2003-05-01	Ribopharma Ag	Medikament zur behandlung einer fibrotischen erkrankung durch rna interferenz
DE10230996A1 (de) *	2001-10-26	2003-07-17	Ribopharma Ag	Medikament zur Behandlung eines Pankreaskarzinoms
DE10202419A1 (de) *	2002-01-22	2003-08-07	Ribopharma Ag	Verfahren zur Hemmung der Expression eines durch eine Chromosomen-Aberration entstandenen Zielgens
EP1572902B1 (en) *	2002-02-01	2014-06-11	Life Technologies Corporation	HIGH POTENCY siRNAS FOR REDUCING THE EXPRESSION OF TARGET GENES
US8067575B2 (en)	2002-02-20	2011-11-29	Merck, Sharp & Dohme Corp.	RNA interference mediated inhibition of cyclin D1 gene expression using short interfering nucleic acid (siNA)
EP1478730A4 (en) *	2002-02-20	2006-01-25	Sirna Therapeutics Inc	INTERFERENCE RNA-INDUCED INHIBITION OF THE GENE EXPRESSION OF SUPERFAMILY TFN AND TFN RECEPTOR SUPERFAMILY USING SHORT INTERFERENCE NUCLEIC ACID (SINA)
US7897752B2 (en)	2002-02-20	2011-03-01	Sirna Therapeutics, Inc.	RNA interference mediated inhibition of telomerase gene expression using short interfering nucleic acid (siNA)
US20090137510A1 (en) *	2002-02-20	2009-05-28	Sirna Therapeutics, Inc.	RNA INTERFERENCE MEDIATED INHIBITION OF NF-KAPPA B/ REL-A GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
US7683165B2 (en)	2002-02-20	2010-03-23	Sirna Therapeutics, Inc.	RNA interference mediated inhibition of interleukin and interleukin receptor gene expression using short interfering nucleic acid (siNA)
JP2005517437A (ja) *	2002-02-20	2005-06-16	サーナ・セラピューティクス・インコーポレイテッド	短干渉核酸（ｓｉＮａ）を用いる表皮成長因子レセプター遺伝子発現のＲＮＡ干渉媒介性阻害
EP1465910A4 (en) *	2002-02-20	2005-03-16	Sirna Therapeutics Inc	INHIBITION OF GENE EXPRESSION OF CHECKPOINT KINASE-1 (CHK-1) IMPROVED BY RNA INTERFERENCE USING SHORT INTERFERING NUCLEIC ACIDS
AU2003220136A1 (en) *	2002-02-20	2003-09-09	Sirna Therapeutics, Inc.	RNA INTERFERENCE MEDIATED INHIBITION OF TGF-BETA AND TGF-BETA RECEPTOR GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
US7662952B2 (en)	2002-02-20	2010-02-16	Sirna Therapeutics, Inc.	RNA interference mediated inhibition of GRB2 associated binding protein (GAB2) gene expression using short interfering nucleic acid (siNA)
US7928219B2 (en)	2002-02-20	2011-04-19	Merck Sharp & Dohme Corp.	RNA interference mediated inhibition of placental growth factor gene expression using short interfering nucleic acid (SINA)
US20090192105A1 (en)	2002-02-20	2009-07-30	Sirna Therapeutics, Inc.	RNA INTERFERENCE MEDIATED INHIBITION OF INTERCELLULAR ADHESION MOLECULE (ICAM) GENE EXPRESSION USING SHORT INTERFERING NUCELIC ACID (siNA)
US7667030B2 (en)	2002-02-20	2010-02-23	Sirna Therapeutics, Inc.	RNA interference mediated inhibition of matrix metalloproteinase 13 (MMP13) gene expression using short interfering nucleic acid (siNA)
US20090253774A1 (en)	2002-02-20	2009-10-08	Sirna Therapeutics, Inc.	RNA INTERFERENCE MEDIATED INHIBITION OF PLATELET DERIVED GROWTH FACTOR (PDGF) AND PLATELET DERIVED GROWTH FACTOR RECEPTOR (PDGFR) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
EP1741781A3 (en) *	2002-02-20	2007-06-06	Sirna Therapeutics, Inc.	RNA interference mediated treatment of Alzheimer's disease using short interfering nucleic acid (siNA)
AU2003219833A1 (en) *	2002-02-20	2003-09-09	Sirna Therapeutics Inc.	RNA INTERFERENCE MEDIATED INHIBITION OF CHROMOSOME TRANSLOCATION GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
JP2005517452A (ja) *	2002-02-20	2005-06-16	サーナ・セラピューティクス・インコーポレイテッド	短干渉核酸（ｓｉＮＡ）を用いるＢＣＬ２遺伝子発現のＲＮＡ干渉媒介性阻害
US8232383B2 (en) *	2002-02-20	2012-07-31	Sirna Therapeutics, Inc.	RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
AU2003211058A1 (en) *	2002-02-20	2003-09-09	Sirna Therapeutics, Inc.	RNA INTERFERENCE MEDIATED TARGET DISCOVERY AND TARGET VALIDATION USING SHORT INTERFERING NUCLEIC ACID (siNA)
AU2003207708A1 (en)	2002-02-20	2003-09-09	Sirna Therapeutics, Inc.	Rna interference mediated inhibition of map kinase genes
US20090247613A1 (en) *	2002-02-20	2009-10-01	Sirna Therapeutics, Inc.	RNA INTERFERENCE MEDIATED INHIBITION OF B-CELL CLL/LYMPHOMA-2 (BCL2) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
US7667029B2 (en)	2002-02-20	2010-02-23	Sirna Therapeutics, Inc.	RNA interference mediated inhibition of checkpoint kinase-1 (CHK-1) gene expression using short interfering nucleic acid (siNA)
US20090099117A1 (en)	2002-02-20	2009-04-16	Sirna Therapeutics, Inc.	RNA INTERFERENCE MEDIATED INHIBITION OF MYOSTATIN GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
EP1710307A3 (en) *	2002-02-20	2007-06-06	Sirna Therapeutics, Inc.	RNA interference mediated inhibition of gene expression using short interfering nucleic acid (siNA)
US9657294B2 (en)	2002-02-20	2017-05-23	Sirna Therapeutics, Inc.	RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
US7897753B2 (en)	2002-02-20	2011-03-01	Sirna Therapeutics, Inc.	RNA interference mediated inhibition of XIAP gene expression using short interfering nucleic acid (siNA)
US7795422B2 (en)	2002-02-20	2010-09-14	Sirna Therapeutics, Inc.	RNA interference mediated inhibition of hypoxia inducible factor 1 (HIF1) gene expression using short interfering nucleic acid (siNA)
US7910724B2 (en)	2002-02-20	2011-03-22	Sirna Therapeutics, Inc.	RNA interference mediated inhibition of Fos gene expression using short interfering nucleic acid (siNA)
US7935812B2 (en)	2002-02-20	2011-05-03	Merck Sharp & Dohme Corp.	RNA interference mediated inhibition of hepatitis C virus (HCV) expression using short interfering nucleic acid (siNA)
US7893248B2 (en)	2002-02-20	2011-02-22	Sirna Therapeutics, Inc.	RNA interference mediated inhibition of Myc and/or Myb gene expression using short interfering nucleic acid (siNA)
US7678897B2 (en)	2002-02-20	2010-03-16	Sirna Therapeutics, Inc.	RNA interference mediated inhibition of platelet-derived endothelial cell growth factor (ECGF1) gene expression using short interfering nucleic acid (siNA)
US20090253773A1 (en)	2002-02-20	2009-10-08	Sirna Therapeutics, Inc.	RNA INTERFERENCE MEDIATED INHIBITION OF TNF AND TNF RECEPTOR GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
US8258288B2 (en)	2002-02-20	2012-09-04	Sirna Therapeutics, Inc.	RNA interference mediated inhibition of respiratory syncytial virus (RSV) expression using short interfering nucleic acid (siNA)
US7700760B2 (en)	2002-02-20	2010-04-20	Sirna Therapeutics, Inc.	RNA interference mediated inhibition of vascular cell adhesion molecule (VCAM) gene expression using short interfering nucleic acid (siNA)
US7928218B2 (en)	2002-02-20	2011-04-19	Merck Sharp & Dohme Corp.	RNA interference mediated inhibition of polycomb group protein EZH2 gene expression using short interfering nucleic acid (siNA)
US7897757B2 (en)	2002-02-20	2011-03-01	Merck Sharp & Dohme Corp.	RNA interference mediated inhibition of protein tyrosine phosphatase-1B (PTP-1B) gene expression using short interfering nucleic acid (siNA)
US7691999B2 (en)	2002-02-20	2010-04-06	Sirna Therapeutics, Inc.	RNA interference mediated inhibition of NOGO and NOGO receptor gene expression using short interfering nucleic acid (siNA)
US7928220B2 (en)	2002-02-20	2011-04-19	Merck Sharp & Dohme Corp.	RNA interference mediated inhibition of stromal cell-derived factor-1 (SDF-1) gene expression using short interfering nucleic acid (siNA)
US8013143B2 (en)	2002-02-20	2011-09-06	Merck Sharp & Dohme Corp.	RNA interference mediated inhibition of CXCR4 gene expression using short interfering nucleic acid (siNA)
US9181551B2 (en)	2002-02-20	2015-11-10	Sirna Therapeutics, Inc.	RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
AU2003216255A1 (en) *	2002-02-20	2003-09-09	Ribozyme Pharmaceuticals, Inc.	RNA INTERFERENCE MEDIATED INHIBITION OF MDR P-GLYCOPROTEIN GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
US7683166B2 (en)	2002-02-20	2010-03-23	Sirna Therapeutics, Inc.	RNA interference mediated inhibition of interleukin and interleukin receptor gene expression using short interfering nucleic acid (siNA)
EP1430157B1 (en) *	2002-02-20	2011-08-10	Sirna Therapeutics, Inc.	RNA INTERFERENCE MEDIATED INHIBITION OF HEPATITIS C VIRUS (HCV) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
BR0308614A (pt)	2002-03-21	2005-02-09	Monsanto Technology Llc	Construções de ácidos nucléicos e processos para a produção de composições oleosas de sementes alteradas
US7166771B2 (en)	2002-06-21	2007-01-23	Monsanto Technology Llc	Coordinated decrease and increase of gene expression of more than one gene using transgenic constructs
US7566813B2 (en)	2002-03-21	2009-07-28	Monsanto Technology, L.L.C.	Nucleic acid constructs and methods for producing altered seed oil compositions
CA2482904A1 (en)	2002-04-18	2003-10-23	Lynkeus Biotech Gmbh	Means and methods for the specific modulation of target genes in the cns and the eye and methods for their identification
US20040180438A1 (en)	2002-04-26	2004-09-16	Pachuk Catherine J.	Methods and compositions for silencing genes without inducing toxicity
EP1546379A4 (en)	2002-05-23	2007-09-26	Ceptyr Inc	MODULATION OF PTP1B SIGNAL TRANSMISSION BY RNA INTERFERENCE
AU2003243541A1 (en) *	2002-06-12	2003-12-31	Ambion, Inc.	Methods and compositions relating to labeled rna molecules that reduce gene expression
US20100075423A1 (en) *	2002-06-12	2010-03-25	Life Technologies Corporation	Methods and compositions relating to polypeptides with rnase iii domains that mediate rna interference
US7655790B2 (en)	2002-07-12	2010-02-02	Sirna Therapeutics, Inc.	Deprotection and purification of oligonucleotides and their derivatives
US7148342B2 (en)	2002-07-24	2006-12-12	The Trustees Of The University Of Pennyslvania	Compositions and methods for sirna inhibition of angiogenesis
US7399851B2 (en)	2002-07-25	2008-07-15	Dana Farber Cancer Institute, Inc.	Composition and method for imaging cells
CA2493364A1 (en)	2002-07-26	2004-02-12	Basf Plant Science Gmbh	Inversion of the negative-selective effect of negative marker proteins using selection methods
ES2389024T3 (es) *	2002-08-05	2012-10-22	Silence Therapeutics Aktiengesellschaft	Moléculas de RNA interferentes de extremos romos
SI2258847T1 (sl)	2002-08-05	2017-08-31	Silence Therapeutics Gmbh	Nadaljnje nove oblike molekul interferenčne RNA
US20050255086A1 (en) *	2002-08-05	2005-11-17	Davidson Beverly L	Nucleic acid silencing of Huntington's Disease gene
US20040023390A1 (en) *	2002-08-05	2004-02-05	Davidson Beverly L.	SiRNA-mediated gene silencing with viral vectors
US20040241854A1 (en)	2002-08-05	2004-12-02	Davidson Beverly L.	siRNA-mediated gene silencing
US20080274989A1 (en)	2002-08-05	2008-11-06	University Of Iowa Research Foundation	Rna Interference Suppression of Neurodegenerative Diseases and Methods of Use Thereof
US20050042646A1 (en) *	2002-08-05	2005-02-24	Davidson Beverly L.	RNA interference suppresion of neurodegenerative diseases and methods of use thereof
EP2278018A3 (en)	2002-08-07	2012-01-04	BASF Plant Science GmbH	Nucleic acid sequences encoding proteins associated with abiotic stress response
US8729036B2 (en)	2002-08-07	2014-05-20	University Of Massachusetts	Compositions for RNA interference and methods of use thereof
US20040029275A1 (en) *	2002-08-10	2004-02-12	David Brown	Methods and compositions for reducing target gene expression using cocktails of siRNAs or constructs expressing siRNAs
DE60328214D1 (de)	2002-08-12	2009-08-13	New England Biolabs Inc	Verfahren und zusammensetzungen in verbindung mit gen-silencing
EP1393742A1 (en)	2002-08-14	2004-03-03	atugen AG	Use of protein kinase N beta
ES2319894T3 (es)	2002-08-14	2009-05-14	Silence Therapeutics Aktiengesellschaft	Uso de la proteina quinasa-n-beta.
JP4754216B2 (ja)	2002-09-04	2011-08-24	ノバルティスアーゲー	ｄｓＲＮＡ投与による神経疾患の処置
US7923547B2 (en)	2002-09-05	2011-04-12	Sirna Therapeutics, Inc.	RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
US20040053289A1 (en) *	2002-09-09	2004-03-18	The Regents Of The University Of California	Short interfering nucleic acid hybrids and methods thereof
US20040242518A1 (en) *	2002-09-28	2004-12-02	Massachusetts Institute Of Technology	Influenza therapeutic
US7122361B2 (en)	2002-10-10	2006-10-17	Wyeth	Compositions employing a novel human kinase
CA2501333A1 (en)	2002-10-18	2004-04-29	Atugen Ag	Factor involved in metastasis and uses thereof
CA2503491A1 (en)	2002-10-24	2004-05-06	Wyeth	Calcineurin-like human phosphoesterase
JP5449639B2 (ja)	2002-11-01	2014-03-19	ザトラスティーズオブザユニバーシティオブペンシルバニア	ＨＩＦ−１アルファのｓｉＲＮＡ阻害に関する組成物及び方法
AU2003295387A1 (en)	2002-11-05	2004-06-03	Isis Parmaceuticals, Inc.	Modified oligonucleotides for use in rna interference
EP1562971B1 (en)	2002-11-05	2014-02-12	Isis Pharmaceuticals, Inc.	Polycyclic sugar surrogate-containing oligomeric compounds and compositions for use in gene modulation
US9150605B2 (en)	2002-11-05	2015-10-06	Isis Pharmaceuticals, Inc.	Compositions comprising alternating 2′-modified nucleosides for use in gene modulation
US9150606B2 (en)	2002-11-05	2015-10-06	Isis Pharmaceuticals, Inc.	Compositions comprising alternating 2'-modified nucleosides for use in gene modulation
CA2504720C (en)	2002-11-05	2013-12-24	Isis Pharmaceuticals, Inc.	Chimeric oligomeric compounds and their use in gene modulation
EP1562635A4 (en) *	2002-11-07	2007-12-19	Chang Lung Ji	MODIFIED DENDRITIC CELLS
US10011836B2 (en)	2002-11-14	2018-07-03	Thermo Fisher Scientific Inc.	Methods and compositions for selecting siRNA of improved functionality
US9228186B2 (en)	2002-11-14	2016-01-05	Thermo Fisher Scientific Inc.	Methods and compositions for selecting siRNA of improved functionality
US9879266B2 (en)	2002-11-14	2018-01-30	Thermo Fisher Scientific Inc.	Methods and compositions for selecting siRNA of improved functionality
WO2006006948A2 (en)	2002-11-14	2006-01-19	Dharmacon, Inc.	METHODS AND COMPOSITIONS FOR SELECTING siRNA OF IMPROVED FUNCTIONALITY
US9771586B2 (en)	2002-11-14	2017-09-26	Thermo Fisher Scientific Inc.	RNAi targeting ZNF205
US9839649B2 (en)	2002-11-14	2017-12-12	Thermo Fisher Scientific Inc.	Methods and compositions for selecting siRNA of improved functionality
US9719094B2 (en)	2002-11-14	2017-08-01	Thermo Fisher Scientific Inc.	RNAi targeting SEC61G
US9719092B2 (en)	2002-11-14	2017-08-01	Thermo Fisher Scientific Inc.	RNAi targeting CNTD2
JP2006514554A (ja)	2002-11-21	2006-05-11	ワイス	腎細胞癌および他の固形腫瘍の診断法
JP4526228B2 (ja) *	2002-11-22	2010-08-18	隆森田	ＲＮＡｉによる新規治療法および治療剤
US7297525B2 (en)	2002-11-27	2007-11-20	Wyeth	Composition employing a novel human kinase
CA2513623A1 (en)	2003-01-16	2004-08-05	The Trustees Of The University Of Pennsylvania	Compositions and methods for sirna inhibition of icam-1
CA2516138A1 (en)	2003-02-14	2004-09-02	Sagres Discovery, Inc.	Therapeutic gpcr targets in cancer
WO2004080406A2 (en)	2003-03-07	2004-09-23	Alnylam Pharmaceuticals	Therapeutic compositions
DK1606406T4 (da)	2003-03-21	2013-12-16	Santaris Pharma As	Short Interfering RNA (siRNA) Analogues
CA2521464C (en)	2003-04-09	2013-02-05	Alnylam Pharmaceuticals, Inc.	Irna conjugates
WO2005014828A2 (en)	2003-08-01	2005-02-17	Basf Plant Science Gmbh	Process for the production of fine chemicals in plants
US20090298914A1 (en) *	2003-04-15	2009-12-03	Sirna Therapeutics, Inc.	RNA Interference Mediated Inhibition of Severe Acute Respiratory Syndrome (SARS) Virus Gene Expression Using Short Interfering Nucleic Acid (siNA)
US20070270360A1 (en) *	2003-04-15	2007-11-22	Sirna Therapeutics, Inc.	Rna Interference Mediated Inhibition of Severe Acute Respiratory Syndrome (Sars) Gene Expression Using Short Interfering Nucleic Acid
US7723509B2 (en)	2003-04-17	2010-05-25	Alnylam Pharmaceuticals	IRNA agents with biocleavable tethers
US8796436B2 (en)	2003-04-17	2014-08-05	Alnylam Pharmaceuticals, Inc.	Modified iRNA agents
US8017762B2 (en)	2003-04-17	2011-09-13	Alnylam Pharmaceuticals, Inc.	Modified iRNA agents
US7851615B2 (en)	2003-04-17	2010-12-14	Alnylam Pharmaceuticals, Inc.	Lipophilic conjugated iRNA agents
JP4991288B2 (ja)	2003-04-17	2012-08-01	アルナイラムファーマシューティカルズ，インコーポレイテッド	二本鎖ｉＲＮＡ剤、および二本鎖ｉＲＮＡ剤の対合の安定性を調節する方法。
CA2522637C (en)	2003-04-17	2014-01-21	Alnylam Pharmaceuticals, Inc.	Modified irna agents
EP1615943A4 (en)	2003-04-18	2006-08-16	Univ Pennsylvania	COMPOSITION AND METHOD FOR SIRNA INHIBITION OF ANGIOPOIETIN 1 AND 2 AND THEIR RECIPIENTS TIE2
BRPI0410886A (pt)	2003-06-03	2006-07-04	Isis Pharmaceuticals Inc	composto de filamento duplo, composição farmacêutica, sal farmaceuticamente aceitável, métodos de modificação do ácido nucleico que codifica a survivina humana, de inibição da expressão da suvivina em células ou tecidos, e de tratamento de uma condição associada com a expressão ou superexpressão da suvivina, e, oligonucleotìdeo de rnai de filamento único
US7595306B2 (en)	2003-06-09	2009-09-29	Alnylam Pharmaceuticals Inc	Method of treating neurodegenerative disease
DK3604537T3 (da)	2003-06-13	2022-02-28	Alnylam Europe Ag	Dobbeltstrenget ribonukleinsyre med forøget effektivitet i en organisme
AU2004252559B2 (en) *	2003-06-25	2010-07-29	Gencia Corporation	Modified vectors for organelle transfection
CA2528963A1 (en) *	2003-06-27	2005-01-13	Sirna Therapeutics, Inc.	Rna interference mediated treatment of alzheimer's disease using short interfering nucleic acid (sina)
WO2005007859A2 (en) *	2003-07-11	2005-01-27	Sirna Therapeutics, Inc.	RNA INTERFERENCE MEDIATED INHIBITION OF ACETYL-COA CARBOXYLASE GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
WO2005021749A1 (en)	2003-08-28	2005-03-10	Novartis Ag	Interfering rna duplex having blunt-ends and 3’-modifications
US20070202505A1 (en) *	2003-09-08	2007-08-30	Alex Chenchik	Methods for gene function analysis
WO2005045037A2 (en) *	2003-10-23	2005-05-19	Sirna Therapeutics, Inc.	RNA INTERFERENCE MEDIATED INHIBITION OF 5-ALPHA REDUCTASE AND ANDROGEN RECEPTOR GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
ATE503014T1 (de) *	2003-11-04	2011-04-15	Geron Corp	Rna-amidate und thioamidateur rnai
WO2005054494A2 (en) *	2003-11-26	2005-06-16	University Of Massachusetts	Sequence-specific inhibition of small rna function
CN1922332B (zh)	2003-12-31	2013-06-12	宾夕法尼亚州研究基金会	预测并克服对卵巢癌化疗的抗性的方法及预测结肠癌发生的方法
WO2005072057A2 (en)	2004-01-30	2005-08-11	Quark Biotech, Inc.	Oligoribonucleotides and methods of use thereof for treatment of fibrotic conditions and other diseases
US20080249039A1 (en) *	2004-01-30	2008-10-09	Santaris Pharma A/S	Modified Short Interfering Rna (Modified Sirna)
US20090280567A1 (en) *	2004-02-06	2009-11-12	Dharmacon, Inc.	Stabilized sirnas as transfection controls and silencing reagents
AU2005213464A1 (en)	2004-02-06	2005-08-25	Wyeth	Diagnosis and therapeutics for cancer
DE602005017362D1 (de) *	2004-02-06	2009-12-10	Dharmacon Inc	Stabilisierte rnas als transfektionskontrollen und silencing-reagentien
ATE452188T1 (de)	2004-02-10	2010-01-15	Sirna Therapeutics Inc	Rna-interferenz-vermittelte hemmung der genexpression unter verwendung multifunktioneller sina (short interfering nucleic acid)
WO2005078848A2 (en)	2004-02-11	2005-08-25	University Of Tennessee Research Foundation	Inhibition of tumor growth and invasion by anti-matrix metalloproteinase dnazymes
WO2005082415A2 (en)	2004-02-25	2005-09-09	Dana Farber Cancer Institute, Inc.	Inhibitors of insulin-like growth factor receptor-1 for inhibiting tumor cell growth
EP2636739B1 (en)	2004-03-12	2014-12-10	Alnylam Pharmaceuticals Inc.	iRNA agents targeting VEGF
KR101147147B1 (ko) *	2004-04-01	2012-05-25	머크 샤프 앤드 돔 코포레이션	Ｒｎａ 간섭의 오프 타겟 효과 감소를 위한 변형된폴리뉴클레오타이드
EP2394662B1 (en)	2004-04-02	2018-03-21	The Regents of The University of California	Methods and compositions for treating and preventing disease associated with alpha v beta 5 integrin
AU2005238034A1 (en)	2004-04-23	2005-11-10	The Trustees Of Columbia University In The City Of New York	Inhibition of hairless protein mRNA
DE102004025881A1 (de)	2004-05-19	2006-01-05	Beiersdorf Ag	Oligoribonukleotide zur Beeinflussung des Haarwachstums
US10508277B2 (en)	2004-05-24	2019-12-17	Sirna Therapeutics, Inc.	Chemically modified multifunctional short interfering nucleic acid molecules that mediate RNA interference
CA2572450A1 (en)	2004-05-28	2005-12-15	Ambion, Inc.	Methods and compositions involving microrna
US8394947B2 (en)	2004-06-03	2013-03-12	Isis Pharmaceuticals, Inc.	Positionally modified siRNA constructs
EP1602926A1 (en)	2004-06-04	2005-12-07	University of Geneva	Novel means and methods for the treatment of hearing loss and phantom hearing
US20060040876A1 (en) *	2004-06-10	2006-02-23	Rong-Hwa Lin	Modulation of peroxisome proliferator-activated receptors
EP1758999B1 (en)	2004-06-22	2011-03-09	The Board Of Trustees Of The University Of Illinois	METHODS OF INHIBITING TUMOR CELL PROLIFERATION WITH FOXM1 siRNA
CA2559760A1 (en)	2004-07-02	2006-07-06	Metanomics Gmbh	Process for the production of fine chemicals
AU2005259799A1 (en)	2004-07-02	2006-01-12	Protiva Biotherapeutics, Inc.	Immunostimulatory siRNA molecules and uses therefor
US7968762B2 (en)	2004-07-13	2011-06-28	Van Andel Research Institute	Immune-compromised transgenic mice expressing human hepatocyte growth factor (hHGF)
US20060024677A1 (en)	2004-07-20	2006-02-02	Morris David W	Novel therapeutic targets in cancer
US20100132058A1 (en)	2004-07-23	2010-05-27	Diatchenko Luda B	Methods and materials for determining pain sensitivity and predicting and treating related disorders
EP2166103B1 (en)	2004-08-02	2013-05-22	BASF Plant Science GmbH	Method for isolation of transcription termination sequences
US7846438B2 (en)	2004-08-03	2010-12-07	Biogen Idec Ma Inc.	Methods of promoting neurite outgrowth with soluble TAJ polypeptides
CA2576233C (en)	2004-08-10	2016-03-15	Alnylam Pharmaceuticals, Inc.	Conjugate comprising an antagomir and a ligand
EA012799B1 (ru)	2004-08-16	2009-12-30	Кварк Фармасьютикалс, Инк.	Терапевтические применения ингибиторов rtp801
CA2577036A1 (en) *	2004-08-18	2006-02-23	Genesense Technologies Inc.	Small interfering rna molecules against ribonucleotide reductase and uses thereof
US7884086B2 (en)	2004-09-08	2011-02-08	Isis Pharmaceuticals, Inc.	Conjugates for use in hepatocyte free uptake assays
EP1793835A4 (en)	2004-09-10	2010-12-01	Somagenics Inc	SMALL INTERFERING RNA EFFECTIVELY INHIBITING VIRAL GENE EXPRESSION AND METHODS OF USE THEREOF
AU2005286427B2 (en)	2004-09-24	2011-09-15	Basf Plant Science Gmbh	Plant cells and plants with increased tolerance to environmental stress
KR101357016B1 (ko)	2004-09-28	2014-02-03	쿠아크 파마수티칼스 인코퍼레이티드	탈모증, 급성신부전증 및 다른 질환의 치료를 위한올리고리보뉴클레오티드 및 그것의 사용방법
EP2163632A1 (en)	2004-10-05	2010-03-17	SunGene GmbH	Constitutive expression cassettes for regulation of plant expression
US7576261B2 (en)	2004-10-13	2009-08-18	University Of Georgia Research Foundation, Inc.	Nematode resistant transgenic plants
US9492400B2 (en)	2004-11-04	2016-11-15	Massachusetts Institute Of Technology	Coated controlled release polymer particles as efficient oral delivery vehicles for biopharmaceuticals
EP1655364A3 (en)	2004-11-05	2006-08-02	BASF Plant Science GmbH	Expression cassettes for seed-preferential expression in plants
EP2281888B1 (en)	2004-11-12	2015-01-07	Asuragen, Inc.	Methods and compositions involving miRNA and miRNA inhibitor molecules
US7923207B2 (en)	2004-11-22	2011-04-12	Dharmacon, Inc.	Apparatus and system having dry gene silencing pools
US20060166234A1 (en) *	2004-11-22	2006-07-27	Barbara Robertson	Apparatus and system having dry control gene silencing compositions
US7935811B2 (en) *	2004-11-22	2011-05-03	Dharmacon, Inc.	Apparatus and system having dry gene silencing compositions
EP2163631B1 (en)	2004-11-25	2013-05-22	SunGene GmbH	Expression cassettes for guard cell-preferential expression in plants
EP1666599A3 (en)	2004-12-04	2006-07-12	SunGene GmbH	Expression cassettes for mesophyll- and/or epidermis-preferential expression in plants
EP2072620B1 (en)	2004-12-08	2013-05-08	SunGene GmbH	Expression casstettes for vascular tissue-preferential expression in plants
EP1669456A3 (en)	2004-12-11	2006-07-12	SunGene GmbH	Expression cassettes for meristem-preferential expression in plants
CA2585798A1 (en)	2004-12-17	2006-06-17	Metanomics Gmbh	Process for the control of production of fine chemicals
US20060142228A1 (en) *	2004-12-23	2006-06-29	Ambion, Inc.	Methods and compositions concerning siRNA's as mediators of RNA interference
TWI386225B (zh)	2004-12-23	2013-02-21	Alcon Inc	用於治療眼睛病症的結締組織生長因子（ＣＴＧＦ）ＲＮＡ干擾（ＲＮＡｉ）抑制技術
BRPI0519468A2 (pt)	2004-12-27	2009-01-27	Silence Therapeutics Ag	complexos de lipÍdeos revestido e seu uso
US20090005332A1 (en) *	2004-12-30	2009-01-01	Hauser Todd M	Compositions and Methods for Modulating Gene Expression Using Self-Protected Oligonucleotides
WO2006072887A1 (en)	2005-01-05	2006-07-13	Eyegate Pharma Sa	Ocular iontophoresis device for delivering sirna and aptamers
DE602006013275D1 (de)	2005-01-07	2010-05-12	Diadexus Inc	Ovr110-antikörperzusammensetzungen und verwendungsverfahren dafür
TW200639253A (en)	2005-02-01	2006-11-16	Alcon Inc	RNAi-mediated inhibition of ocular targets
EP2147977A1 (en)	2005-02-09	2010-01-27	BASF Plant Science GmbH	Expression cassettes for regulation of expression in monocotyledonous plants
CA2598307C (en)	2005-02-26	2014-12-30	Basf Plant Science Gmbh	Expression cassettes for seed-preferential expression in plants
US8084625B2 (en)	2005-03-03	2011-12-27	Wako Pure Chemical Industries, Ltd.	Crosslinking agent, crosslinking method, method of controlling gene expression, and method of examining gene function
CN102925479A (zh)	2005-03-08	2013-02-13	巴斯福植物科学有限公司	增强表达的内含子序列
AU2006223131A1 (en)	2005-03-11	2006-09-21	Alcon, Inc.	RNAi-mediated inhibition of frizzled related protein-1 for treatment of glaucoma
US20060223777A1 (en) *	2005-03-29	2006-10-05	Dharmacon, Inc.	Highly functional short hairpin RNA
TWI335352B (en)	2005-03-31	2011-01-01	Calando Pharmaceuticals Inc	Inhibitors of ribonucleotide reductase subunit 2 and uses thereof
JP2008535857A (ja)	2005-04-07	2008-09-04	ノバルティスヴァクシンズアンドダイアグノスティクスインコーポレイテッド	癌の診断、検出および処置におけるｃａｃｎａ１ｅ
WO2006110585A2 (en)	2005-04-07	2006-10-19	Novartis Vaccines And Diagnostics Inc.	Cancer-related genes (prlr)
US20090203055A1 (en) *	2005-04-18	2009-08-13	Massachusetts Institute Of Technology	Compositions and methods for RNA interference with sialidase expression and uses thereof
JP4967137B2 (ja) *	2005-04-18	2012-07-04	国立大学法人浜松医科大学	癌治療用組成物
WO2006120197A2 (en)	2005-05-10	2006-11-16	Basf Plant Science Gmbh	Expression cassettes for seed-preferential expression in plants
WO2006124699A2 (en)	2005-05-12	2006-11-23	Wisconsin Alumni Research Foundation	Blockade of pin1 prevents cytokine production by activated immune cells
FR2885808B1 (fr)	2005-05-19	2007-07-06	Oreal	Vectorisation de dsrna par des particules cationiques et utilisation topique.
DE602006019588D1 (de)	2005-06-23	2011-02-24	Basf Plant Science Gmbh	Verbesserte verfahren zur herstellung stabil transformierter und fruchtbarer buntmais-pflanzen
WO2007011702A2 (en)	2005-07-15	2007-01-25	The University Of North Carolina At Chapel Hill	Use of egfr inhibitors to prevent or treat obesity
EP1764107A1 (en) *	2005-09-14	2007-03-21	Gunther Hartmann	Compositions comprising immunostimulatory RNA oligonucleotides and methods for producing said RNA oligonucleotides
WO2007039454A1 (en)	2005-09-20	2007-04-12	Basf Plant Science Gmbh	Methods for controlling gene expression using ta-siran
EP1934348B1 (en)	2005-10-11	2018-05-02	Ben-Gurion University Of The Negev Research And Development Authority	Compositions for silencing the expression of vdac1 and uses thereof
EP1941059A4 (en)	2005-10-28	2010-11-03	Alnylam Pharmaceuticals Inc	COMPOSITIONS AND METHODS FOR INHIBITING THE EXPRESSION OF THE HUNTINGTIN GENE
WO2007051303A1 (en)	2005-11-02	2007-05-10	Protiva Biotherapeutics, Inc.	MODIFIED siRNA MOLECULES AND USES THEREOF
AU2006311725B2 (en)	2005-11-04	2011-11-24	Alnylam Pharmaceuticals, Inc.	Compositions and methods for inhibiting expression of NAV1.8 gene
AU2006311089C1 (en)	2005-11-08	2012-11-08	Basf Plant Science Gmbh	Use of armadillo repeat (ARM1) polynucleotides for obtaining pathogen resistance in plants
EP1945270B1 (en)	2005-11-09	2011-05-25	Alnylam Pharmaceuticals Inc.	Compositions and methods for inhibiting expression of factor v leiden mutant gene
DK2463388T3 (en)	2005-11-29	2018-02-26	Cambridge Entpr Ltd	Markers for breast cancer
WO2007070682A2 (en)	2005-12-15	2007-06-21	Massachusetts Institute Of Technology	System for screening particles
CA2646833C (en)	2005-12-30	2019-07-30	Evonik Roehm Gmbh	Peptides useful as cell-penetrating peptides
EP1974041A2 (en)	2006-01-06	2008-10-01	University Of Georgia Research Foundation, Inc.	Cyst nematode resistant transgenic plants
EP1979484B1 (en)	2006-01-12	2014-03-19	BASF Plant Science GmbH	Use of stomatin (stm1) polynucleotides for achieving a pathogen resistance in plants
US7825099B2 (en)	2006-01-20	2010-11-02	Quark Pharmaceuticals, Inc.	Treatment or prevention of oto-pathologies by inhibition of pro-apoptotic genes
UY30097A1 (es)	2006-01-20	2007-08-31	Atugen Ag	Usos terapeuticos de inhibidores de rtp801
CA2638837A1 (en) *	2006-01-27	2007-08-02	Santaris Pharma A/S	Lna modified phosphorothiolated oligonucleotides
US8669345B2 (en)	2006-01-27	2014-03-11	Biogen Idec Ma Inc.	Nogo receptor antagonists
CN101421406B (zh)	2006-02-13	2016-08-31	孟山都技术有限公司	用于产生改变的种子油组成的核酸构建体和方法
US7910566B2 (en)	2006-03-09	2011-03-22	Quark Pharmaceuticals Inc.	Prevention and treatment of acute renal failure and other kidney diseases by inhibition of p53 by siRNA
EA015563B1 (ru)	2006-03-23	2011-08-30	Сантарис Фарма А/С	Короткая внутренне сегментированная интерферирующая рнк
FR2898908A1 (fr)	2006-03-24	2007-09-28	Agronomique Inst Nat Rech	Procede de preparation de cellules aviaires differenciees et genes impliques dans le maintien de la pluripotence
US8968702B2 (en)	2006-03-30	2015-03-03	Duke University	Inhibition of HIF-1 activation for anti-tumor and anti-inflammatory responses
JP5704741B2 (ja)	2006-03-31	2015-04-22	アルナイラムファーマシューティカルズ，インコーポレイテッドＡｌｎｙｌａｍＰｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ．	Ｅｇ５遺伝子発現の抑制のための組成物および方法
WO2008034648A1 (en)	2006-04-05	2008-03-27	Metanomics Gmbh	Process for the production of a fine chemical
KR20090010194A (ko)	2006-04-13	2009-01-29	노바티스 백신즈 앤드 다이아그노스틱스, 인크.	암의 치료, 진단 또는 검출 방법
US7691824B2 (en)	2006-04-28	2010-04-06	Alnylam Pharmaceuticals, Inc.	Compositions and methods for inhibiting expression of a gene from the JC virus
GB0608838D0 (en)	2006-05-04	2006-06-14	Novartis Ag	Organic compounds
EP2584047B1 (en)	2006-05-11	2014-11-19	Alnylam Pharmaceuticals Inc.	Compositions and methods for inhibiting expression of the PCSK9 gene
CA2652280C (en)	2006-05-15	2014-01-28	Massachusetts Institute Of Technology	Polymers for functional particles
CN101489566B (zh)	2006-05-19	2012-04-18	阿尔尼拉姆医药品有限公司	Aha基因的RNAi调控及其治疗性应用
WO2007137220A2 (en)	2006-05-22	2007-11-29	Alnylam Pharmaceuticals, Inc.	Compositions and methods for inhibiting expression of ikk-b gene
EP2026843A4 (en)	2006-06-09	2011-06-22	Quark Pharmaceuticals Inc	THERAPEUTIC USES OF RTP801L INHIBITORS
US7915399B2 (en)	2006-06-09	2011-03-29	Protiva Biotherapeutics, Inc.	Modified siRNA molecules and uses thereof
WO2007150030A2 (en)	2006-06-23	2007-12-27	Massachusetts Institute Of Technology	Microfluidic synthesis of organic nanoparticles
WO2008054561A2 (en)	2006-07-11	2008-05-08	University Of Medicine And Dentistry Of New Jersey	Proteins, nucleic acids encoding the same and associated methods of use
RU2553561C2 (ru)	2006-07-21	2015-06-20	Сайленс Терапьютикс Аг	Средства ингибирования экспрессии протеинкиназы 3
WO2008014426A2 (en)	2006-07-28	2008-01-31	Children's Memorial Hospital	Methods of inhibiting tumor cell aggressiveness using the microenvironment of human embryonic stem cells
US7872118B2 (en)	2006-09-08	2011-01-18	Opko Ophthalmics, Llc	siRNA and methods of manufacture
WO2008036638A2 (en)	2006-09-18	2008-03-27	Alnylam Pharmaceuticals, Inc.	Rnai modulation of scap and therapeutic uses thereof
US20090209478A1 (en)	2006-09-21	2009-08-20	Tomoko Nakayama	Compositions and methods for inhibiting expression of the hamp gene
US8809514B2 (en) *	2006-09-22	2014-08-19	Ge Healthcare Dharmacon, Inc.	Tripartite oligonucleotide complexes and methods for gene silencing by RNA interference
JP2010507387A (ja)	2006-10-25	2010-03-11	クアーク・ファーマスーティカルス、インコーポレイテッド	新規のｓｉＲＮＡおよびその使用方法
ATE508191T1 (de) *	2006-11-01	2011-05-15	Medical Res And Infrastructure Fund Of The Tel Aviv Sourasky Medical Ct	Adipozytenspezifische konstrukte und verfahren zur hemmung der expression von blutplättchen-typ- 12-lipoxygenase
US20080199475A1 (en)	2006-11-27	2008-08-21	Patrys Limited	Novel glycosylated peptide target in neoplastic cells
WO2008067283A2 (en)	2006-11-27	2008-06-05	Diadexus, Inc.	Ovr110 antibody compositions and methods of use
EP2097448A4 (en)	2006-12-22	2010-07-21	Univ Utah Res Found	PROCEDURE FOR THE EVIDENCE OF EYE DISEASES AND SUFFERINGS AND THEIR TREATMENT
EP2057273A2 (en)	2007-01-15	2009-05-13	BASF Plant Science GmbH	Use of subtilisin (rnr9) polynucleotides for achieving a pathogen resistance in plants
JP2010516786A (ja)	2007-01-26	2010-05-20	ユニバーシティーオブルイヴィルリサーチファウンデーション，インコーポレーテッド	ワクチンとしての使用のためのエキソソーム成分の改変
WO2008098165A2 (en)	2007-02-09	2008-08-14	Massachusetts Institute Of Technology	Oscillating cell culture bioreactor
WO2008099013A1 (en)	2007-02-16	2008-08-21	Basf Plant Science Gmbh	Nucleic acid sequences for regulation of embryo-specific expression in monocotyledonous plants
JP2010518880A (ja)	2007-02-26	2010-06-03	クアーク・ファーマスーティカルス、インコーポレイテッド	Ｒｔｐ８０１のインヒビター及びその疾患の治療における使用
US8846005B2 (en)	2007-03-14	2014-09-30	Novartis Ag	APCDD1 inhibitors for treating, diagnosing or detecting cancer
PT2129680E (pt)	2007-03-21	2015-08-28	Brookhaven Science Ass Llc	Composições combinadas de gancho de cabelo e antissentido e métodos para modulação da expressão
US7812002B2 (en)	2007-03-21	2010-10-12	Quark Pharmaceuticals, Inc.	Oligoribonucleotide inhibitors of NRF2 and methods of use thereof for treatment of cancer
PE20090064A1 (es)	2007-03-26	2009-03-02	Novartis Ag	Acido ribonucleico de doble cadena para inhibir la expresion del gen e6ap humano y composicion farmaceutica que lo comprende
US7759320B2 (en)	2007-03-29	2010-07-20	Alnylam Pharmaceuticals, Inc.	Compositions and methods for inhibiting expression of a gene from the Ebola
JP2010523595A (ja)	2007-04-04	2010-07-15	マサチューセッツインスティテュートオブテクノロジー	ポリ（アミノ酸）ターゲッティング部分
JP5744513B2 (ja)	2007-04-17	2015-07-08	バクスター・インターナショナル・インコーポレイテッドＢａｘｔｅｒＩｎｔｅｒｎａｔｉｏｎａｌＩｎｃｏｒｐ０Ｒａｔｅｄ	肺送達のための核酸微小粒子
WO2009014565A2 (en)	2007-04-26	2009-01-29	Ludwig Institute For Cancer Research, Ltd.	Methods for diagnosing and treating astrocytomas
US20100291042A1 (en)	2007-05-03	2010-11-18	The Brigham And Women's Hospital, Inc.	Multipotent stem cells and uses thereof
JP5296328B2 (ja)	2007-05-09	2013-09-25	独立行政法人理化学研究所	１本鎖環状ｒｎａおよびその製造方法
MX2009012568A (es)	2007-05-22	2009-12-08	Mdrna Inc	Oligonucleotidos de acido ribonucleico sustituidos con hidroximetilo y complejos de acido ribonucleico.
AR066642A1 (es)	2007-05-22	2009-09-02	Basf Plant Gmbh	Celulas vegetales y plantas con mayor tolerancia y/o resistencia al estres ambiental y mayor produccion de biomasa producidas por silenciamiento de genes
US8097422B2 (en)	2007-06-20	2012-01-17	Salk Institute For Biological Studies	Kir channel modulators
HRP20140522T1 (hr)	2007-06-27	2014-08-15	Quark Pharmaceuticals, Inc.	Pripravci i metode za inhibiranje izražaja proapoptotiäśkih gena
CN101688206B (zh)	2007-07-05	2013-05-15	诺瓦提斯公司	用于治疗病毒感染的dsRNA
US9689031B2 (en)	2007-07-14	2017-06-27	Ionian Technologies, Inc.	Nicking and extension amplification reaction for the exponential amplification of nucleic acids
WO2009012263A2 (en)	2007-07-18	2009-01-22	The Trustees Of Columbia University In The City Of New York	Tissue-specific micrornas and compositions and uses thereof
EP2185719B1 (en)	2007-08-02	2013-11-13	NovImmune SA	Anti-rantes antibodies and methods of use thereof
CN102316888A (zh)	2007-08-23	2012-01-11	利兰斯坦福青年大学托管委员会	突触发生的调控
WO2009033027A2 (en)	2007-09-05	2009-03-12	Medtronic, Inc.	Suppression of scn9a gene expression and/or function for the treatment of pain
US8361714B2 (en)	2007-09-14	2013-01-29	Asuragen, Inc.	Micrornas differentially expressed in cervical cancer and uses thereof
US20100286241A1 (en) *	2007-09-18	2010-11-11	Intradigm Corporation	Compositions comprising k-ras sirna and methods of use
US20100280097A1 (en) *	2007-09-18	2010-11-04	Intradigm Corporation	Compositions comprising hif-1 alpha sirna and methods of use thereof
DK2195428T3 (en)	2007-09-19	2014-03-03	Applied Biosystems Llc	SIRNA SEQUENCE-INDEPENDENT MODIFICATION FORMS TO REDUCE TARGET-FAILING PHENOTYPIC EFFECTS OF RNAI, AND STABILIZED FORMS THEREOF
DK2644192T3 (en)	2007-09-28	2017-06-26	Pfizer	Cancer cell targeting using nanoparticles
CA2701845A1 (en)	2007-10-03	2009-04-09	Quark Pharmaceuticals, Inc.	Novel sirna structures
EP2394657A1 (en)	2007-10-12	2011-12-14	Massachusetts Institute Of Technology	Vaccine nanotechnology
US8097712B2 (en)	2007-11-07	2012-01-17	Beelogics Inc.	Compositions for conferring tolerance to viral disease in social insects, and the use thereof
CA2930393C (en)	2007-12-04	2022-11-29	Alnylam Pharmaceuticals, Inc.	Carbohydrate conjugates as delivery agents for oligonucleotides
AU2008335202A1 (en)	2007-12-10	2009-06-18	Alnylam Pharmaceuticals, Inc.	Compositions and methods for inhibiting expression of Factor VII gene
US20100204305A1 (en) *	2007-12-11	2010-08-12	Lorus Therapeutics Inc.	Small interfering rna molecules against ribonucleotide reductase and uses thereof
US8614311B2 (en)	2007-12-12	2013-12-24	Quark Pharmaceuticals, Inc.	RTP801L siRNA compounds and methods of use thereof
DE112008003433T5 (de)	2007-12-21	2010-11-04	Basf Plant Science Gmbh	Pflanzen mit erhöhtem Ertrag (KO NUE)
EP2242854A4 (en) *	2008-01-15	2012-08-15	Quark Pharmaceuticals Inc	COMPOUNDS AND USES THEREOF
US8188060B2 (en)	2008-02-11	2012-05-29	Dharmacon, Inc.	Duplex oligonucleotides with enhanced functionality in gene regulation
JP5697993B2 (ja)	2008-02-11	2015-04-08	アールエックスアイファーマシューティカルズコーポレーション	修飾ＲＮＡｉポリヌクレオチドおよびその使用
KR101397407B1 (ko)	2008-03-05	2014-06-19	알닐람 파마슈티칼스 인코포레이티드	Ｅｇ5 및 ＶＥＧＦ 유전자의 발현을 억제하기 위한 조성물 및 방법
CA2717496A1 (en) *	2008-03-12	2009-09-17	Intradigm Corporation	Compositions comprising notch1 sirna and methods of use thereof
CA2720473A1 (en)	2008-04-04	2009-10-08	Calando Pharmaceuticals, Inc.	Compositions and use of epas1 inhibitors
AU2009234266B2 (en)	2008-04-11	2015-08-06	Tekmira Pharmaceuticals Corporation	Site-specific delivery of nucleic acids by combining targeting ligands with endosomolytic components
US8278287B2 (en)	2008-04-15	2012-10-02	Quark Pharmaceuticals Inc.	siRNA compounds for inhibiting NRF2
GB0807018D0 (en)	2008-04-17	2008-05-21	Fusion Antibodies Ltd	Antibodies and treatment
EP2285960B1 (en)	2008-05-08	2015-07-08	Asuragen, INC.	Compositions and methods related to mir-184 modulation of neovascularization or angiogenesis
EP2293800B1 (en) *	2008-06-06	2016-10-05	Quark Pharmaceuticals, Inc.	Compositions and methods for treatment of ear disorders
TWI455944B (zh)	2008-07-01	2014-10-11	Daiichi Sankyo Co Ltd	雙股多核苷酸
WO2010008582A2 (en)	2008-07-18	2010-01-21	Rxi Pharmaceuticals Corporation	Phagocytic cell drug delivery system
WO2011011027A1 (en)	2009-07-20	2011-01-27	Bristol-Myers Squibb Company	Combination of anti-ctla4 antibody with diverse therapeutic regimens for the synergistic treatment of proliferative diseases
WO2010021718A1 (en)	2008-08-19	2010-02-25	Nektar Therapeutics	Complexes of small-interfering nucleic acids
WO2010028054A1 (en)	2008-09-02	2010-03-11	Alnylam Europe Ag.	Compositions and methods for inhibiting expression of mutant egfr gene
WO2011028218A1 (en)	2009-09-02	2011-03-10	Alnylam Pharmaceuticals, Inc.	Process for triphosphate oligonucleotide synthesis
EP2165710A1 (en)	2008-09-19	2010-03-24	Institut Curie	Tyrosine kinase receptor Tyro3 as a therapeutic target in the treatment of a bladder tumor
JP2012502991A (ja)	2008-09-22	2012-02-02	アールエックスアイファーマシューティカルズコーポレーション	皮膚適用におけるｒｎａ干渉
CA2737661C (en)	2008-09-23	2019-08-20	Alnylam Pharmaceuticals, Inc.	Chemical modifications of monomers and oligonucleotides with cycloaddition
AU2009296395A1 (en)	2008-09-25	2010-04-01	Alnylam Pharmaceuticals, Inc.	Lipid formulated compositions and methods for inhibiting expression of Serum Amyloid A gene
UY32145A (es)	2008-09-29	2010-04-30	Monsanto Technology Llc	Evento transgénico de soja mon87705 y métodos para detectar el mismo
US8343497B2 (en)	2008-10-12	2013-01-01	The Brigham And Women's Hospital, Inc.	Targeting of antigen presenting cells with immunonanotherapeutics
US8343498B2 (en)	2008-10-12	2013-01-01	Massachusetts Institute Of Technology	Adjuvant incorporation in immunonanotherapeutics
US8591905B2 (en)	2008-10-12	2013-11-26	The Brigham And Women's Hospital, Inc.	Nicotine immunonanotherapeutics
US8277812B2 (en)	2008-10-12	2012-10-02	Massachusetts Institute Of Technology	Immunonanotherapeutics that provide IgG humoral response without T-cell antigen
WO2010045384A2 (en)	2008-10-15	2010-04-22	Somagenics Inc.	Short hairpin rnas for inhibition of gene expression
IL302142B2 (en)	2008-10-20	2024-07-01	Alnylam Pharmaceuticals Inc	Compounds and methods for inhibiting transthyretin expression
US9289475B2 (en)	2008-11-06	2016-03-22	The Johns Hopkins University	Treatment of chronic inflammatory respiratory disorders
US8735082B2 (en)	2008-11-10	2014-05-27	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Gene signature for predicting prognosis of patients with solid tumors
CA3033577A1 (en)	2008-11-10	2010-05-14	Arbutus Biopharma Corporation	Novel lipids and compositions for the delivery of therapeutics
WO2010059226A2 (en)	2008-11-19	2010-05-27	Rxi Pharmaceuticals Corporation	Inhibition of map4k4 through rnai
BRPI0922355A8 (pt)	2008-12-03	2017-12-12	Marina Biotech Inc	Ácidos nucléicos, métodos para reduzir a expressão de um gene em uma célula in vitro, uso do ácido nucléico, complexo de rna e uso do complexo de rna
WO2010065834A1 (en)	2008-12-04	2010-06-10	Opko Ophthalmics, Llc	Compositions and methods for selective inhibition of pro-angiogenic vegf isoforms
NZ593618A (en)	2008-12-10	2013-02-22	Alnylam Pharmaceuticals Inc	Gnaq targeted dsrna compositions and methods for inhibiting expression
EP2198879A1 (en)	2008-12-11	2010-06-23	Institut Curie	CD74 modulator agent for regulating dendritic cell migration and device for studying the motility capacity of a cell
WO2010077894A2 (en)	2008-12-16	2010-07-08	Bristol-Myers Squibb Company	Methods of inhibiting quiescent tumor proliferation
WO2010080452A2 (en)	2008-12-18	2010-07-15	Quark Pharmaceuticals, Inc.	siRNA COMPOUNDS AND METHODS OF USE THEREOF
JP2012513464A (ja)	2008-12-23	2012-06-14	ザトラスティーズオブコロンビアユニヴァーシティインザシティオブニューヨーク	ホスホジエステラーゼ阻害剤及びその使用
WO2010074783A1 (en)	2008-12-23	2010-07-01	The Trustees Of Columbia University In The City Of New York	Phosphodiesterase inhibitors and uses thereof
US9493774B2 (en)	2009-01-05	2016-11-15	Rxi Pharmaceuticals Corporation	Inhibition of PCSK9 through RNAi
WO2010090762A1 (en)	2009-02-04	2010-08-12	Rxi Pharmaceuticals Corporation	Rna duplexes with single stranded phosphorothioate nucleotide regions for additional functionality
US20110319476A1 (en) *	2009-02-12	2011-12-29	Opko Curna, Llc	Treatment of glial cell derived neurotrophic factor (gdnf) related diseases by inhibition of natural antisense transcript to gdnf
CN101525388B (zh) *	2009-02-20	2012-02-01	中国人民解放军第四军医大学	特异性双链rna结合蛋白嵌合体及其在病毒感染性疾病中的应用
US20120041051A1 (en)	2009-02-26	2012-02-16	Kevin Fitzgerald	Compositions And Methods For Inhibiting Expression Of MIG-12 Gene
AU2010221419B2 (en)	2009-03-02	2015-10-01	Alnylam Pharmaceuticals, Inc.	Nucleic acid chemical modifications
CA2754043A1 (en)	2009-03-12	2010-09-16	Alnylam Pharmaceuticals, Inc.	Lipid formulated compositions and methods for inhibiting expression of eg5 and vegf genes
US20120035247A1 (en)	2009-03-19	2012-02-09	Merck Sharp & Dohme Corp.	RNA Interference Mediated Inhibition of Signal Transducer and Activator of Transcription 6 (STAT6) Gene Expression Using Short Interfering Nucleic Acid (siNA)
WO2010107955A2 (en)	2009-03-19	2010-09-23	Merck Sharp & Dohme Corp.	RNA INTERFERENCE MEDIATED INHIBITION OF BTB AND CNC HOMOLOGY 1, BASIC LEUCINE ZIPPER TRANSCRIPTION FACTOR 1 (BACH 1) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) SEQUENCE LISTING
US20120029054A1 (en)	2009-03-19	2012-02-02	Merck Sharp & Dohme Corp.	RNA Interference Mediated Inhibition of GATA Binding Protein 3 (GATA3) Gene Expression Using Short Intefering Nucleic Acid (siNA)
WO2010107952A2 (en)	2009-03-19	2010-09-23	Merck Sharp & Dohme Corp.	RNA INTERFERENCE MEDIATED INHIBITION OF CONNECTIVE TISSUE GROWTH FACTOR (CTGF) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
EP2411516A1 (en)	2009-03-27	2012-02-01	Merck Sharp&Dohme Corp.	RNA INTERFERENCE MEDIATED INHIBITION OF APOPTOSIS SIGNAL-REGULATING KINASE 1 (ASK1) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
JP2012521762A (ja)	2009-03-27	2012-09-20	メルク・シャープ・エンド・ドーム・コーポレイション	低分子干渉核酸（ｓｉＮＡ）を用いた神経成長因子β鎖（ＮＧＦβ）遺伝子発現のＲＮＡ干渉媒介性阻害
EP2411520A2 (en)	2009-03-27	2012-02-01	Merck Sharp&Dohme Corp.	RNA INTERFERENCE MEDIATED INHIBITION OF THE THYMIC STROMAL LYMPHOPOIETIN (TSLP) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
MX2011010072A (es)	2009-03-27	2011-10-06	Merck Sharp & Dohme	Inhibicion mediada por interferencia de acido ribonucleico de la expresion del gen de la molecula de adhesion intercelular 1 usando acido nucleico corto de interferencia.
US20120022142A1 (en)	2009-03-27	2012-01-26	Merck Sharp & Dohme Corp.	RNA Interference Mediated Inhibition of Signal Transducer and Activator of Transcription 1 (STAT1) Gene Expression Using Short Interfering Nucleic Acid (siNA)
WO2010118243A2 (en)	2009-04-08	2010-10-14	Genentech, Inc.	Use of il-27 antagonists to treat lupus
US8283332B2 (en)	2009-04-17	2012-10-09	University Of Louisville Research Foundation, Inc.	PFKFB4 inhibitors and methods of using the same
US10519458B2 (en)	2009-04-22	2019-12-31	Basf Plant Science Company Gmbh	Whole seed specific promoter
MX352992B (es)	2009-05-05	2017-12-15	Beeologics Inc	Prevencion y tratamiento de la enfermedad de nosema en abejas.
JP5875976B2 (ja)	2009-06-01	2016-03-02	ヘイロー−バイオアールエヌエーアイセラピューティクス，インコーポレイテッド	多価ｒｎａ干渉のためのポリヌクレオチド、組成物およびそれらの使用方法
EP2258858A1 (en)	2009-06-05	2010-12-08	Universitätsklinikum Freiburg	Transgenic LSD1 animal model for cancer
SMT201800499T1 (it)	2009-06-10	2018-11-09	Arbutus Biopharma Corp	Formulazione lipidica migliorata
NZ597504A (en)	2009-06-15	2013-10-25	Alnylam Pharmaceuticals Inc	Lipid formulated dsrna targeting the pcsk9 gene
US9051567B2 (en)	2009-06-15	2015-06-09	Tekmira Pharmaceuticals Corporation	Methods for increasing efficacy of lipid formulated siRNA
EP2266550A1 (en)	2009-06-15	2010-12-29	Institut Curie	Antagonists of ß-catenin for preventing and/or treating neurodegenerative disorders
AU2010270309A1 (en)	2009-07-10	2012-02-02	Basf Plant Science Company Gmbh	Expression cassettes for endosperm-specific expression in plants
US8871730B2 (en)	2009-07-13	2014-10-28	Somagenics Inc.	Chemical modification of short small hairpin RNAs for inhibition of gene expression
DK2453923T3 (en)	2009-07-14	2016-02-15	Mayo Foundation	Non-covalent peptide-FEED of active agents across the blood brain barrier
CA2767409C (en)	2009-07-24	2018-10-30	The Regents Of The University Of California	Methods and compositions for treating and preventing disease associated with .alpha.v.beta.5 integrin
US20110039789A1 (en) *	2009-08-14	2011-02-17	Institut Curie	Use of Huntingtin Protein for the Diagnosis and the Treatment of Cancer
US9029338B2 (en)	2009-08-14	2015-05-12	Alnylam Pharmaceuticals, Inc.	Lipid formulated compositions and methods for inhibiting expression of a gene from the ebola virus
US8916693B2 (en)	2009-09-17	2014-12-23	Nektar Therapeutics	Monoconjugated chitosans as delivery agents for small interfering nucleic acids
US20150025122A1 (en)	2009-10-12	2015-01-22	Larry J. Smith	Methods and Compositions for Modulating Gene Expression Using Oligonucleotide Based Drugs Administered in vivo or in vitro
US8962584B2 (en)	2009-10-14	2015-02-24	Yissum Research Development Company Of The Hebrew University Of Jerusalem, Ltd.	Compositions for controlling Varroa mites in bees
BR112012012254B1 (pt)	2009-11-23	2020-11-24	Aquabounty Technologies, Inc	Construto de expressao isolado, e, metodos para produzir um peixe femea de finalizaqao de linhagem, para propagar peixes transgenicos com construto de esterilidade materna, e para gerar uma geraqao esteril de peixes
EP2504435B1 (en)	2009-11-26	2019-11-13	Quark Pharmaceuticals, Inc.	Sirna compounds comprising terminal substitutions
EP3002332A3 (en)	2009-12-03	2016-06-29	BASF Plant Science Company GmbH	Expression cassettes for embryo-specific expression in plants
WO2011071860A2 (en)	2009-12-07	2011-06-16	Alnylam Pharmaceuticals, Inc.	Compositions for nucleic acid delivery
CA2785996C (en)	2009-12-07	2021-04-13	The Johns Hopkins University	Sr-bi as a predictor of human female infertility and responsiveness to treatment
EP2510098B1 (en)	2009-12-09	2015-02-11	Quark Pharmaceuticals, Inc.	Methods and compositions for treating diseases, disorders or injury of the cns
KR101692063B1 (ko)	2009-12-09	2017-01-03	닛토덴코 가부시키가이샤	hsp47 발현의 조절
ES2764999T3 (es)	2009-12-10	2020-06-05	Univ Columbia	Activadores de histona acetiltransferasa y usos de los mismos
US10640457B2 (en)	2009-12-10	2020-05-05	The Trustees Of Columbia University In The City Of New York	Histone acetyltransferase activators and uses thereof
WO2011075656A1 (en)	2009-12-18	2011-06-23	The University Of British Columbia	Methods and compositions for delivery of nucleic acids
CN102686729B (zh)	2009-12-18	2015-09-23	箭头研究公司	用于治疗hsf1相关疾病的有机组合物
CA3009891C (en)	2009-12-23	2020-09-15	Novartis Ag	Lipids, lipid compositions, and methods of using them
WO2011084193A1 (en)	2010-01-07	2011-07-14	Quark Pharmaceuticals, Inc.	Oligonucleotide compounds comprising non-nucleotide overhangs
EP2529033B1 (en)	2010-01-26	2017-05-24	National Jewish Health	Methods for risk prediction, diagnosis, prognosis of pulmonary disorders
WO2011094580A2 (en)	2010-01-28	2011-08-04	Alnylam Pharmaceuticals, Inc.	Chelated copper for use in the preparation of conjugated oligonucleotides
US9198972B2 (en)	2010-01-28	2015-12-01	Alnylam Pharmaceuticals, Inc.	Monomers and oligonucleotides comprising cycloaddition adduct(s)
BR112012019902A2 (pt)	2010-02-10	2019-09-24	Novartis Ag	"método e compostos para o crescimento muscular"
CN103200945B (zh)	2010-03-24	2016-07-06	雷克西制药公司	眼部症候中的rna干扰
EP3560503B1 (en)	2010-03-24	2021-11-17	Phio Pharmaceuticals Corp.	Rna interference in dermal and fibrotic indications
US9080171B2 (en)	2010-03-24	2015-07-14	RXi Parmaceuticals Corporation	Reduced size self-delivering RNAi compounds
EP2552460A1 (en)	2010-03-29	2013-02-06	Universite De Strasbourg	Polymers for delivering molecules of interest
WO2011123468A1 (en)	2010-03-29	2011-10-06	Alnylam Pharmaceuticals, Inc.	Sirna therapy for transthyretin (ttr) related ocular amyloidosis
US9102938B2 (en)	2010-04-01	2015-08-11	Alnylam Pharmaceuticals, Inc.	2′ and 5′ modified monomers and oligonucleotides
JP2013523162A (ja)	2010-04-06	2013-06-17	アルナイラムファーマシューティカルズ，インコーポレイテッド	Ｃｄ２７４／ｐｄ−ｌ１遺伝子の発現を阻害するための組成物および方法
WO2011133931A1 (en)	2010-04-22	2011-10-27	Genentech, Inc.	Use of il-27 antagonists for treating inflammatory bowel disease
WO2011133871A2 (en)	2010-04-22	2011-10-27	Alnylam Pharmaceuticals, Inc.	5'-end derivatives
WO2011133876A2 (en)	2010-04-22	2011-10-27	Alnylam Pharmaceuticals, Inc.	Oligonucleotides comprising acyclic and abasic nucleosides and analogs
US20130260460A1 (en)	2010-04-22	2013-10-03	Isis Pharmaceuticals Inc	Conformationally restricted dinucleotide monomers and oligonucleotides
AR081082A1 (es)	2010-04-23	2012-06-06	Novartis Ag	Composiciones organicas para tratar enfermedades relacionadas con beta-enac
KR101223660B1 (ko)	2010-05-20	2013-01-17	광주과학기술원	ＨＩＦ－２α 억제제를 유효성분으로 포함하는 관절염 예방 또는 치료용 약제학적 조성물
AU2011255203B2 (en)	2010-05-21	2016-01-21	Peptimed, Inc.	Reagents and methods for treating cancer
EP2575773A4 (en)	2010-05-26	2014-06-25	Selecta Biosciences Inc	SYNTHETIC NANOTRÄGERKOMBINATIONSIMPFSTOFFE
US20130149320A1 (en)	2010-05-31	2013-06-13	Centre National De La Recherche Scientifique	Asf1b as a Prognosis Marker and Therapeutic Target in Human Cancer
US9944671B2 (en)	2010-06-02	2018-04-17	Alnylam Pharmaceuticals, Inc.	Compositions and methods directed to treating liver fibrosis
WO2011163121A1 (en)	2010-06-21	2011-12-29	Alnylam Pharmaceuticals, Inc.	Multifunctional copolymers for nucleic acid delivery
WO2011163466A1 (en)	2010-06-23	2011-12-29	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Regulation of skin pigmentation by neuregulin-1 (nrg-1)
US20130323269A1 (en)	2010-07-30	2013-12-05	Muthiah Manoharan	Methods and compositions for delivery of active agents
WO2012016188A2 (en)	2010-07-30	2012-02-02	Alnylam Pharmaceuticals, Inc.	Methods and compositions for delivery of active agents
CA2805265A1 (en)	2010-08-02	2012-02-09	Merck Sharp & Dohme Corp.	Rna interference mediated inhibition of catenin (cadherin-associated protein), beta 1 (ctnnb1) gene expression using short interfering nucleic acid (sina)
HRP20191232T1 (hr)	2010-08-17	2019-11-01	Sirna Therapeutics Inc	Inhibicija, posredovana rna interferencijom, ekspresije gena virusa hepatitisa b (hbv) korištenjem kratkih interferirajućih nukleinskih kiselina (sina)
EP3372684B1 (en)	2010-08-24	2020-10-07	Sirna Therapeutics, Inc.	Single-stranded rnai agents containing an internal, non-nucleic acid spacer
EP2609106A4 (en)	2010-08-26	2014-03-19	Merck Sharp & Dohme	RNA INTERFERENCE MEDIATED INHIBITION OF PROLYL HYDROXYLASE DOMAIN 2 (PHD2) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
EP2433644A1 (en)	2010-09-22	2012-03-28	IMBA-Institut für Molekulare Biotechnologie GmbH	Breast cancer therapeutics
US20140134231A1 (en)	2010-10-11	2014-05-15	Sanford-Burnham Medical Research Institute	Mir-211 expression and related pathways in human melanoma
AR083445A1 (es)	2010-10-14	2013-02-27	Univ Mie	siARN CONTRA LA FIBROSIS
BR112013009196A2 (pt)	2010-10-15	2020-08-25	The Trustees Of Columbia University In The City Of New York	usos de polipeptídeo para redução da aquisição de ácido graxo e da ingestão de alimento, bem como para promoção de saciedade relacionados à obesidade
DK2632472T3 (en)	2010-10-29	2018-03-19	Sirna Therapeutics Inc	RNA INTERFERENCE-MEDIATED INHIBITION OF GENE EXPRESSION USING SHORT INTERFERRING NUCLEIC ACIDS (SINA)
CA2816584A1 (en)	2010-11-01	2012-05-10	Peptimed, Inc.	Compositions of a peptide-based system for cell-specific targeting
PL2635299T3 (pl)	2010-11-02	2020-03-31	The Trustees Of Columbia University In The City Of New York	Sposoby leczenia zaburzeń utraty włosów
US9198911B2 (en)	2010-11-02	2015-12-01	The Trustees Of Columbia University In The City Of New York	Methods for treating hair loss disorders
CN110123830A (zh)	2010-11-09	2019-08-16	阿尔尼拉姆医药品有限公司	用于抑制Eg5和VEGF基因的表达的脂质配制的组合物和方法
EP2455456A1 (en)	2010-11-22	2012-05-23	Institut Curie	Use of kinesin inhibitors in HIV infection treatment and a method for screening them
AU2011338682B2 (en)	2010-12-06	2017-04-27	Quark Pharmaceuticals, Inc.	Double stranded oligonucleotide compounds comprising threose modifications
US9150926B2 (en)	2010-12-06	2015-10-06	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Diagnosis and treatment of adrenocortical tumors using human microRNA-483
WO2012102793A2 (en)	2010-12-10	2012-08-02	Zirus, Inc.	Mammalian genes involved in toxicity and infection
CN103347392B (zh)	2010-12-22	2016-10-12	纽约市哥伦比亚大学理事会	组蛋白乙酰转移酶调节剂和其用途
US20140056811A1 (en)	2010-12-27	2014-02-27	Compugen Ltd.	New cell-penetrating peptides and uses thereof
EP2663548B1 (en)	2011-01-11	2017-04-05	Alnylam Pharmaceuticals, Inc.	Pegylated lipids and their use for drug delivery
WO2012118911A1 (en)	2011-03-03	2012-09-07	Quark Pharmaceuticals, Inc.	Oligonucleotide modulators of the toll-like receptor pathway
US9796979B2 (en)	2011-03-03	2017-10-24	Quark Pharmaceuticals Inc.	Oligonucleotide modulators of the toll-like receptor pathway
SG192961A1 (en)	2011-03-03	2013-09-30	Quark Pharmaceuticals Inc	Compositions and methods for treating lung disease and injury
WO2012119764A1 (en)	2011-03-08	2012-09-13	Società Bulloneria Europea S.B.E. Spa	A high load flanged fastener to be installed by tensioning tools
CN103841991B (zh)	2011-03-15	2018-03-27	犹他大学研究基金会	诊断和治疗血管相关黄斑病及其症状的方法
KR101291668B1 (ko)	2011-04-21	2013-08-01	서울대학교산학협력단	미코박테리아―대장균용 셔틀 벡터 및 이의 용도
US10196637B2 (en)	2011-06-08	2019-02-05	Nitto Denko Corporation	Retinoid-lipid drug carrier
TWI658830B (zh)	2011-06-08	2019-05-11	日東電工股份有限公司	Ｈｓｐ47表現調控強化用類視色素脂質體
US9315813B2 (en)	2011-06-21	2016-04-19	Alnylam Pharmaceuticals, Inc	Compositions and methods for inhibition of expression of apolipoprotein C-III (APOC3) genes
EP3388068A1 (en)	2011-06-21	2018-10-17	Alnylam Pharmaceuticals, Inc.	Composition and methods for inhibition of expression of protein c (proc) genes
US20140275211A1 (en)	2011-06-21	2014-09-18	Alnylam Pharmaceuticals, Inc.	Assays and methods for determining activity of a therapeutic agent in a subject
EP2723861A4 (en)	2011-06-21	2014-12-10	Alnylam Pharmaceuticals Inc	COMPOSITIONS AND METHODS FOR INHIBITING HEPCIDINE ANTIMICROBIAL PEPTIDE (HAMP) OR THE ASSOCIATED GENE EXPRESSION
US20140235693A1 (en)	2011-06-23	2014-08-21	Alnylam Pharmaceuticals, Inc.	Serpina1 sirnas: compositions of matter and methods of treatment
US20140227293A1 (en)	2011-06-30	2014-08-14	Trustees Of Boston University	Method for controlling tumor growth, angiogenesis and metastasis using immunoglobulin containing and proline rich receptor-1 (igpr-1)
MX2014002536A (es)	2011-09-02	2014-09-01	Novartis Ag	Composiciones organicas para tratar enfermedades relacionadas con el factor de choque de calor 1 (hsf1).
JP2014531425A (ja)	2011-09-02	2014-11-27	ザトラスティーズオブコロンビアユニヴァーシティインザシティオブニューヨーク	肥満の代謝異常を治療するためのＣａＭＫＩＩ、ＩＰ３Ｒ、カルシニューリン、ｐ３８、およびＭＫ２／３阻害剤
US9644241B2 (en)	2011-09-13	2017-05-09	Interpace Diagnostics, Llc	Methods and compositions involving miR-135B for distinguishing pancreatic cancer from benign pancreatic disease
US9352312B2 (en)	2011-09-23	2016-05-31	Alere Switzerland Gmbh	System and apparatus for reactions
US9701623B2 (en)	2011-09-27	2017-07-11	Alnylam Pharmaceuticals, Inc.	Di-aliphatic substituted pegylated lipids
KR102102862B1 (ko)	2011-10-14	2020-04-22	제넨테크, 인크.	항-HtrA1 항체 및 사용 방법
AU2012325997C1 (en)	2011-10-18	2018-07-05	Dicerna Pharmaceuticals, Inc.	Amine cationic lipids and uses thereof
CN103917647B (zh)	2011-11-03	2020-07-10	夸克制药公司	用于神经保护的方法和组合物
EP2776565A1 (en)	2011-11-08	2014-09-17	Quark Pharmaceuticals, Inc.	Methods and compositions for treating diseases, disorders or injury of the nervous system
AU2013208720A1 (en)	2012-01-09	2014-07-24	Arrowhead Research Corporation	RNAi agents to treat Beta-Catenin related diseases
KR101371696B1 (ko)	2012-02-02	2014-03-07	세종대학교산학협력단	벼도열병 발병인자의 스크리닝 방법
EA033803B1 (ru)	2012-02-07	2019-11-27	Global Bio Therapeutics Inc	Способ доставки нуклеиновых кислот с разделением, их композиции и использование
SI2830662T1 (sl)	2012-03-29	2019-01-31	The Trustees Of Columbia University In The City Of New York	Postopki zdravljenja motenj izgube las
EP2844261B1 (en)	2012-05-02	2018-10-17	Sirna Therapeutics, Inc.	SHORT INTERFERING NUCLEIC ACID (siNA) COMPOSITIONS
CA2872304C (en)	2012-05-02	2022-12-06	Novartis Ag	Organic compositions to treat kras-related diseases
JP2015521041A (ja)	2012-05-16	2015-07-27	サイレンス・セラピューティクス・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング	Ｐｋｎ３阻害剤投与のためのバイオマーカーとしてのｖｅｇｆｒ１の使用
WO2013187556A1 (en)	2012-06-14	2013-12-19	Scripps Korea Antibody Institute	Novel antibody specific for clec14a and uses thereof
US9726661B2 (en)	2012-07-06	2017-08-08	Institut Gustave-Roussy	Simultaneous detection of cannibalism and senescence as prognostic marker for cancer
WO2014018375A1 (en)	2012-07-23	2014-01-30	Xenon Pharmaceuticals Inc.	Cyp8b1 and uses thereof in therapeutic and diagnostic methods
ES2817897T3 (es)	2012-07-23	2021-04-08	La Jolla Inst Allergy & Immunology	PTPRS y proteoglicanos en enfermedad autoinmune
EP2700949A1 (en)	2012-08-24	2014-02-26	IMG Institut für medizinische Genomforschung Planungsgesellschaft M.B.H.	Use of biliverdin reductase proteins as cancer marker
CA2886120A1 (en)	2012-10-08	2014-04-17	St. Jude Children's Research Hospital	Therapies based on control of regulatory t cell stability and function via a neuropilin-1:semaphorin axis
WO2014068072A1 (en)	2012-10-31	2014-05-08	Institut Gustave-Roussy	Identification, assessment and therapy of essential thrombocythemia with resistance to jak2 inhibitors
EP3336187A1 (en)	2012-12-05	2018-06-20	Alnylam Pharmaceuticals, Inc.	Pcsk9 irna compositions and methods of use thereof
JP2016511256A (ja)	2013-02-28	2016-04-14	アローヘッドリサーチコーポレイション	Ｅｐａｓ１関連疾患を治療するための有機組成物
WO2014135655A1 (en)	2013-03-06	2014-09-12	Institut Curie	Compositions and methods for treating muscle-invasive bladder cancer
KR102255108B1 (ko)	2013-03-08	2021-05-24	노파르티스 아게	활성제의 전달을 위한 지질 및 지질 조성물
DK2968424T3 (da)	2013-03-13	2020-03-30	Geneweave Biosciences Inc	Ikke-replikative transduktionspartikler og transduktionspartikelbaserede reportersystemer
CA2907152A1 (en)	2013-03-15	2014-09-25	The Trustees Of Columbia University In The City Of New York	Fusion proteins and methods thereof
EP2971129B1 (en)	2013-03-15	2018-05-09	Sutter Bay Hospitals	Falz for use as a target for therapies to treat cancer
WO2014160871A2 (en)	2013-03-27	2014-10-02	The General Hospital Corporation	Methods and agents for treating alzheimer's disease
JP6896420B2 (ja)	2013-07-03	2021-06-30	シティ・オブ・ホープＣｉｔｙｏｆＨｏｐｅ	抗癌組成物
CA2917108A1 (en)	2013-07-10	2015-01-15	Basf Se	Rnai for the control of phytopathogenic fungi and oomycetes by inhibiting the expression of cyp51 genes
JP6668236B2 (ja)	2013-07-19	2020-03-18	モンサントテクノロジーエルエルシー	Ｌｅｐｔｉｎｏｔａｒｓａ防除用組成物及びその方法
US20160208247A1 (en)	2013-07-31	2016-07-21	Qbi Enterprises Ltd.	Methods of use of sphingolipid polyalkylamine oligonucleotide compounds
US9889200B2 (en)	2013-07-31	2018-02-13	Qbi Enterprises Ltd.	Sphingolipid-polyalkylamine-oligonucleotide compounds
ES2733911T3 (es)	2013-08-08	2019-12-03	Global Bio Therapeutics Inc	Dispositivo de sujeción para procedimientos minimamente invasivos
CA2920303C (en)	2013-08-08	2017-08-29	Global Bio Therapeutics, Inc.	Injection device for minimally invasive procedures and uses thereof
US9988627B2 (en)	2013-10-04	2018-06-05	Novartis Ag	Formats for organic compounds for use in RNA interference
WO2015051044A2 (en)	2013-10-04	2015-04-09	Novartis Ag	Novel formats for organic compounds for use in rna interference
JP6546161B2 (ja)	2013-10-04	2019-07-17	ノバルティスアーゲー	Ｂ型肝炎ウイルスを治療するための有機化合物
CA2925129C (en)	2013-10-04	2023-04-04	Novartis Ag	3' end caps for rnai agents for use in rna interference
WO2015051135A2 (en)	2013-10-04	2015-04-09	Novartis Ag	Organic compositions to treat hepcidin-related diseases
EP3055426B1 (en)	2013-10-09	2019-06-19	The United States of America as represented by The Secretary Department of Health and Human Services	Detection of hepatitis delta virus (hdv) for the diagnosis and treatment of sjögren's syndrome and lymphoma
CN105814078A (zh)	2013-10-11	2016-07-27	豪夫迈·罗氏有限公司	Nsp4抑制剂及其使用方法
AU2014346457A1 (en)	2013-11-11	2016-06-02	Sirna Therapeutics, Inc.	Systemic delivery of myostatin short interfering nucleic acids (siNA) conjugated to a lipophilic moiety
WO2015084897A2 (en)	2013-12-02	2015-06-11	Mirimmune, Llc	Immunotherapy of cancer
US10059655B2 (en)	2013-12-19	2018-08-28	Novartis Ag	Lipids and lipid compositions for the delivery of active agents
ES2908827T3 (es)	2013-12-19	2022-05-04	Novartis Ag	Lípidos y composiciones lipídicas para el suministro de agentes activos
US9682123B2 (en)	2013-12-20	2017-06-20	The Trustees Of Columbia University In The City Of New York	Methods of treating metabolic disease
US9274117B2 (en)	2013-12-21	2016-03-01	Catholic University Industry Academic	Use of SIRT7 as novel cancer therapy target and method for treating cancer using the same
JP6372930B2 (ja)	2013-12-27	2018-08-15	国立大学法人高知大学	悪性腫瘍の治療薬
US10100313B2 (en)	2014-02-10	2018-10-16	Institut Curie	Use of Mcoln-1 modulators to regulate cell migration
EP3116902B1 (en)	2014-03-11	2020-01-01	Cellectis	Method for generating t-cells compatible for allogenic transplantation
EP3122365B1 (en)	2014-03-25	2023-05-03	Arcturus Therapeutics, Inc.	Transthyretin allele selective una oligomers for gene silencing
US9856475B2 (en)	2014-03-25	2018-01-02	Arcturus Therapeutics, Inc.	Formulations for treating amyloidosis
WO2015148580A2 (en)	2014-03-25	2015-10-01	Arcturus Therapeutics, Inc.	Una oligomers having reduced off-target effects in gene silencing
US10703798B2 (en)	2014-03-31	2020-07-07	Debiopharm International Sa	Methods of cancer therapy by inhibiting fusion polypeptides comprising fibroblast growth factor receptor 2 (FGFR2) and vinculin (VCL)
CN106413390B (zh)	2014-04-01	2019-09-27	孟山都技术公司	用于控制虫害的组合物和方法
CA2947270A1 (en)	2014-04-28	2015-11-05	Rxi Pharmaceuticals Corporation	Methods for treating cancer using nucleic acids targeting mdm2 or mycn
KR101633881B1 (ko)	2014-05-08	2016-06-28	고려대학교 산학협력단	도파민 의존성 신경장애 치료를 위한 REV-ERBα 유전자의 용도
KR101633876B1 (ko)	2014-05-08	2016-06-28	고려대학교 산학협력단	정서장애 및 중독질환 치료를 위한 REV-ERBα 유전자의 용도
EP3169784B1 (en)	2014-07-16	2020-06-10	Arrowhead Pharmaceuticals, Inc.	Rnai compositions to treat apoc3-related diseases
ES2949172T3 (es)	2014-07-16	2023-09-26	Novartis Ag	Método de encapsulamiento de un ácido nucleico en un hospedante de nanopartículas lipídicas
US10378012B2 (en)	2014-07-29	2019-08-13	Monsanto Technology Llc	Compositions and methods for controlling insect pests
CN115054687A (zh)	2014-08-22	2022-09-16	广州英恩迈生物医药科技有限公司	治疗和/或预防与ifp35蛋白家族的异常水平和/或活性相关的疾病或不适的方法和组合物
KR102506169B1 (ko)	2014-09-05	2023-03-08	피오 파마슈티칼스 코프.	Tyr 또는 mmp1을 표적화하는 핵산을 사용한 노화 및 피부 장애의 치료 방법
ES2969956T3 (es)	2014-09-05	2024-05-23	Novartis Ag	Lípidos y composiciones lipídicas para el suministro de agentes activos
US11390885B2 (en)	2014-09-15	2022-07-19	Children's Medical Center Corporation	Methods and compositions to increase somatic cell nuclear transfer (SCNT) efficiency by removing histone H3-lysine trimethylation
WO2016049110A1 (en)	2014-09-25	2016-03-31	Cold Spring Harbor Laboratory	Treatment of rett syndrome
US20170304459A1 (en)	2014-10-10	2017-10-26	Alnylam Pharmaceuticals, Inc.	Methods and compositions for inhalation delivery of conjugated oligonucleotide
WO2016077624A1 (en)	2014-11-12	2016-05-19	Nmc, Inc.	Transgenic plants with engineered redox sensitive modulation of photosynthetic antenna complex pigments and methods for making the same
WO2016105517A1 (en)	2014-12-23	2016-06-30	The Trustees Of Columbia University In The City Of New York	Fusion proteins and methods thereof
US10264976B2 (en)	2014-12-26	2019-04-23	The University Of Akron	Biocompatible flavonoid compounds for organelle and cell imaging
JP6942632B2 (ja)	2015-01-22	2021-09-29	モンサントテクノロジーエルエルシー	Ｌｅｐｔｉｎｏｔａｒｓａ防除用組成物及びその方法
EP3265107B1 (en)	2015-03-02	2024-10-02	180 Therapeutics LP	Method of treating a localized fibrotic disorder using a tnf receptor 2 antagonist
US10584144B2 (en)	2015-03-09	2020-03-10	University Of Kentucky Research Foundation	RNA nanoparticles for brain tumor treatment
US10781446B2 (en)	2015-03-09	2020-09-22	University Of Kentucky Research Foundation	RNA nanoparticle for treatment of gastric cancer
CN107429251A (zh)	2015-03-09	2017-12-01	肯塔基大学研究基金会	用于治疗乳腺癌的miRNA
KR101797569B1 (ko)	2015-03-18	2017-11-22	한국교통대학교산학협력단	금속 나노입자 기반 간 표적성 핵산 전달체 및 이의 제조방법
JP6830441B2 (ja)	2015-04-01	2021-02-17	アークトゥラス・セラピューティクス・インコーポレイテッドＡｒｃｔｕｒｕｓＴｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ．	治療上のｕｎａオリゴマーおよびその使用
US11279768B1 (en)	2015-04-03	2022-03-22	Precision Biologics, Inc.	Anti-cancer antibodies, combination therapies, and uses thereof
CN107614685B (zh)	2015-04-17	2021-10-19	肯塔基大学研究基金会	Rna纳米颗粒及其使用方法
WO2016176617A2 (en)	2015-04-29	2016-11-03	New York University	Method for treating high-grade gliomas
CN116063499A (zh)	2015-06-12	2023-05-05	艾利妥	抗cd33抗体及其使用方法
EP3307779A2 (en)	2015-06-12	2018-04-18	Alector LLC	Anti-cd33 antibodies and methods of use thereof
JP6980534B2 (ja)	2015-06-25	2021-12-15	ザチルドレンズメディカルセンターコーポレーション	造血幹細胞の増大、富化、および維持に関する方法および組成物
CA2991598A1 (en)	2015-07-06	2017-01-12	Rxi Pharmaceuticals Corporation	Nucleic acid molecules targeting superoxide dismutase 1 (sod1)
WO2017007825A1 (en)	2015-07-06	2017-01-12	Rxi Pharmaceuticals Corporation	Methods for treating neurological disorders using a synergistic small molecule and nucleic acids therapeutic approach
WO2017013270A1 (en)	2015-07-23	2017-01-26	Universite De Strasbourg	Use of leptin signaling inhibitor for protecting kidneys from patients having ciliopathy
WO2017015671A1 (en)	2015-07-23	2017-01-26	Arcturus Therapeutics, Inc.	Compositions for treating amyloidosis
WO2017035278A1 (en)	2015-08-24	2017-03-02	Halo-Bio Rnai Therapeutics, Inc.	Polynucleotide nanoparticles for the modulation of gene expression and uses thereof
US10072065B2 (en)	2015-08-24	2018-09-11	Mayo Foundation For Medical Education And Research	Peptide-mediated delivery of immunoglobulins across the blood-brain barrier
CN115960235A (zh)	2015-08-28	2023-04-14	艾利妥	抗siglec-7抗体及其使用方法
CN114525280A (zh)	2015-09-02	2022-05-24	阿尔尼拉姆医药品有限公司	程序性细胞死亡1配体1（PD-L1）的iRNA组合物及其使用方法
EP3702470A3 (en)	2015-09-09	2020-10-07	The Trustees of Columbia University in the City of New York	Reduction of er-mam-localized app-c99 and methods of treating alzheimer's disease
JP7628764B2 (ja)	2015-09-29	2025-02-12	アムジエン・インコーポレーテツド	Ａｓｇｒ阻害剤
US11285142B2 (en)	2015-09-29	2022-03-29	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Compositions and methods for identifying and treating dystonia disorders
US11021707B2 (en)	2015-10-19	2021-06-01	Phio Pharmaceuticals Corp.	Reduced size self-delivering nucleic acid compounds targeting long non-coding RNA
EP3368575B1 (en)	2015-10-29	2025-05-07	Alector LLC	Anti-siglec-9 antibodies and methods of use thereof
WO2017075212A1 (en)	2015-10-30	2017-05-04	Genentech, Inc.	Anti-htra1 antibodies and methods of use thereof
AU2016371624B2 (en)	2015-12-13	2020-08-27	Nitto Denko Corporation	siRNA structures for high activity and reduced off target
EP3423568A4 (en)	2016-03-04	2019-11-13	University Of Louisville Research Foundation, Inc.	METHOD AND COMPOSITIONS FOR EX-VIVO REPRODUCTION OF VERY SMALL EMBRYONAL STEM CELLS (VSELS)
JP7080179B2 (ja)	2016-03-15	2022-06-03	ザチルドレンズメディカルセンターコーポレーション	造血幹細胞の増大に関する方法および組成物
WO2017173327A1 (en)	2016-03-31	2017-10-05	The Schepens Eye Research Institute, Inc.	Endomucin inhibitor as an anti-angiogenic agent
MA45349A (fr)	2016-04-01	2019-02-06	Avidity Biosciences Llc	Acides nucléiques egfr et leurs utilisations
MA45470A (fr)	2016-04-01	2019-02-06	Avidity Biosciences Llc	Acides nucléiques kras et leurs utilisations
MA45469A (fr)	2016-04-01	2019-02-06	Avidity Biosciences Llc	Acides nucléiques de bêta-caténine et leurs utilisations
MA45328A (fr)	2016-04-01	2019-02-06	Avidity Biosciences Llc	Compositions acide nucléique-polypeptide et utilisations de celles-ci
AU2017261812B2 (en)	2016-05-13	2019-04-18	4D Molecular Therapeutics Inc.	Adeno-associated virus variant capsids and methods of use thereof
EP3519582A1 (en)	2016-07-29	2019-08-07	Danmarks Tekniske Universitet	Methods for decoupling cell growth from production of biochemicals and recombinant polypeptides
WO2018057575A1 (en)	2016-09-21	2018-03-29	Alnylam Pharmaceuticals, Inc	Myostatin irna compositions and methods of use thereof
WO2018102397A1 (en)	2016-11-29	2018-06-07	PureTech Health LLC	Exosomes for delivery of therapeutic agents
US11147249B2 (en)	2016-12-08	2021-10-19	Alector Llc	Siglec transgenic mice and methods of use thereof
BR112019012253A2 (pt)	2016-12-16	2020-01-28	Centre Hospitalier Univ Bordeaux	inibidores de mmp9 e usos dos mesmos na prevenção ou tratamento de um transtorno de despigmentação
WO2018195355A1 (en)	2017-04-19	2018-10-25	Rxi Pharmaceuticals Corporation	Topical delivery of nucleic acid compounds
EP3625258A1 (en)	2017-05-16	2020-03-25	Alector LLC	Anti-siglec-5 antibodies and methods of use thereof
EP3624841A4 (en)	2017-06-15	2021-01-27	Cancer Advances, Inc.,	COMPOSITIONS AND METHODS FOR INDUCING HUMORAL AND CELLULAR IMMUNITIES AGAINST TUMORS AND CANCER
US12150978B2 (en)	2017-06-15	2024-11-26	Cancer Advances Inc.	Compositions and methods for preventing tumors and cancer
KR102656200B1 (ko)	2017-06-16	2024-04-12	아이엠비에이 - 인스티튜트 퓌어 몰레쿨라레 바이오테크놀로지 게엠베하	혈관 오가노이드, 상기 오가노이드의 제조 및 사용 방법
KR102733407B1 (ko)	2017-08-03	2024-11-21	알렉터 엘엘씨	항-cd33 항체 및 이의 이용 방법
US11155819B2 (en)	2017-09-07	2021-10-26	Beijing Tide Pharmaceutical Co., Ltd.	Double-stranded RNA molecule targeting CKIP-1 and use thereof
JOP20200054A1 (ar)	2017-09-11	2020-03-10	Arrowhead Pharmaceuticals Inc	عوامل RNAi وتركيبات لتثبيط تعبير صَميمُ البروتينِ الشَّحْمِيّ C-III (APOC3)
US12428641B2 (en)	2017-09-15	2025-09-30	Commonwealth Scientific And Industrial Research Organisation	RNA molecules
KR20250011726A (ko)	2017-09-20	2025-01-21	4디 몰레큘러 테라퓨틱스 아이엔씨.	아데노-관련 바이러스 변이체 캡시드 및 그 용도
KR20250052478A (ko)	2017-11-27	2025-04-18	4디 몰레큘러 테라퓨틱스 아이엔씨.	아데노-관련 바이러스 변이체 캡시드 및 혈관 신생을 억제하기 위한 용도
WO2019113393A1 (en)	2017-12-06	2019-06-13	Avidity Biosciences Llc	Compositions and methods of treating muscle atrophy and myotonic dystrophy
US11470827B2 (en)	2017-12-12	2022-10-18	Alector Llc	Transgenic mice expressing human TREM proteins and methods of use thereof
WO2019126651A1 (en)	2017-12-21	2019-06-27	Alnylam Pharmaceuticals, Inc.	Chirally-enriched double-stranded rna agents
WO2019199673A1 (en)	2018-04-09	2019-10-17	President And Fellows Of Harvard College	Modulating nuclear receptors and methods of using same
CN112703196A (zh)	2018-05-24	2021-04-23	圣诺制药公司	用于核酸治疗的可控偶联多肽纳米颗粒导入系统的组合物及方法
EP3801767A1 (en)	2018-06-08	2021-04-14	Alector LLC	Anti-siglec-7 antibodies and methods of use thereof
MX2021000933A (es)	2018-07-27	2021-05-27	Alector Llc	Anticuerpos anti-siglec-5 y métodos para su uso.
US12247073B2 (en)	2018-08-31	2025-03-11	Alector Llc	Anti-CD33 antibodies and methods of use thereof
CN113015746A (zh)	2018-09-19	2021-06-22	拉荷亚免疫研究所	在类风湿性关节炎中的ptprs和蛋白聚糖
PT3880212T (pt)	2018-11-16	2024-02-08	Nitto Denko Corp	Formulação e métodos de administração de rna de interferência para tumores malignos
WO2020139897A1 (en)	2018-12-27	2020-07-02	Sirnaomics, Inc.	Silencing tgf-beta 1 and cox2 using sirnas delivered in combination with immune checkpoint inhibitors to treat cancer
US12215382B2 (en)	2019-03-01	2025-02-04	The General Hospital Corporation	Liver protective MARC variants and uses thereof
IT201900005918A1 (it)	2019-04-16	2020-10-16	Pastificio Rana Spa	Macchina per cuocere una dose di pasta in un contenitore
US20220290156A1 (en)	2019-08-27	2022-09-15	Sanofi	Compositions and methods for inhibiting pcsk9
KR102100163B1 (ko)	2019-09-24	2020-04-13	테고사이언스 (주)	켈로이드 또는 비후성 반흔 예방 또는 치료용 조성물
JP2023506842A (ja)	2019-12-18	2023-02-20	ノバルティスアーゲー	異常ヘモグロビン症の治療用組成物及び方法
BR112022011796A2 (pt)	2019-12-18	2022-08-30	Novartis Ag	Derivados de 3-(5-metóxi-1- oxoisoindolin-2-il)piperidina-2,6-diona e usos dos mesmos
WO2021142191A1 (en)	2020-01-08	2021-07-15	Regeneron Pharmaceuticals, Inc.	Treatment of fibrodysplasia ossificans progressiva
US12178902B1 (en)	2020-01-12	2024-12-31	University Of Southern California	Methods and compositions for fluid drainage by Piezo ion channel activation
US20210222128A1 (en)	2020-01-22	2021-07-22	Massachusetts Institute Of Technology	Inducible tissue constructs and uses thereof
WO2021173965A1 (en)	2020-02-28	2021-09-02	Massachusetts Institute Of Technology	Identification of variable influenza residues and uses thereof
CA3172111A1 (en)	2020-03-19	2021-09-23	Barbora MALECOVA	Compositions and methods of treating facioscapulohumeral muscular dystrophy
JP2023546175A (ja)	2020-10-14	2023-11-01	ジョージ・メイソン・リサーチ・ファウンデーション・インコーポレイテッド	脂質ナノ粒子製造の方法及びそれに由来する組成物
TW202241479A (zh)	2020-12-30	2022-11-01	美商安迅生物製藥公司	遞送外來抗原之溶瘤病毒及表現靶向外來抗原之嵌合受體之經工程化免疫細胞之組合療法
MX2023014041A (es)	2021-05-28	2023-12-15	Shanghai Regenelead Therapies Co Ltd	Virus adenoasociado recombinante que tiene una capsida variante y su aplicacion.
US20250127809A1 (en)	2021-06-23	2025-04-24	Novartis Ag	Compositions and methods for the treatment of hemoglobinopathies
WO2023012165A1 (en)	2021-08-02	2023-02-09	Universite De Montpellier	Compositions and methods for treating cmt1a or cmt1e diseases with rnai molecules targeting pmp22
PE20241173A1 (es)	2021-10-14	2024-05-28	Arsenal Biosciences Inc	Celulas inmunitarias que tienen arnhc coexpresados y sistemas de compuerta logica
IL319487A (en)	2022-09-13	2025-05-01	Arsenal Biosciences Inc	Immune cells having co-expressed tgfbr shrnas
EP4587570A2 (en)	2022-09-16	2025-07-23	Arsenal Biosciences, Inc.	Immune cells with combination gene perturbations
IL322949A (en)	2023-03-03	2025-10-01	Arsenal Biosciences Inc	Systems targeting PSMA and CA9
WO2025157614A1 (en)	2024-01-24	2025-07-31	Basf Se	Mixtures comprising rna and fungicides to control phytopathogenic fungi
WO2025157612A1 (en)	2024-01-24	2025-07-31	Basf Se	Mixtures comprising rna to control phytopathogenic fungi.
WO2025157611A1 (en)	2024-01-24	2025-07-31	Basf Se	Mixtures comprising rna and fungicides to control phytopathogenic fungi
WO2025199338A1 (en)	2024-03-20	2025-09-25	Arsenal Biosciences, Inc.	Systems targeting slc34a2 and tmprss4 and methods of use thereof

Citations (121)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4868116A (en)	1985-07-05	1989-09-19	Whitehead Institute For Biomedical Research	Introduction and expression of foreign genetic material in epithelial cells
US4980286A (en)	1985-07-05	1990-12-25	Whitehead Institute For Biomedical Research	In vivo introduction and expression of foreign genetic material in epithelial cells
US4987071A (en)	1986-12-03	1991-01-22	University Patents, Inc.	RNA ribozyme polymerases, dephosphorylases, restriction endoribonucleases and methods
US5107065A (en)	1986-03-28	1992-04-21	Calgene, Inc.	Anti-sense regulation of gene expression in plant cells
US5112734A (en)	1989-05-26	1992-05-12	Gene-Trak Systems	Target-dependent synthesis of an artificial gene for the synthesis of a replicatable rna
US5190931A (en)	1983-10-20	1993-03-02	The Research Foundation Of State University Of New York	Regulation of gene expression by employing translational inhibition of MRNA utilizing interfering complementary MRNA
US5208149A (en)	1983-10-20	1993-05-04	The Research Foundation Of State University Of New York	Nucleic acid constructs containing stable stem and loop structures
US5212295A (en)	1990-01-11	1993-05-18	Isis Pharmaceuticals	Monomers for preparation of oligonucleotides having chiral phosphorus linkages
US5225347A (en)	1989-09-25	1993-07-06	Innovir Laboratories, Inc.	Therapeutic ribozyme compositions and expression vectors
US5246921A (en)	1990-06-26	1993-09-21	The Wistar Institute Of Anatomy And Biology	Method for treating leukemias
US5254678A (en)	1987-12-15	1993-10-19	Gene Shears Pty. Limited	Ribozymes
WO1994001550A1 (en) *	1992-07-02	1994-01-20	Hybridon, Inc.	Self-stabilized oligonucleotides as therapeutic agents
US5328470A (en)	1989-03-31	1994-07-12	The Regents Of The University Of Michigan	Treatment of diseases by site-specific instillation of cells or site-specific transformation of cells and kits therefor
US5496698A (en)	1992-08-26	1996-03-05	Ribozyme Pharmaceuticals, Inc.	Method of isolating ribozyme targets
US5525468A (en)	1992-05-14	1996-06-11	Ribozyme Pharmaceuticals, Inc.	Assay for Ribozyme target site
US5574142A (en)	1992-12-15	1996-11-12	Microprobe Corporation	Peptide linkers for improved oligonucleotide delivery
US5587361A (en)	1991-10-15	1996-12-24	Isis Pharmaceuticals, Inc.	Oligonucleotides having phosphorothioate linkages of high chiral purity
WO1997005266A1 (en)	1995-07-25	1997-02-13	Introgene B.V.	Methods and means for targeted gene delivery
US5616459A (en)	1990-07-16	1997-04-01	The Public Health Research Institute Of The City Of New York, Inc.	Selection of ribozymes that efficiently cleave target RNA
US5624803A (en)	1993-10-14	1997-04-29	The Regents Of The University Of California	In vivo oligonucleotide generator, and methods of testing the binding affinity of triplex forming oligonucleotides derived therefrom
US5635385A (en)	1993-09-15	1997-06-03	Temple University-Of The Commonwealth System Of Higher Education	Multi-unit ribozyme inhibition of oncogene gene expression
US5639655A (en)	1993-01-19	1997-06-17	Ribozyme Pharmaceuticals, Inc.	PML-RARA targeted ribozymes
US5674683A (en)	1995-03-21	1997-10-07	Research Corporation Technologies, Inc.	Stem-loop and circular oligonucleotides and method of using
DE19618797A1 (de)	1996-05-10	1997-11-13	Bertling Wolf Prof Dr	Vehikel zum Transport molekularer Substanz
US5703054A (en) *	1992-03-16	1997-12-30	Isis Pharmaceuticals, Inc.	Oligonucleotide modulation of protein kinase C
US5712257A (en)	1987-08-12	1998-01-27	Hem Research, Inc.	Topically active compositions of mismatched dsRNAs
DE19631919A1 (de)	1996-08-07	1998-02-12	Deutsches Krebsforsch	Anti-Sinn-RNA mit Sekundärstruktur
US5719271A (en)	1992-03-05	1998-02-17	Isis Pharmaceuticals, Inc.	Covalently cross-linked oligonucleotides
US5731181A (en)	1996-06-17	1998-03-24	Thomas Jefferson University	Chimeric mutational vectors having non-natural nucleotides
US5739271A (en)	1995-06-07	1998-04-14	Gen-Probe Incorporated	Thiocationic lipids
US5789230A (en)	1993-10-14	1998-08-04	Boehringer Ingelheim International Gmbh	Endosomolytically active particles
US5801154A (en) *	1993-10-18	1998-09-01	Isis Pharmaceuticals, Inc.	Antisense oligonucleotide modulation of multidrug resistance-associated protein
US5811275A (en)	1993-05-17	1998-09-22	The Regents Of The University Of California	HIV-specific ribozymes
US5811300A (en)	1992-12-07	1998-09-22	Ribozyme Pharmaceuticals, Inc.	TNF-α ribozymes
US5814500A (en)	1996-10-31	1998-09-29	The Johns Hopkins University School Of Medicine	Delivery construct for antisense nucleic acids and methods of use
US5824519A (en)	1995-11-08	1998-10-20	Medical University Of South Carolina	Tissue-specific and target RNA-specific ribozymes
US5837510A (en)	1989-01-23	1998-11-17	Goldsmith; Mark A.	Methods and polynucleotide constructs for treating host cells for infection or hyperproliferative disorders
US5854067A (en)	1996-01-19	1998-12-29	Board Of Regents, The University Of Texas System	Hexokinase inhibitors
US5864028A (en)	1992-11-03	1999-01-26	Gene Shears Pty. Limited	Degradation resistant mRNA derivatives linked to TNF-α ribozymes
US5866701A (en)	1988-09-20	1999-02-02	The Board Of Regents For Northern Illinois University Of Dekalb	HIV targeted hairpin ribozymes
US5891717A (en)	1996-01-19	1999-04-06	Betagene, Inc.	Methods and compositions for inhibiting hexokinase
US5898031A (en)	1996-06-06	1999-04-27	Isis Pharmaceuticals, Inc.	Oligoribonucleotides for cleaving RNA
US5908779A (en)	1993-12-01	1999-06-01	University Of Connecticut	Targeted RNA degradation using nuclear antisense RNA
US5939262A (en)	1996-07-03	1999-08-17	Ambion, Inc.	Ribonuclease resistant RNA preparation and utilization
US5968737A (en)	1996-11-12	1999-10-19	The University Of Mississippi	Method of identifying inhibitors of glutathione S-transferase (GST) gene expression
US5985620A (en)	1992-11-03	1999-11-16	Gene Shears Pty. Limited	TNF-α Ribozymes
US5998203A (en) *	1996-04-16	1999-12-07	Ribozyme Pharmaceuticals, Inc.	Enzymatic nucleic acids containing 5'-and/or 3'-cap structures
US6054299A (en)	1994-04-29	2000-04-25	Conrad; Charles A.	Stem-loop cloning vector and method
US6057156A (en)	1997-01-31	2000-05-02	Robozyme Pharmaceuticals, Inc.	Enzymatic nucleic acid treatment of diseases or conditions related to levels of epidermal growth factor receptors
US6071890A (en)	1994-12-09	2000-06-06	Genzyme Corporation	Organ-specific targeting of cationic amphiphile/DNA complexes for gene therapy
US6077705A (en)	1996-05-17	2000-06-20	Thomas Jefferson University	Ribozyme-mediated gene replacement
US6080851A (en)	1992-12-04	2000-06-27	American Home Products Corporation	Ribozymes with linked anchor sequences
US6087164A (en)	1997-10-03	2000-07-11	Yissum Research Development Company Of The Hebrew University Of Jerusalem	Methods and compositions for inducing tumor-specific cytotoxicity
US6087172A (en)	1997-10-31	2000-07-11	Hisamitsu Pharmaceutical Co., Inc.	Ribozymes targeted to human IL-15 mRNA
US6100444A (en)	1997-02-11	2000-08-08	University Of Rochester Medical Center	Prostate specific regulatory nucleic acid sequences and transgenic non-human animals expressing prostate specific antigen
US6100087A (en)	1998-03-11	2000-08-08	City Of Hope	Ribozymes targeted to human CCR5 mRNA
US6099823A (en)	1996-02-16	2000-08-08	Millennium Pharmaceuticals, Inc.	Compositions and methods for the treatment and diagnosis of cardiovascular disease
DE19956568A1 (de)	1999-01-30	2000-08-17	Roland Kreutzer	Verfahren und Medikament zur Hemmung der Expression eines vorgegebenen Gens
US6127533A (en)	1997-02-14	2000-10-03	Isis Pharmaceuticals, Inc.	2'-O-aminooxy-modified oligonucleotides
US6166197A (en)	1995-03-06	2000-12-26	Isis Pharmaceuticals, Inc.	Oligomeric compounds having pyrimidine nucleotide (S) with 2'and 5 substitutions
US6183959B1 (en)	1997-07-03	2001-02-06	Ribozyme Pharmaceuticals, Inc.	Method for target site selection and discovery
WO2001018197A1 (en)	1999-09-08	2001-03-15	Ramot University Authority For Applied Research & Industrial Development Ltd.	Genetic screening methods
WO2001029058A1 (en)	1999-10-15	2001-04-26	University Of Massachusetts	Rna interference pathway genes as tools for targeted genetic interference
US6225291B1 (en)	1997-04-21	2001-05-01	University Of Florida	Rod opsin mRNA-specific ribozyme compositions and methods for the treatment of retinal diseases
WO2001036646A1 (en)	1999-11-19	2001-05-25	Cancer Research Ventures Limited	Inhibiting gene expression with dsrna
US6245748B1 (en)	1997-09-26	2001-06-12	Georgetown University	Inhibition of an FGF-binding protein using ribozymes
US6245560B1 (en)	1990-01-18	2001-06-12	The United States Of America As Represented By The Department Of Health And Human Services	Vector with multiple target response elements affecting gene expression
WO2001042443A1 (en)	1999-12-09	2001-06-14	Institut Molekulyarnoi Biologii Im. V.A.Engelgardta Rossiiskoi Akademii Nauk	Method for modifying genetic characteristics of an organism
US6255071B1 (en)	1996-09-20	2001-07-03	Cold Spring Harbor Laboratory	Mammalian viral vectors and their uses
WO2001048183A2 (en)	1999-12-24	2001-07-05	Devgen Nv	Improvements relating to double-stranded rna inhibition
US6271358B1 (en)	1998-07-27	2001-08-07	Isis Pharmaceuticals, Inc.	RNA targeted 2′-modified oligonucleotides that are conformationally preorganized
WO2001068836A2 (en)	2000-03-16	2001-09-20	Genetica, Inc.	Methods and compositions for rna interference
WO2001070949A1 (en)	2000-03-17	2001-09-27	Benitec Australia Ltd	Genetic silencing
WO2001075164A2 (en)	2000-03-30	2001-10-11	Whitehead Institute For Biomedical Research	Rna sequence-specific mediators of rna interference
WO2001092513A1 (en)	2000-05-30	2001-12-06	Johnson & Johnson Research Pty Limited	METHODS FOR MEDIATING GENE SUPPRESION BY USING FACTORS THAT ENHANCE RNAi
US6346398B1 (en)	1995-10-26	2002-02-12	Ribozyme Pharmaceuticals, Inc.	Method and reagent for the treatment of diseases or conditions related to levels of vascular endothelial growth factor receptor
WO2002016620A2 (en)	2000-08-19	2002-02-28	Axordia Limited	Modulation of stem cell differentiation
US6355415B1 (en)	1997-09-29	2002-03-12	Ohio University	Compositions and methods for the use of ribozymes to determine gene function
WO2002026780A2 (en)	2000-09-26	2002-04-04	The Burnham Institute	Paad domain-containing polypeptides, encoding nucleic acids, and methods of use
DE10100586C1 (de)	2001-01-09	2002-04-11	Ribopharma Ag	Verfahren zur Hemmung der Expression eines Ziegens
WO2002044321A2 (en)	2000-12-01	2002-06-06	MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V.	Rna interference mediating small rna molecules
WO2002055693A2 (de)	2001-01-09	2002-07-18	Ribopharma Ag	Verfahren zur hemmung der expression eines zielgens
US6423489B1 (en)	1992-09-10	2002-07-23	Isis Pharmaceuticals, Inc.	Compositions and methods for treatment of Hepatitis C virus-associated diseases
WO2002061034A2 (en)	2000-12-08	2002-08-08	Invitrogen Corporation	Compositions and methods for rapidly generating recombinant nucleic acid molecules
US20020114784A1 (en)	1999-01-28	2002-08-22	Medical College Of Georgia Research Institute, Inc.	Composition and method for in vivo and in vitro attenuation of gene expression using double stranded RNA
US20020123034A1 (en)	1999-09-08	2002-09-05	Dan Canaani	Genetic screening methods
WO2002068637A2 (en)	2000-10-20	2002-09-06	Ribozyme Pharmaceuticals, Inc.	Nucleic acid-based treatment of diseases or conditions related to west nile virus infection
WO2002068635A2 (en)	2001-02-28	2002-09-06	Novartis Forschungsstiftung Zweigniederlassung Friedrich Miescher Institute For Biomedical Research	Methods of inhibiting expression of a target gene in mammalian cells
US20020132346A1 (en)	2001-03-08	2002-09-19	Jose Cibelli	Use of RNA interference for the creation of lineage specific ES and other undifferentiated cells and production of differentiated cells in vitro by co-culture
US6482803B1 (en)	1995-09-01	2002-11-19	Board Of Regents, The University Of Texas System	Modification of mutated P53 gene in tumors by retroviral delivery of ribozyme A
US20020173478A1 (en)	2000-11-14	2002-11-21	The Trustees Of The University Of Pennsylvania	Post-transcriptional gene silencing by RNAi in mammalian cells
US6486299B1 (en)	1998-09-28	2002-11-26	Curagen Corporation	Genes and proteins predictive and therapeutic for stroke, hypertension, diabetes and obesity
US6506559B1 (en) *	1997-12-23	2003-01-14	Carnegie Institute Of Washington	Genetic inhibition by double-stranded RNA
WO2003006477A1 (en)	2001-07-12	2003-01-23	University Of Massachusetts	IN VIVO PRODUCTION OF SMALL INTERFERING RNAs THAT MEDIATE GENE SILENCING
WO2003012052A2 (en)	2001-07-30	2003-02-13	The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services	Specific inhibition of gene expression by small double stranded rnas
WO2003012082A2 (en)	2001-07-26	2003-02-13	Axordia Limited	Method for modulating stem cell differentiation using stem loop rna
WO2003016572A1 (en)	2001-08-17	2003-02-27	Eli Lilly And Company	Oligonucleotide therapeutics for treating hepatitis c virus infections
WO2003033700A1 (de)	2001-10-12	2003-04-24	Ribopharma Ag	Verfahren zur hemmung der replikation von viren
WO2003035868A1 (de)	2001-10-26	2003-05-01	Ribopharma Ag	Medikament zur erhöhung der wirksamkeit eines rezeptor-vermittelt apoptose in tumorzellen auslösenden arzeimittels
WO2003035869A1 (de)	2001-10-26	2003-05-01	Ribopharma Ag	Verwendung einer doppelsträngigen ribonukleinsäure zur gezielten hemmung der expression eines vorgegebenen zielgens
WO2003035082A1 (de)	2001-10-26	2003-05-01	Ribopharma Ag	Medikament zur hemmung der expression eines zielgens
WO2003035876A1 (de)	2001-10-26	2003-05-01	Ribopharma Ag	Verwendung einer doppelsträngigen ribonukleinsäure zur behandlung einer infektion mit einem (+)-strang-rna-virus
WO2003035870A1 (de)	2001-10-26	2003-05-01	Ribopharma Ag	Medikament zur behandlung eines pankreaskarzinoms
US6573046B1 (en)	1998-05-12	2003-06-03	Valigen (Us), Inc	Eukaryotic use of improved chimeric mutational vectors
US20030125281A1 (en)	2001-08-27	2003-07-03	David Lewis	Compositions and processes using siRNA, amphipathic compounds and polycations
US20030134808A1 (en)	1997-09-12	2003-07-17	Jesper Wengel	Oligonucleotide analogues
US20030143732A1 (en)	2001-04-05	2003-07-31	Kathy Fosnaugh	RNA interference mediated inhibition of adenosine A1 receptor (ADORA1) gene expression using short interfering RNA
DE69233117D1 (de)	1991-04-25	2003-08-07	Genset Sa	In sich geschlossende "sens-" und "antisense"-oligonukleotide und deren verwendungen
US20030148341A1 (en)	2001-11-15	2003-08-07	Sin Wun Chey	Gene amplification and overexpression in cancer
US20030157030A1 (en)	2001-11-02	2003-08-21	Insert Therapeutics, Inc.	Methods and compositions for therapeutic use of rna interference
WO2003070972A2 (en)	2002-02-20	2003-08-28	Sirna Therapeutics Inc.	RNA INTERFERENCE MEDIATED INHIBITION OF CHROMOSOME TRANSLOCATION GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
WO2003070283A2 (en)	2002-02-22	2003-08-28	Klaus Strebhardt	Agent for inhibiting development or progress of proliferative diseases and especially cancer diseases and pharmaceutical composition containing said agent
WO2003070750A2 (en)	2002-02-20	2003-08-28	Sirna Therapeutics, Inc	Rna interference mediated inhibition of hepatitis c virus
WO2003070969A2 (en)	2002-02-20	2003-08-28	Sirna Therapeutics, Inc.	RNA INTERFERENCE MEDIATED INHIBITION OF BCL2 GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
WO2003074654A2 (en)	2002-02-20	2003-09-12	Sirna Therapeurics, Inc	Rna interference mediated inhibition of gene expression using short interfering nucleic acid (sina)
US20030176671A1 (en)	2001-02-07	2003-09-18	The Burnham Institute	Apoptosis modulator BCL-B and methods for making and using same
US20030180756A1 (en)	2002-03-21	2003-09-25	Yang Shi	Compositions and methods for suppressing eukaryotic gene expression
US20030190635A1 (en)	2002-02-20	2003-10-09	Mcswiggen James A.	RNA interference mediated treatment of Alzheimer's disease using short interfering RNA
US20030198627A1 (en)	2001-09-01	2003-10-23	Gert-Jan Arts	siRNA knockout assay method and constructs
WO2004015107A3 (en)	2002-08-05	2004-04-29	Atugen Ag	Further novel forms of interfering rna molecules
US20060258608A1 (en)	2005-01-07	2006-11-16	Rachel Meyers	RNAi modulation of RSV and therapeutic uses thereof

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP0633318A1 (en)	1987-09-11	1995-01-11	Whitehead Institute For Biomedical Research	Transduced fibroblasts and uses therefor
WO1989005345A1 (en)	1987-12-11	1989-06-15	Whitehead Institute For Biomedical Research	Genetic modification of endothelial cells
US5100087A (en) *	1989-03-06	1992-03-31	Ashby Stephen B	Fastening device for container liners
EP0400047B1 (en)	1988-02-05	1997-04-23	Whitehead Institute For Biomedical Research	Modified hepatocytes and uses therefor
US5683867A (en) *	1990-06-11	1997-11-04	Nexstar Pharmaceuticals, Inc.	Systematic evolution of ligands by exponential enrichment: blended SELEX
EP0556345B2 (en)	1990-10-31	2005-10-12	Cell Genesys, Inc.	Retroviral vectors useful for gene therapy
US5238470A (en) *	1992-02-21	1993-08-24	Westavco Corporation	Emission control device
FR2703053B1 (fr) *	1993-03-26	1995-06-16	Genset Sa	Oligonucleotides agrafes et semi-agrafes, procede de preparation et applications .
US5755269A (en) *	1993-12-09	1998-05-26	Ciba Corning Diagnostics Corp.	Fluid delivery system
WO1996017057A1 (en)	1994-11-29	1996-06-06	The University Of Queensland	Sox-9 gene and protein and use in the regeneration of bone or cartilage
US5683873A (en)	1995-01-13	1997-11-04	Innovir Laboratories, Inc.	EGS-mediated inactivation of target RNA
CA2253382A1 (en) *	1996-01-16	1997-07-24	Ribozyme Pharmaceuticals, Inc.	Synthesis of methoxy nucleosides and enzymatic nucleic acid molecules
GB9710475D0 (en)	1997-05-21	1997-07-16	Zeneca Ltd	Gene silencing
GB9720148D0 (en)	1997-09-22	1997-11-26	Innes John Centre Innov Ltd	Gene silencing materials and methods
AU743316C (en) *	1998-03-20	2005-09-15	Commonwealth Scientific And Industrial Research Organisation	Control of gene expression
CA2325344C (en) *	1998-04-08	2017-12-05	Commonwealth Scientific And Industrial Research Organisation	Methods and means for obtaining modified phenotypes
JP2003525017A (ja)	1998-04-20	2003-08-26	リボザイム・ファーマシューティカルズ・インコーポレーテッド	遺伝子発現を調節しうる新規な化学組成を有する核酸分子
AR020078A1 (es) *	1998-05-26	2002-04-10	Syngenta Participations Ag	Metodo para alterar la expresion de un gen objetivo en una celula de planta
GB9827152D0 (en)	1998-07-03	1999-02-03	Devgen Nv	Characterisation of gene function using double stranded rna inhibition
BR9914773A (pt)	1998-10-09	2002-02-05	Ingene Inc	Conjunto de elementos genéricos, método para a produção de dna de cordão único, transcrição de mrna, construção de ácido nucléico, transcrição de ssdna, vetor, sistema vetor, célula hospedeira, conjunto para a produção de uma sequência de ácido nucléico de cordão único, método para a produção in vivo ou in vitro de uma sequência de ácido nucléico de cordão único, transcrição de cdna de cordão único, ácido nucléico inibidor, molécula heteroduplex, e composição farmacêutica
CA2346155A1 (en)	1998-10-09	2000-04-20	Ingene, Inc.	Enzymatic synthesis of ssdna
US6200924B1 (en)	1999-01-29	2001-03-13	E. I. Du Pont De Nemours And Company	Porous highly fluorinated acidic polymer catalyst
JP2002542263A (ja) *	1999-04-21	2002-12-10	ワイス	ポリヌクレオチド配列の機能を阻害するための方法および組成物
CA2369422A1 (en)	1999-05-10	2000-11-16	Syngenta Participations Ag	Regulation of viral gene expression
US7829693B2 (en)	1999-11-24	2010-11-09	Alnylam Pharmaceuticals, Inc.	Compositions and methods for inhibiting expression of a target gene
US8546143B2 (en)	2001-01-09	2013-10-01	Alnylam Pharmaceuticals, Inc.	Compositions and methods for inhibiting expression of a target gene
DE10100588A1 (de)	2001-01-09	2002-07-18	Ribopharma Ag	Verfahren zur Hemmung der Expression eines Zielgens
US6335415B1 (en) *	2001-01-30	2002-01-01	Council Of Scientific & Industrial Research	Process for the preparation of a polyester
US6787063B2 (en)	2001-03-12	2004-09-07	Seiko Epson Corporation	Compositions, methods for producing films, functional elements, methods for producing functional elements, methods for producing electro-optical devices and methods for producing electronic apparatus
US7745418B2 (en)	2001-10-12	2010-06-29	Alnylam Pharmaceuticals, Inc.	Compositions and methods for inhibiting viral replication
DE10230997A1 (de)	2001-10-26	2003-07-17	Ribopharma Ag	Medikament zur Erhöhung der Wirksamkeit eines Rezeptor-vermittelt Apoptose in Tumorzellen auslösenden Arzneimittels
FR2832154B1 (fr)	2001-11-09	2007-03-16	Centre Nat Rech Scient	Oligonucleotides inhibiteurs et leur utilisation pour reprimer specifiquement un gene
DE10202419A1 (de)	2002-01-22	2003-08-07	Ribopharma Ag	Verfahren zur Hemmung der Expression eines durch eine Chromosomen-Aberration entstandenen Zielgens
DE10230966A1 (de)	2002-07-10	2004-01-22	Ina-Schaeffler Kg	Elektromagnetisches Hydraulikventil, insbesondere Proportionalventil zur Steuerung einer Vorrichtung zur Drehwinkelverstellung einer Nockenwelle gegenüber einer Kurbelwelle einer Brennkraftmaschine
EP1546344A4 (en)	2002-09-18	2007-10-03	Isis Pharmaceuticals Inc	EFFICIENT PRODUCTION OF TARGET RNAS USING SINGLE AND DOUBLE-STRONG OLIGOMER COMPOUNDS
AU2003295600A1 (en)	2002-11-14	2004-06-15	Dharmacon, Inc.	Functional and hyperfunctional sirna
DE10302421A1 (de)	2003-01-21	2004-07-29	Ribopharma Ag	Doppelsträngige Ribonukleinsäure mit verbesserter Wirksamkeit
GB0317988D0 (en)	2003-07-31	2003-09-03	Milner Jo	Splicing variants
JP5704741B2 (ja)	2006-03-31	2015-04-22	アルナイラムファーマシューティカルズ，インコーポレイテッドＡｌｎｙｌａｍＰｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ．	Ｅｇ５遺伝子発現の抑制のための組成物および方法

1999
- 1999-11-24 DE DE19956568A patent/DE19956568A1/de not_active Withdrawn
2000
- 2000-01-29 CA CA002359180A patent/CA2359180C/en not_active Expired - Lifetime
- 2000-01-29 DK DK02003683.6T patent/DK1214945T4/da active
- 2000-01-29 PT PT02003683T patent/PT1214945E/pt unknown
- 2000-01-29 PT PT05002454T patent/PT1550719E/pt unknown
- 2000-01-29 ES ES10011217.6T patent/ES2597953T3/es not_active Expired - Lifetime
- 2000-01-29 ES ES05002454T patent/ES2321409T3/es not_active Expired - Lifetime
- 2000-01-29 AU AU2000032713A patent/AU778474B2/en not_active Expired
- 2000-01-29 DE DE50015501T patent/DE50015501D1/de not_active Expired - Lifetime
- 2000-01-29 DE DE10066235.8A patent/DE10066235C5/de not_active Expired - Fee Related
- 2000-01-29 EP EP00910510A patent/EP1144623B9/de not_active Revoked
- 2000-01-29 PT PT100112176T patent/PT2363479T/pt unknown
- 2000-01-29 AT AT00910510T patent/ATE222953T1/de not_active IP Right Cessation
- 2000-01-29 DK DK05002454T patent/DK1550719T3/da active
- 2000-01-29 EP EP15194718.1A patent/EP3018207A1/de not_active Withdrawn
- 2000-01-29 EP EP05002454A patent/EP1550719B1/de not_active Revoked
- 2000-01-29 ES ES00910510T patent/ES2182791T3/es not_active Expired - Lifetime
- 2000-01-29 DE DE10080167T patent/DE10080167B4/de not_active Revoked
- 2000-01-29 PT PT60253895T patent/PT1798285T/pt unknown
- 2000-01-29 DE DE50010528T patent/DE50010528D1/de not_active Expired - Lifetime
- 2000-01-29 WO PCT/DE2000/000244 patent/WO2000044895A1/de not_active Ceased
- 2000-01-29 DK DK10011217.6T patent/DK2363479T3/en active
- 2000-01-29 ES ES06025389.5T patent/ES2628535T3/es not_active Expired - Lifetime
- 2000-01-29 AT AT02003683T patent/ATE297463T1/de active
- 2000-01-29 EP EP02003683.6A patent/EP1214945B2/de not_active Expired - Lifetime
- 2000-01-29 EP EP10011217.6A patent/EP2363479B1/de not_active Expired - Lifetime
- 2000-01-29 ES ES02003683T patent/ES2243608T5/es not_active Expired - Lifetime
- 2000-01-29 DE DE20023125U patent/DE20023125U1/de not_active Expired - Lifetime
- 2000-01-29 JP JP2000596137A patent/JP2003502012A/ja not_active Withdrawn
- 2000-01-29 DE DE50000414T patent/DE50000414D1/de not_active Revoked
- 2000-01-29 AT AT05002454T patent/ATE418610T1/de active
- 2000-01-29 DK DK06025389.5T patent/DK1798285T3/en active
- 2000-01-29 EP EP06025389.5A patent/EP1798285B1/de not_active Revoked
2001
- 2001-07-18 ZA ZA200105909A patent/ZA200105909B/en unknown
2003
- 2003-03-06 US US10/383,099 patent/US8119608B2/en not_active Expired - Fee Related
- 2003-03-06 US US10/382,768 patent/US8168776B2/en not_active Expired - Fee Related
- 2003-03-06 US US10/382,395 patent/US8101584B2/en not_active Expired - Fee Related
- 2003-07-02 US US10/612,179 patent/US8202980B2/en not_active Expired - Fee Related
2005
- 2005-03-09 AU AU2005201044A patent/AU2005201044B2/en not_active Expired
2006
- 2006-09-13 JP JP2006248528A patent/JP2007031443A/ja not_active Withdrawn
- 2006-09-13 JP JP2006248529A patent/JP2006340732A/ja not_active Withdrawn
2007
- 2007-07-17 JP JP2007186341A patent/JP2007312784A/ja active Pending
- 2007-07-17 JP JP2007186339A patent/JP2008005844A/ja active Pending
- 2007-07-17 JP JP2007186340A patent/JP2007314555A/ja active Pending
- 2007-10-31 US US11/982,345 patent/US8729037B2/en not_active Expired - Fee Related
- 2007-10-31 US US11/982,425 patent/US8183362B2/en not_active Expired - Fee Related
- 2007-10-31 US US11/982,325 patent/US20080171862A1/en not_active Abandoned
- 2007-10-31 US US11/982,441 patent/US8114981B2/en not_active Expired - Fee Related
- 2007-10-31 US US11/982,305 patent/US8101742B2/en not_active Expired - Fee Related
- 2007-10-31 US US11/982,434 patent/US8114851B2/en not_active Expired - Fee Related
2009
- 2009-01-08 JP JP2009002825A patent/JP2009102380A/ja active Pending
- 2009-01-08 JP JP2009002826A patent/JP2009100758A/ja active Pending
- 2009-01-08 JP JP2009002824A patent/JP2009100757A/ja active Pending
- 2009-03-20 CY CY20091100310T patent/CY1108896T1/el unknown
- 2009-12-16 JP JP2009285705A patent/JP2010057514A/ja not_active Withdrawn
- 2009-12-16 JP JP2009285706A patent/JP2010057515A/ja active Pending
2012
- 2012-10-19 US US13/656,513 patent/US8877726B2/en not_active Expired - Fee Related
- 2012-10-19 US US13/656,548 patent/US9902954B2/en not_active Expired - Fee Related
- 2012-10-19 US US13/656,540 patent/US20130164366A1/en not_active Abandoned
2013
- 2013-01-17 JP JP2013006076A patent/JP5990468B2/ja not_active Expired - Lifetime
- 2013-01-29 US US13/753,438 patent/US20130177631A1/en not_active Abandoned
2014
- 2014-03-18 US US14/218,476 patent/US9133454B2/en not_active Expired - Fee Related
- 2014-03-18 US US14/218,489 patent/US9902955B2/en not_active Expired - Fee Related
2015
- 2015-05-13 JP JP2015098123A patent/JP6471901B2/ja not_active Expired - Lifetime
2016
- 2016-10-12 CY CY20161101011T patent/CY1118264T1/el unknown
2017
- 2017-06-15 CY CY20171100634T patent/CY1119221T1/el unknown
2018
- 2018-01-12 US US15/870,380 patent/US20180179526A1/en not_active Abandoned
- 2018-09-19 JP JP2018174668A patent/JP2019017390A/ja active Pending

Patent Citations (151)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5190931A (en)	1983-10-20	1993-03-02	The Research Foundation Of State University Of New York	Regulation of gene expression by employing translational inhibition of MRNA utilizing interfering complementary MRNA
US5208149A (en)	1983-10-20	1993-05-04	The Research Foundation Of State University Of New York	Nucleic acid constructs containing stable stem and loop structures
US4980286A (en)	1985-07-05	1990-12-25	Whitehead Institute For Biomedical Research	In vivo introduction and expression of foreign genetic material in epithelial cells
US4868116A (en)	1985-07-05	1989-09-19	Whitehead Institute For Biomedical Research	Introduction and expression of foreign genetic material in epithelial cells
US5107065A (en)	1986-03-28	1992-04-21	Calgene, Inc.	Anti-sense regulation of gene expression in plant cells
US4987071A (en)	1986-12-03	1991-01-22	University Patents, Inc.	RNA ribozyme polymerases, dephosphorylases, restriction endoribonucleases and methods
US6025167A (en)	1986-12-03	2000-02-15	Competitive Technologies, Inc.	RNA ribozyme polymerases, dephosphorylases, restriction endoribonucleases and methods
US5712257A (en)	1987-08-12	1998-01-27	Hem Research, Inc.	Topically active compositions of mismatched dsRNAs
US5254678A (en)	1987-12-15	1993-10-19	Gene Shears Pty. Limited	Ribozymes
US5866701A (en)	1988-09-20	1999-02-02	The Board Of Regents For Northern Illinois University Of Dekalb	HIV targeted hairpin ribozymes
US5837510A (en)	1989-01-23	1998-11-17	Goldsmith; Mark A.	Methods and polynucleotide constructs for treating host cells for infection or hyperproliferative disorders
US5328470A (en)	1989-03-31	1994-07-12	The Regents Of The University Of Michigan	Treatment of diseases by site-specific instillation of cells or site-specific transformation of cells and kits therefor
US5112734A (en)	1989-05-26	1992-05-12	Gene-Trak Systems	Target-dependent synthesis of an artificial gene for the synthesis of a replicatable rna
US5225347A (en)	1989-09-25	1993-07-06	Innovir Laboratories, Inc.	Therapeutic ribozyme compositions and expression vectors
US5212295A (en)	1990-01-11	1993-05-18	Isis Pharmaceuticals	Monomers for preparation of oligonucleotides having chiral phosphorus linkages
US6245560B1 (en)	1990-01-18	2001-06-12	The United States Of America As Represented By The Department Of Health And Human Services	Vector with multiple target response elements affecting gene expression
US5246921A (en)	1990-06-26	1993-09-21	The Wistar Institute Of Anatomy And Biology	Method for treating leukemias
US5616459A (en)	1990-07-16	1997-04-01	The Public Health Research Institute Of The City Of New York, Inc.	Selection of ribozymes that efficiently cleave target RNA
DE69233117D1 (de)	1991-04-25	2003-08-07	Genset Sa	In sich geschlossende "sens-" und "antisense"-oligonukleotide und deren verwendungen
US5587361A (en)	1991-10-15	1996-12-24	Isis Pharmaceuticals, Inc.	Oligonucleotides having phosphorothioate linkages of high chiral purity
US5719271A (en)	1992-03-05	1998-02-17	Isis Pharmaceuticals, Inc.	Covalently cross-linked oligonucleotides
US5703054A (en) *	1992-03-16	1997-12-30	Isis Pharmaceuticals, Inc.	Oligonucleotide modulation of protein kinase C
US5525468A (en)	1992-05-14	1996-06-11	Ribozyme Pharmaceuticals, Inc.	Assay for Ribozyme target site
WO1994001550A1 (en) *	1992-07-02	1994-01-20	Hybridon, Inc.	Self-stabilized oligonucleotides as therapeutic agents
US5496698A (en)	1992-08-26	1996-03-05	Ribozyme Pharmaceuticals, Inc.	Method of isolating ribozyme targets
US6423489B1 (en)	1992-09-10	2002-07-23	Isis Pharmaceuticals, Inc.	Compositions and methods for treatment of Hepatitis C virus-associated diseases
US5864028A (en)	1992-11-03	1999-01-26	Gene Shears Pty. Limited	Degradation resistant mRNA derivatives linked to TNF-α ribozymes
US5985620A (en)	1992-11-03	1999-11-16	Gene Shears Pty. Limited	TNF-α Ribozymes
US6080851A (en)	1992-12-04	2000-06-27	American Home Products Corporation	Ribozymes with linked anchor sequences
US5811300A (en)	1992-12-07	1998-09-22	Ribozyme Pharmaceuticals, Inc.	TNF-α ribozymes
US5574142A (en)	1992-12-15	1996-11-12	Microprobe Corporation	Peptide linkers for improved oligonucleotide delivery
US5639655A (en)	1993-01-19	1997-06-17	Ribozyme Pharmaceuticals, Inc.	PML-RARA targeted ribozymes
US5811275A (en)	1993-05-17	1998-09-22	The Regents Of The University Of California	HIV-specific ribozymes
US5635385A (en)	1993-09-15	1997-06-03	Temple University-Of The Commonwealth System Of Higher Education	Multi-unit ribozyme inhibition of oncogene gene expression
US5624803A (en)	1993-10-14	1997-04-29	The Regents Of The University Of California	In vivo oligonucleotide generator, and methods of testing the binding affinity of triplex forming oligonucleotides derived therefrom
US5789230A (en)	1993-10-14	1998-08-04	Boehringer Ingelheim International Gmbh	Endosomolytically active particles
US5801154A (en) *	1993-10-18	1998-09-01	Isis Pharmaceuticals, Inc.	Antisense oligonucleotide modulation of multidrug resistance-associated protein
US5908779A (en)	1993-12-01	1999-06-01	University Of Connecticut	Targeted RNA degradation using nuclear antisense RNA
US6054299A (en)	1994-04-29	2000-04-25	Conrad; Charles A.	Stem-loop cloning vector and method
US6071890A (en)	1994-12-09	2000-06-06	Genzyme Corporation	Organ-specific targeting of cationic amphiphile/DNA complexes for gene therapy
US6166197A (en)	1995-03-06	2000-12-26	Isis Pharmaceuticals, Inc.	Oligomeric compounds having pyrimidine nucleotide (S) with 2'and 5 substitutions
US5674683A (en)	1995-03-21	1997-10-07	Research Corporation Technologies, Inc.	Stem-loop and circular oligonucleotides and method of using
US5739271A (en)	1995-06-07	1998-04-14	Gen-Probe Incorporated	Thiocationic lipids
WO1997005266A1 (en)	1995-07-25	1997-02-13	Introgene B.V.	Methods and means for targeted gene delivery
US6482803B1 (en)	1995-09-01	2002-11-19	Board Of Regents, The University Of Texas System	Modification of mutated P53 gene in tumors by retroviral delivery of ribozyme A
US6346398B1 (en)	1995-10-26	2002-02-12	Ribozyme Pharmaceuticals, Inc.	Method and reagent for the treatment of diseases or conditions related to levels of vascular endothelial growth factor receptor
US5824519A (en)	1995-11-08	1998-10-20	Medical University Of South Carolina	Tissue-specific and target RNA-specific ribozymes
US5891717A (en)	1996-01-19	1999-04-06	Betagene, Inc.	Methods and compositions for inhibiting hexokinase
US5854067A (en)	1996-01-19	1998-12-29	Board Of Regents, The University Of Texas System	Hexokinase inhibitors
US6099823A (en)	1996-02-16	2000-08-08	Millennium Pharmaceuticals, Inc.	Compositions and methods for the treatment and diagnosis of cardiovascular disease
US5998203A (en) *	1996-04-16	1999-12-07	Ribozyme Pharmaceuticals, Inc.	Enzymatic nucleic acids containing 5'-and/or 3'-cap structures
AU717543B2 (en)	1996-05-10	2000-03-30	Responsif Gmbh	Vehicle for the transport of molecular substances
DE19618797A1 (de)	1996-05-10	1997-11-13	Bertling Wolf Prof Dr	Vehikel zum Transport molekularer Substanz
US6077705A (en)	1996-05-17	2000-06-20	Thomas Jefferson University	Ribozyme-mediated gene replacement
US5898031A (en)	1996-06-06	1999-04-27	Isis Pharmaceuticals, Inc.	Oligoribonucleotides for cleaving RNA
US6107094A (en)	1996-06-06	2000-08-22	Isis Pharmaceuticals, Inc.	Oligoribonucleotides and ribonucleases for cleaving RNA
US5731181A (en)	1996-06-17	1998-03-24	Thomas Jefferson University	Chimeric mutational vectors having non-natural nucleotides
US5939262A (en)	1996-07-03	1999-08-17	Ambion, Inc.	Ribonuclease resistant RNA preparation and utilization
DE19631919A1 (de)	1996-08-07	1998-02-12	Deutsches Krebsforsch	Anti-Sinn-RNA mit Sekundärstruktur
DE19631919C2 (de)	1996-08-07	1998-07-16	Deutsches Krebsforsch	Anti-Sinn-RNA mit Sekundärstruktur
US6255071B1 (en)	1996-09-20	2001-07-03	Cold Spring Harbor Laboratory	Mammalian viral vectors and their uses
US5814500A (en)	1996-10-31	1998-09-29	The Johns Hopkins University School Of Medicine	Delivery construct for antisense nucleic acids and methods of use
US5968737A (en)	1996-11-12	1999-10-19	The University Of Mississippi	Method of identifying inhibitors of glutathione S-transferase (GST) gene expression
US6057156A (en)	1997-01-31	2000-05-02	Robozyme Pharmaceuticals, Inc.	Enzymatic nucleic acid treatment of diseases or conditions related to levels of epidermal growth factor receptors
US6100444A (en)	1997-02-11	2000-08-08	University Of Rochester Medical Center	Prostate specific regulatory nucleic acid sequences and transgenic non-human animals expressing prostate specific antigen
US6127533A (en)	1997-02-14	2000-10-03	Isis Pharmaceuticals, Inc.	2'-O-aminooxy-modified oligonucleotides
US6225291B1 (en)	1997-04-21	2001-05-01	University Of Florida	Rod opsin mRNA-specific ribozyme compositions and methods for the treatment of retinal diseases
US6183959B1 (en)	1997-07-03	2001-02-06	Ribozyme Pharmaceuticals, Inc.	Method for target site selection and discovery
US20030134808A1 (en)	1997-09-12	2003-07-17	Jesper Wengel	Oligonucleotide analogues
US6245748B1 (en)	1997-09-26	2001-06-12	Georgetown University	Inhibition of an FGF-binding protein using ribozymes
US6355415B1 (en)	1997-09-29	2002-03-12	Ohio University	Compositions and methods for the use of ribozymes to determine gene function
US6087164A (en)	1997-10-03	2000-07-11	Yissum Research Development Company Of The Hebrew University Of Jerusalem	Methods and compositions for inducing tumor-specific cytotoxicity
US6087172A (en)	1997-10-31	2000-07-11	Hisamitsu Pharmaceutical Co., Inc.	Ribozymes targeted to human IL-15 mRNA
US6506559B1 (en) *	1997-12-23	2003-01-14	Carnegie Institute Of Washington	Genetic inhibition by double-stranded RNA
US6100087A (en)	1998-03-11	2000-08-08	City Of Hope	Ribozymes targeted to human CCR5 mRNA
US6573046B1 (en)	1998-05-12	2003-06-03	Valigen (Us), Inc	Eukaryotic use of improved chimeric mutational vectors
US6271358B1 (en)	1998-07-27	2001-08-07	Isis Pharmaceuticals, Inc.	RNA targeted 2′-modified oligonucleotides that are conformationally preorganized
US6486299B1 (en)	1998-09-28	2002-11-26	Curagen Corporation	Genes and proteins predictive and therapeutic for stroke, hypertension, diabetes and obesity
US20020114784A1 (en)	1999-01-28	2002-08-22	Medical College Of Georgia Research Institute, Inc.	Composition and method for in vivo and in vitro attenuation of gene expression using double stranded RNA
US20080261303A1 (en)	1999-01-30	2008-10-23	Roland Kreutzer	Method and medicament for inhibiting the expression of a given gene
AU778474B2 (en)	1999-01-30	2004-12-09	Alnylam Pharmaceuticals, Inc.	Method and medicament for inhibiting the expression of a defined gene
US20080182981A1 (en)	1999-01-30	2008-07-31	Roland Kreutzer	Method and medicament for inhibiting the expression of a given gene
US20080166800A1 (en)	1999-01-30	2008-07-10	Roland Kreutzer	Method and medicament for inhibiting the expression of a given gene
AU2005201044B2 (en)	1999-01-30	2008-05-29	Alnylam Pharmaceuticals, Inc.	Method and medicament for inhibiting the expression of a defined gene
DE10066235B4 (de)	1999-01-30	2008-04-10	Alnylam Europe Ag	Verfahren und Medikament zur Hemmung der Expression eines vorgegebenen Gens
EP1214945A2 (de)	1999-01-30	2002-06-19	Ribopharma AG	Verfahren und Medikament zur Hemmung der Expression eines vorgegebenen Gens
DE10080167B4 (de)	1999-01-30	2008-03-20	Alnylam Europe Ag	Medikament zur Hemmung der Expression eines vorgegebenen Gens
EP1550719A1 (de)	1999-01-30	2005-07-06	Alnylam Europe AG	Verfahren und Medikament zur Hemmung der Expression eines vorgegebenen Gens
DE20023125U1 (de)	1999-01-30	2003-05-15	Ribopharma AG, 95326 Kulmbach	Medikament zur Hemmung der Expression eines vorgegebenen Gens
US20080233651A1 (en)	1999-01-30	2008-09-25	Roland Kreutzer	Method and medicament for inhibiting the expression of a given gene
US20080171862A1 (en)	1999-01-30	2008-07-17	Roland Kreutzer	Method and medicament for inhibiting the expression of a given gene
EP1550719B1 (de)	1999-01-30	2008-12-24	Alnylam Europe AG	Doppelsträngige RNA (dsRNA) zur Hemmung der Expression eines vorgegebenen Gens
EP1144623B1 (de)	1999-01-30	2002-08-28	Ribopharma AG	Verfahren und medikament zur hemmung der expression eines vorgegebenen gens
DE19956568A1 (de)	1999-01-30	2000-08-17	Roland Kreutzer	Verfahren und Medikament zur Hemmung der Expression eines vorgegebenen Gens
US20040072779A1 (en)	1999-01-30	2004-04-15	Ribopharma Ag	Method and medicament for inhibiting the expression of a given gene
US20040053875A1 (en)	1999-01-30	2004-03-18	Ribopharma Ag	Method and medicament for inhibiting the expression of a given gene
WO2001018197A1 (en)	1999-09-08	2001-03-15	Ramot University Authority For Applied Research & Industrial Development Ltd.	Genetic screening methods
US20020123034A1 (en)	1999-09-08	2002-09-05	Dan Canaani	Genetic screening methods
WO2001029058A1 (en)	1999-10-15	2001-04-26	University Of Massachusetts	Rna interference pathway genes as tools for targeted genetic interference
WO2001036646A1 (en)	1999-11-19	2001-05-25	Cancer Research Ventures Limited	Inhibiting gene expression with dsrna
US20030027783A1 (en)	1999-11-19	2003-02-06	Magdalena Zernicka-Goetz	Inhibiting gene expression with dsRNA
EP1230375B1 (en)	1999-11-19	2005-07-06	Cancer Research Technology Limited	Inhibiting gene expression with dsrna
WO2001042443A1 (en)	1999-12-09	2001-06-14	Institut Molekulyarnoi Biologii Im. V.A.Engelgardta Rossiiskoi Akademii Nauk	Method for modifying genetic characteristics of an organism
WO2001048183A2 (en)	1999-12-24	2001-07-05	Devgen Nv	Improvements relating to double-stranded rna inhibition
US20020162126A1 (en)	2000-03-16	2002-10-31	David Beach	Methods and compositions for RNA interference
WO2001068836A2 (en)	2000-03-16	2001-09-20	Genetica, Inc.	Methods and compositions for rna interference
WO2001070949A1 (en)	2000-03-17	2001-09-27	Benitec Australia Ltd	Genetic silencing
WO2001075164A2 (en)	2000-03-30	2001-10-11	Whitehead Institute For Biomedical Research	Rna sequence-specific mediators of rna interference
US20020086356A1 (en)	2000-03-30	2002-07-04	Whitehead Institute For Biomedical Research	RNA sequence-specific mediators of RNA interference
US20030108923A1 (en)	2000-03-30	2003-06-12	Whitehead Institute For Biomedical Research	RNA sequence-specific mediators of RNA interference
WO2001092513A1 (en)	2000-05-30	2001-12-06	Johnson & Johnson Research Pty Limited	METHODS FOR MEDIATING GENE SUPPRESION BY USING FACTORS THAT ENHANCE RNAi
WO2002016620A2 (en)	2000-08-19	2002-02-28	Axordia Limited	Modulation of stem cell differentiation
WO2002026780A2 (en)	2000-09-26	2002-04-04	The Burnham Institute	Paad domain-containing polypeptides, encoding nucleic acids, and methods of use
WO2002068637A2 (en)	2000-10-20	2002-09-06	Ribozyme Pharmaceuticals, Inc.	Nucleic acid-based treatment of diseases or conditions related to west nile virus infection
US20020173478A1 (en)	2000-11-14	2002-11-21	The Trustees Of The University Of Pennsylvania	Post-transcriptional gene silencing by RNAi in mammalian cells
WO2002044321A2 (en)	2000-12-01	2002-06-06	MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V.	Rna interference mediating small rna molecules
WO2002061034A2 (en)	2000-12-08	2002-08-08	Invitrogen Corporation	Compositions and methods for rapidly generating recombinant nucleic acid molecules
WO2002055693A2 (de)	2001-01-09	2002-07-18	Ribopharma Ag	Verfahren zur hemmung der expression eines zielgens
DE10100586C1 (de)	2001-01-09	2002-04-11	Ribopharma Ag	Verfahren zur Hemmung der Expression eines Ziegens
US20040001811A1 (en)	2001-01-09	2004-01-01	Ribopharma Ag	Compositions and methods for inhibiting expression of anti-apoptotic genes
WO2002055692A2 (de)	2001-01-09	2002-07-18	Ribopharma Ag	Verfahren zur hemmung der expression eines zielgens und medikament zur therapie einer tumorerkrankung
US20030176671A1 (en)	2001-02-07	2003-09-18	The Burnham Institute	Apoptosis modulator BCL-B and methods for making and using same
WO2002068635A2 (en)	2001-02-28	2002-09-06	Novartis Forschungsstiftung Zweigniederlassung Friedrich Miescher Institute For Biomedical Research	Methods of inhibiting expression of a target gene in mammalian cells
US20020132346A1 (en)	2001-03-08	2002-09-19	Jose Cibelli	Use of RNA interference for the creation of lineage specific ES and other undifferentiated cells and production of differentiated cells in vitro by co-culture
US20030143732A1 (en)	2001-04-05	2003-07-31	Kathy Fosnaugh	RNA interference mediated inhibition of adenosine A1 receptor (ADORA1) gene expression using short interfering RNA
WO2003006477A1 (en)	2001-07-12	2003-01-23	University Of Massachusetts	IN VIVO PRODUCTION OF SMALL INTERFERING RNAs THAT MEDIATE GENE SILENCING
WO2003012082A2 (en)	2001-07-26	2003-02-13	Axordia Limited	Method for modulating stem cell differentiation using stem loop rna
WO2003012052A2 (en)	2001-07-30	2003-02-13	The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services	Specific inhibition of gene expression by small double stranded rnas
WO2003016572A1 (en)	2001-08-17	2003-02-27	Eli Lilly And Company	Oligonucleotide therapeutics for treating hepatitis c virus infections
WO2003080794A2 (en)	2001-08-27	2003-10-02	Mirus Corporation	Inhibition of rna function by delivery of inhibitors to animal cells
US20030125281A1 (en)	2001-08-27	2003-07-03	David Lewis	Compositions and processes using siRNA, amphipathic compounds and polycations
US20030198627A1 (en)	2001-09-01	2003-10-23	Gert-Jan Arts	siRNA knockout assay method and constructs
WO2003033700A1 (de)	2001-10-12	2003-04-24	Ribopharma Ag	Verfahren zur hemmung der replikation von viren
WO2003035870A1 (de)	2001-10-26	2003-05-01	Ribopharma Ag	Medikament zur behandlung eines pankreaskarzinoms
WO2003035876A1 (de)	2001-10-26	2003-05-01	Ribopharma Ag	Verwendung einer doppelsträngigen ribonukleinsäure zur behandlung einer infektion mit einem (+)-strang-rna-virus
WO2003035082A1 (de)	2001-10-26	2003-05-01	Ribopharma Ag	Medikament zur hemmung der expression eines zielgens
WO2003035869A1 (de)	2001-10-26	2003-05-01	Ribopharma Ag	Verwendung einer doppelsträngigen ribonukleinsäure zur gezielten hemmung der expression eines vorgegebenen zielgens
WO2003035083A1 (de)	2001-10-26	2003-05-01	Ribopharma Ag	Medikament zur behandlung einer fibrotischen erkrankung durch rna interferenz
WO2003035868A1 (de)	2001-10-26	2003-05-01	Ribopharma Ag	Medikament zur erhöhung der wirksamkeit eines rezeptor-vermittelt apoptose in tumorzellen auslösenden arzeimittels
US20030157030A1 (en)	2001-11-02	2003-08-21	Insert Therapeutics, Inc.	Methods and compositions for therapeutic use of rna interference
US20030148341A1 (en)	2001-11-15	2003-08-07	Sin Wun Chey	Gene amplification and overexpression in cancer
WO2003070969A2 (en)	2002-02-20	2003-08-28	Sirna Therapeutics, Inc.	RNA INTERFERENCE MEDIATED INHIBITION OF BCL2 GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
US20030190635A1 (en)	2002-02-20	2003-10-09	Mcswiggen James A.	RNA interference mediated treatment of Alzheimer's disease using short interfering RNA
WO2003074654A2 (en)	2002-02-20	2003-09-12	Sirna Therapeurics, Inc	Rna interference mediated inhibition of gene expression using short interfering nucleic acid (sina)
WO2003070750A2 (en)	2002-02-20	2003-08-28	Sirna Therapeutics, Inc	Rna interference mediated inhibition of hepatitis c virus
WO2003070972A2 (en)	2002-02-20	2003-08-28	Sirna Therapeutics Inc.	RNA INTERFERENCE MEDIATED INHIBITION OF CHROMOSOME TRANSLOCATION GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
WO2003070283A2 (en)	2002-02-22	2003-08-28	Klaus Strebhardt	Agent for inhibiting development or progress of proliferative diseases and especially cancer diseases and pharmaceutical composition containing said agent
WO2003080807A2 (en)	2002-03-21	2003-10-02	President And Fellows Of Harvard College	Compositions and methods for suppressing eukaryotic gene expression
US20030180756A1 (en)	2002-03-21	2003-09-25	Yang Shi	Compositions and methods for suppressing eukaryotic gene expression
WO2004015107A3 (en)	2002-08-05	2004-04-29	Atugen Ag	Further novel forms of interfering rna molecules
US20060258608A1 (en)	2005-01-07	2006-11-16	Rachel Meyers	RNAi modulation of RSV and therapeutic uses thereof

Non-Patent Citations (528)

* Cited by examiner, † Cited by third party
Title
"InBase, The Intein Database: The Intein Registry—Inteins Sorted by Species," http://tools.neb.com/inbase/list.php (database updated on May 22, 2006).
Agami, R. "RNAi and related mechanisms and their potential use for therapy". Current Opinion in Chemical Biology, 2002, vol. 6., pp. 829-834.
Agrawal et al., "Antisense Therapeutics: is it as simple as complementary base recognition?", Molecular Medicine Today 2000, vol. 6, pp. 72-81.
Agrawal et al., 1995, 105-21, Editors: Akhtar, Saghir, Publisher CRC.
Agrawal, S., "Antisense oligonucleotides: towards clinical trials," Tibtech (1996), 14: 376-387.
Agrawal, S., et al., "Oligodeoxynucleoside phosphoramidates and phosphorothioates as inhibitors of human immunodeficiency virus," Proc. Natl. Acad. Sci. USA (1988), 85:7079-7083.
Agrawal, S., et al., "Protocols for Oligonucleotides and Analogs," Chapters 5 and 6, 1993, pp. 81-140, Humana Press, Totowa, NH.
Alfonzo et al., "The mechanism of U insertion/deletion RNA editing in kinetoplastid mitochondria," Nucleic Acid Research, 25:3751-3759, 1997.
Ambros, V., (2001), "Dicing Up RNAs", Science, 293:811-813.
Anderson, "Human Gene Therapy" Nature, 392:25-30, 1998.
Armentano et al., "Expression of human factor IX in rabbit hepatocytes by retrovirus-mediated gene transfer: Potential for gene therapy of hemophilia B" Proc. Natl. Acad. Sci USA 87:614-645, 1990.
Asanuma, H. et al., (1999), "Photoregulation der Bildung und Dissoziation eines DNA-Duplexes-durch cis-trans-Isomerisierung einer Azobenzoleinheit", Angew. Chem., 111:2547-2549.
Ausubel et al., "Cationic Lipid-Mediated Transfection of Suspension Cells with DNA" Curr. Protocols Mol. Biol. Supp. 48:9.4.7-9.4.8 (1999).
Auszug aus der online-Rolle des EPA, Excerpt from the European Patent Register for EP 1147204, Database last updated on Jun. 18, 2008, 4 Pages.
Azhayeva, E. et al., (1997), "Inhibitory properties of double helix forming circular oligonucleotides", Nucl. Acids Res., 25:4954-4961.
Bahramian et al.; Molecular and Cellular Biology, vol. 19:274-283, Transcriptional and Posttranscriptional Silencing of Rodent alphal(I) Collagen by a Homologous Transcriptionally Self-Silenced Transgene Jan. 1999.
Bahramian et al.; Molecular and Cellular Biology, vol. 19:274-283, Transcriptional and Posttranscriptional Silencing of Rodent αl(I) Collagen by a Homologous Transcriptionally Self-Silenced Transgene Jan. 1999.
Barber et al., "Mutants of the RNA-Dependent Protein Kinase (PKR) Lacking Double-Stranded RNA Binding Domain I Can Act as Transdominant Inhibitors and Induce Malignant Transformation," Mol. Cell. Biol., 15(6):3138-3146 (1995).
Barlow et al., "Interferon synthesis in the early post-implantation mouse embryo" Differentiation 27:229-235 (1984).
Barwkar, D.A. et al.; Proc. Natl. Acad. Sci USA, vol. 95:11047-11052, Sep. 1998, Chemistry, Biochemistry.
Basbaum et al., "Focalized proteolysis: spatial and temporal regulation of extra cellular matrix degradation at the cell surface"Curr. Opin. Cell Biol. 8:731-738, 1996.
Bass, B.L., (2000), "Double-Stranded RNA as a Template for Gene Silencing", Cell, 101:235-238.
Baulcombe, D.C., et al., "Mechanisms of Pathogen-Derived Resistance to Viruses in Transgenic Plants," The Plant Cell (1996), 8: 1833-1844.
Baxevanis, A., "The Molecular Biology Database Collection: 2003 udpate," Nucleic Acids Research, 2003, pp. 1-12, vol. 31, No. 1.
Beck, "Unknotting the Complexities of Multidrug Resistance: The Involvement of DNA Topoisomerases in Drug Action and Resistance" J. Natl. Cancer Inst. 81:1683-1685, 1989.
Berkner et al., "Development of Adenovirus Vectors for the Expression of Heterologous Genes" BioTechniues 6 (7):616-629, 1998.
Bernstein et al. Nature vol. 409, Jan. 18, 2001. *
Bhan et al., Acid Research, 1997; vol. 25; p. 3310.
Billy, et al. (2001) PNAS 98(25):14428-33.
Biotechnology Applied Biochemistry vol. 29, Part 1, Feb. 1999, which shows Braun, H., et al., "Oligonucleotide and plasmid DNA packaging into polyoma VPI virus-like particles expressed in Escherichia coli," as first published on the internet Dec. 22, 1998.
Birkedal-Hansen et al., "Matrix Metalloproteinases: A Review" Crit. Rev.Oral Biol. Med. 4:197-250, 1993.
Boese et al., "Mechanistic Insights Aid Computational Short Interfering RNA Design" Methods in Enzymology 392:73-95, 2005.
Borecky et al. (1981-82) Tex Rep Biol Med 41:575-81 Abstract Only.
Boyd, "Invasion and metastasis" Cancer Metastass Rev. 15:77-89, 1996.
Braasch et al., "Locked nucleic acid (LNA): fine-tuning the recognition of DNA and RNA" Chem. Biol. 8:1-7, 2001.
Braich et al., "Regiospecific Solic-Phase Synthesis of Branched Oligonucleotides. Effect of Vicinal 2', 5'-(or 2', 3'-) and 3', 5'-Phosphodiester Linkages on the Formation of Hairpin DNA" Bioconjugate Chem. 8:370-377 (1997).
Braich et al., "Regiospecific Solic-Phase Synthesis of Branched Oligonucleotides. Effect of Vicinal 2′, 5′-(or 2′, 3′-) and 3′, 5′-Phosphodiester Linkages on the Formation of Hairpin DNA" Bioconjugate Chem. 8:370-377 (1997).
Branch, "A good antisense molecule is hard to find" TIBS, 23:45-50, 1998.
Braun, H., et al., "Oligonucleotide and plasmid DNA packaging into polyoma VPI virus-like particles expressed in Escherichia coli," Biotechnol. Appl. Biochem, 1999, pp. 31-43.
Brennicke et al., "RNA editing," FEMS Microbiology Reviews, 23:297-316 (1999).
Brinckerhoff et al., "Matrix metalloproteinases: a tail of a frog that became a prince" Nature Reviews 3:207-214, 2002.
Bruening, "Plant Gene Silencing Regularized" Proc. Natl Acad Science 95:13349-13351, 1998.
Bucchini et al., "Pancreatic Expression of Human Insulin Gene in Transgenic Mice" PNAS USA 83:2511-1515,1986.
Bumcrot, D., et al., "RNAi therapeutics: a potential new class of pharmaceutical drugs," Nature Chemical Biology (2006), 2(12): 711-719.
Burke et al., "Appearance of Interferon Inducibility and Sensitivity during Differentiation of Murine Teratocarcinoma Cells in Vitro" Cell 13:243-248 (1978).
Burke, "Appearance of Interferon Inducibility and Sensitivity during Differentiation of Murine Teratocarcinoma cells In Vitro" Cell 13:243-248 (1978).
Byrom et al., "Inducing RNA1 with siRNA Cocktails Generated by RNase III", Ambion, Technical Library, TechNotes, vol. 10:1, Jun. 19, 2004.
Byrom et al., "Inducing RNAi with siRNA Cocktails Generated by RNase III," TechNotes 10(1), Ambion, http://www.ambion.com/techlib/tn/101/4.html (2004).
Cameron et al., "Inhibition of Gene Expression by a Short Sense Fragment" Nucleic Acids Research, 19:469-475, 1991.
Caplen et al., "dsRNA-Mediated Gene Silencing in Cultured Drosophila Cells: a Tissue Culture Model for the Analysis of RNA Interference" Gene 252:95-105, 2000.
Caplen, N.J. et al., (2001), "Specific inhibition of gene expression by small double-stranded RNAs in invertebrate and vertebrate systems", Proc. Natl. Acad. Sci. USA, 98(17):9742-9747.
Caplen, N.J., (2002), "A new approach to the inhibition of gene expression", TRENDS in Biotechnology, 20(2):49-51.
Caplen, NJ. RNAi as a gene therapy approach. Expert Opinion Biol. Thera. (2003). vol. 3(4):575-586. Ashley Publications Ltd. *
Castelli, J. et al., (998), "The 2-5A system in viral infection and apoptosis", Biomed. Pharmacother., 52:386-390.
Chao et al., "BCL-2 Family: Regulators of Cell Death" Annu. Rev. Immunol. 16:395-419, 1998.
Check, E. "RNA to the rescue?", Nature, 2003, vol. 425, pp. 10-12.
Chen et al., "Gene therapy for brain tumors: regression of experimental gliomas by adenovirus-mediated gene transfer in vivo" Proc. Natl Acad Sci. USA 91:3054-3057, 1994.
Chen, M., et al., "A universal plasmid library encoding all permutations of small interfering RNA," PNAS, Feb. 15, 2005, pp. 2356-2361, vol. 102, No. 7.
Chien et al., "Novel cationic cardiolipin analogue-based liposome for efficient DNA and small interfering RNA delivery in vitro and in vivo," Cancer Gene Therapy, pp. 1-8 (2004).
Childs et al., The MDR Superfamily of Genes and Its Biological Implciations Imp. Adv. Oncol. 21-36, 1994.
Chowdhury et al., "Long-Term Improvement of Hypercholesteromlemia AfterEx Vivo Gene Therapy in LDLR-Deficient Rabbits" Science 254:1802-1805, 1991.
Chu, C-Y., et al., "Potent RNAi by short RNA triggers," RNA, Report, 2008, pp. 1714-1719, vol. 14.
Cioca et al., "RNA interference is a functional pathway with therapeutic potential in human myeloid leukemia cell lines" Cancer Gene Therapy 10:125-133, 2003.
Clemens MJ: PKR—a protein kinase regulated by double-stranded RNA. Int J Biochem Cell Biol 1997, 29(7):945-949.
Cobaleda, C. et al., (2000), "In vivo inhibition by a site-specific catalytic RNA subunit of Rnase P designed against the BCR-ABL oncogenic products: a novel approach for cancer treatment", Blood, 95(3):731-737.
Coburn et al., "siRNAs: a new wave of RNA-based therapeutics Journal of Antimicrobial Chemotherapy", 2003, vol. 51, pp. 753-756.
Cole et al., "Overexpression of a Transporter Gene in a Multidrug-Resistant Human Lung Cancer Cell Line" Science258: 1650-1654, 1992.
Communication in opposition proceedings for German Patent No. 10066235.8 (Jun. 23, 2009).
Communication of Technical Board of Appeal in opposition to European Patent No. 1 144 623 (Sep. 22, 2008). (translation attached).
Cone et al., "High-efficiency gene transfer into mammalian cells: Generation of helper-free recombinant retrovirus with broad mammalian host range" Proc. Natl Acad Sci. USA 81:6349-6353, 1984.
Cook, "Medicinal chemistry of antisense oligonucleotides—future opportunities" Anti-Cancer Drug Design 6:585-607, 1991.
Corey, D.R., "Chemical modification: the key to clinical application of RNA interference?" The Journal of Clinical Investigation (2007), 117(12): 3615-3622.
Cornetta et al., "Safety Issues Related to Retroviral-Mediated Gene Transfer in Humans" Human Gene Threapy2(1):5-14, 1991.
Cotten et al., "Ribozyme Mediated Destruction of RNA in vivo" EMBO J. 8:3861-3866, 1989.
Couture et al., "Anti-gene therapy: the use of ribozymes to inhibit gene function: Trends in Genetics." 12:510-515, 1996.
Couzin, "Small RNAs Make Big Splash," Science, 298:2296-2297 (2002).
Crooke et al., "Pharmacokinetic Properties of Several Novel Oligonucleotdies Analogs in Mice" J. Pharmacol. Exp. Ther. 277:923-937, 1996.
Crooke, S., et al., "Antisense Research and Applications," Chapters 16 and 18, 1993, CRC Press, Boca Raton, 21 pages.
Crooke, ST, Basic Principles of Antisense Therapeutics. Antisense Research and Application (1998), Chapter 1, Springer-Verlag, New York. *
Current version of Curriculum Vitae of David M. Stalker, 2010, 13 pages.
Czaudema et al., "Structural variations and stabilizing modifications of synthetic siRNAs in mammalian cells," Nucleic Acids Res., 31(11):1-12 (2003).
Czaudema, Frank et al., "Structural variations and stabilising modifications of synthetic siRNAs in mammalian cells", Nucleic Acids Research, 2003, vol. 31, No. 11, 2705-2716.
Dai et al., "Gene therapy via primary myoblasts: Long-term expression of factor IX protein following transplantation in vivo" Proc. Natl Acad. Sci. USA 89:10892-10895, 1992.
Damha, M., et al., "Chapter 5: Oligoribdonucleotides synthesis: the silyl-phosphoramidite method," Methods in Molecular Biology 20, Humana Press NJ: 81-114 (1993).
Danos et al., "Safe and efficient generation of recombinant retroviruses with amphotropic and ecotropic host ranges" Proc. Natl. Acad. Sci. USA 85:6460-6464, 1998.
D'Ari, "Cycle-regulated genes and cell cycle regulation" Bioassays 23: 563-565, 2001.
Datenbank Medline bei STN: AN 1999091059 Medline; DN 99091059 zu: Use of dsRNA-mediated genetic interference to demonstrate that frizzled and frizzled 2 act in the wingless pathway, Abstract Only.
De Fougerolles et al., "RNA interference in vivo: toward synthetic smallinhibitory RNA-based therapeutics," Methods in Enzyme. 392:278-296 (2005).
Dean, N.M., et al., "Identification and Characterization of Second-Generation Antisense Oligonucleotides," Antisense & Nucleic Acid Drug Development (1997), 7: 229-233.
Decision by German Patent Office in opposition proceedings for DE 10080167.6 (Feb. 17, 2009), 20 pages.
Decision of Board of Appeal in Opposition for EP 114 46 23 (Mar. 29, 2009) (translation attached).
Decision of Rejection for Japan Patent Application No. 2009-002824, Mar. 9, 2010, 4 Pages.
Decision of Rejection for Japan Patent Application No. 2009-002826, Mar. 9, 2010, 4 Pages.
Decision of the Board of Appeal of May 19, 2010 in Opposition to European Patent No. EP 1214945, Jul. 20, 2010, 28 pages.
Decision of the Technical Board of Appeals for European Patent No. 1144623, Dec. 9, 2008, 50 Pages.
Decision on the revocation of European Patent No. 1214945, Mar. 31, 2009, 61 Pages.
Decision to revoke European Patent EP 10080167 of Alnylam Europe AG, Mar. 18, 2009, 26 Pages.
Decision to revoke European Patent EP 1144623 of Alnylam Europe AG, Dec. 19, 2008, 50 Pages.
Decision to revoke European Patent EP 1214945 of Alnylam Europe AG, Jan. 20, 2009, 56 Pages.
Declaration of David Keith Myers filed in opposition proceedings for Australian Patent 778474 (Nov. 7, 2008).
Declaration of David M. Stalker filed in opposition proceedings for Australian Patent 778474 (Nov. 4, 2008) (17 pages).
Declaration of David M. Stalker filed in opposition proceedings for Australian Patent 778474 (Nov. 4, 2008) (45 pages).
Delgado et al., "The Uses and Properties of PEG-Linked Proteins" Crit. Rev. Therap. Drug Carrier Sys. 9:249-304, 1992.
Dellweg et al., ed., Römpp Lexikon Biotechnologie, p. 354 and p. 673 (1992) (in German).
Docherty et al., "Nutrient regulation of insulin gene expression" FASEB J. 8:20-27, 1994.
Doench, J.G. et al., (2003), "siRNAs can function as miRNAs", Genes & Development, 17:438-442.
Dolinnaya, et al., "Oligonucleotide circularization by template-directed chemical ligation" Nucleic Acids Research, 21:5403-5407, 1993.
Donzé, O. et al., (2002), "RNA interference in mammalian cells using siRNAs synthesized with T7 RNA Polymerase", Nucleic Acids Research, 30(10):e46(4pages).
Downward, J. et al., (1990), "Identification of a nucleotide exchange-promoting activity for p21ras", Proc. Natl. Acad. Sci. USA, 87:5998-6002.
Eder et al., "Monitoring of BCR-ABL expression using real-time RT-PCR in CML after bone marrow or peripheral blood stem cell transplantation" Leukemia 13:1383-1389, 1999.
Eglitis et al., "Gene Expression in Mice After High Efficiency Retroviral-Mediated Gene Transfer" Science 230:1395-1398, 1985.
Elbashir et al. Functional anatomy of siRNAs for mediating efficient RNAi in Drosophila melanogaster embryo lysate. *
Elbashir et al., "Analysis of gene function in somatic mammalian cells using small interfering RNAs," Methods, 26:199-213 (2002).
Elbashir, et al. (2001) Nature 411:494-498.
Elbashir, S.M. et al., (2001), "Functional anatomy of siRNAs for mediating efficient RNAi in Drosophila melanogaster embryo lysate", The EMBO Journal, 20(23):6877-6888.
Elbashir, S.M. et al., (2001), "RNA interference is mediated by 21- and 22-nucleotide RNAs", Genes & Development, 15:188-200.
Eriksson et al., "Establishment and characterization of mouse stain (TLL) that spontaneously develops T-cell lymphomas/leukemia" Exp. Hematol. 27:682:688, 1999.
Examination Report for German Divisional Patent Application No. DE 10066382.6, Apr. 8, 2011, 13 pages.
Exhibit 1 of David Keith Myers Declaration filed in opposition proceedings for Australian Patent 778474 (Nov. 7, 2008).
Exhibit 2 of David Keith Myers Declaration filed in opposition proceedings for Australian Patent 778474 (Nov. 7, 2008).
Expert-Bezancon et al., "Precise localization of several covalent RNA-RNA cross-link in Escherichia coli 16S RNA" European Journal of Biochemistry, 136:267-274, 1983.
Extended European Search Report and Written Opinion, mailed Aug. 8, 2011 for European Patent Application No. EP 10011217.6, 21 Pages.
Fallert-Müller, ed., Encyclopedia of Biochemistry, vol. J-Z, pp. 448-449 (2000) (in German).
Fan et al., "Reversal of Multidrug Resistance in Cancer", ed. Kellen, CRC, Boca Raton, FL, pp. 93-125.
Ferry et al., "Retroviral-mediated gene transfer into hepatocytes in vivo" Proc. Natl. Acad Sci. USA 88:8377-8381, 1991.
Fire et al., "RNA Interferences—gene silencing by double-stranded RNA" The Nobel Prize in Physiology or Medicine, press release, 2006.
Fire, 9/99, RNA-triggered gene silencing, Trends Genet, 15: 358-363.
Fire, A. et al., (1998), "Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans", Nature, 391:806-811.
Fire, A., "Gene Silencing By Double Stranded RNA," Nobel Lecture, Dec. 8, 2006, pp. 198-233.
Fire, A., et al., 1991, Production of Antisense RNA leads to effective and specific inhibition of gene expression in C. elegans muscle, Development 113: 503-514.
Forstova, J. et al., "Polyoma Virus Pseudocapsids as Efficient Carriers of Heterologous DNA into Mammalian Cells," Human Gene Therapy (1995), 6: 297-306.
Fotedar et al., "Apoptosis and the cell cycle" Prog. Cell Cycle Res. 2:147-163,1996.
Gait, M., "Chapter 16: Oligoribdonucleotides," Antisense Research and Applications, CRC Press 289-302, 1993.
Gao et al. Nucleic Acids Research vol. 23, No. 2, 1995. *
Gao et al., "Circularization of oligonucleotides by disulfide bridge formation" Nucleic Acids Research, 23:2025-2029, 1995.
Garnier, L. et al., "Incorporation of Pseudorabies Virus gD into Human Immunodeficiency Virus Type 1 Gag Particles Produced in Baculovirus-Infected Cells," Journal of Virology (1995) 69(7): 4060-4068.
Gassmann et al., "Maintenance of an extrachromosomal plasmid vector in mouse embryonic stem cells" PNAS USA 92:1292-1296, 1995.
Gautschi, O. et al., (2001), "Activity of a Novel bcl-2/bcl-xL-Bispecific Antisense Oligonucleotide Against Tumors of Diverse Histologic Origins", Journal of the National Cancer Institute, 93(6):463-471.
GenBank Accession No. M13994, "Human B-cell leukemia/lymphoma 2 (bc102) proto-oncogene mRNA encoding bcl-2 beta protein" Oct. 31, 1994.
GenBank Accession No. M13995, "Human B-cell leukemia/lymphoma 2 (bc102) proto-oncogene mRNA encoding bcl-2 beta protein" Oct. 31, 1994.
GenBank Accession No. U55763, "Cloning vector pEGFP-CA, complete sequence, enhanced green fluorescent protein (egfp) and neomycin phosphotransferase genes" Jun. 15, 1996.
German Opposition, filed by Pfizer Inc. on Jun. 19, 2008, in opposition to German Patent DE 10066235.8 (Lederer & Keller) 34 pages.
Gewirtz, A., et al., "Nucleic Acid Therapeutics: State of the Art and Future Prospects," Blood, Aug. 1, 1998, pp. 712-736, vol. 92, No. 3.
Gibbs, J.B. et al., (1988), "Purification of ras GTPase activating protein from bovine brain", Proc. Natl. Acad. Sci. USA, 85:5026-5030.
Gillock, E. T. et al., "Polyomavirus Major Capsid Protein VP1 is Capable of Packaging Cellular DNA When Expressed in the Baculovius System," Journal of Virology (1997),71(4): 2857-2865.
Graessman et al., "Inhibition of SV40 Gene Expression by Microinjected Small Antisense RNA and DNA Molecules" Nucleic Acids Research 19:53-59, 1991.
Graham, "Mapping Transgene Activity in Plants Using Visible Phenotypes" Australian Society for Biochemistry and Molecular Biology Incorporated and Australian Society of Plant Physiologists Incorporated, vol. 28, Abstract SYM-18-06 (1996).
Grasby, JA et al.; Biochemistry Mar. 28, 1995; 34(12);4068-76.
Green et al. Antisense Oligonucleotides: An evolving technology for the modulation of gene expression in human disease. J AM Coll Surg. 2000, vol. 191:93-105. American College of Surgeons. *
Grierson et al., "Does Co-Suppression of Sense Genes in Transgenic Plants Involve Antisense RNA?" Trends in Biotechnology 9:122-123, 1991.
Griffey, RH et al.; J Med Chem Dec. 20, 1996; 39(26);5100-9.
Grounds of Appeal filed by Alnylam Europe AG for European Patent EP 1214945, filed Aug. 5, 2009, 21 pages.
Grounds of Appeal filed by Appellant Sanofi-Aventis Deutschland GmbH, on Oct. 26, 2010, against German Patent No. DE 10066235.8, 21 pages.
Grounds of Appeal filed by Appellant Silence Therapeutics AG, on Nov. 23, 2010, against German Patent No. DE 10066235.8, 48 pages.
Gryaznov et al., "Template controlled coupling and recombination of oligonucleotide blocks containing thiophosphoryl groups,"Nucleic Acids Res., 21(6):1403-1408 (1993).
Guang et al., "An Argonaute Transports siRNAs from the Cytoplasm to the Nucleus" Science 321:537-541, 2008.
Guo et al., "Par-1 a Gene Required for Establishing Polarity in C. elegans Embryos, Encodes a Putative Ser/Thr Kinase That is Asymmetrically Distributed" Cell 81:611-620, 1995.
Ha, I et al.; Genes Dev Dec. 1, 1996;10(23);3041-50.
Haborth et al., Identification of essential genes in cultured mammalian cells using small interfering RNAs, Journal of Cell Science 114:4557-4565, 2001.
Hamada M. et al., "Effects of RNA Interference in Gene Expression (RNAi) in Cultured Mammalian Cells of Mismatches and the Introduction of Chemical Modifications at the 3′-Ends of siRNAs," Antisense and Nucleic Acid Drug Development, 2002, vol. 12, pp. 301-309.
Hamilton et al.; Science, vol. 286:950-951, A Species of Small Antisense RNA in Posttranscriptional Gene Silencing in Plants (Oct. 29, 1999).
Hamm et al., "Incorportation of 2′-Deoxy-2′mercaptocytidine into Oligonucleotides via Phosphoramidite Chemistry" J. Org. Chem. 62:3415-3420, 1997.
Hammond, S.M. et al., (2000), "An RNA-directed nuclease mediates post-transcriptional gene silencing in Drosophila cells", Nature, 404:293-296.
Hanahan et al., "The Hallmarks of Cancer" Cell 100:57-70, 2000.
Harada et al., "Absence of the Type I IFN System in EC Cells: Transcriptional Activator (IRF-1) and Repressor (IRF-2) Genes Are Developmentally Regulated" Cell 83:303-312 (1990).
Harada et al., "Absence of the Type I IFN System in EC Cells: Transcriptional Activator (IRF-1) and Repressor (IRF-2) Genes are Developmentally Regulated," Cell 83:303-312 (1990).
Harborth, J. et al., (2001), "Identification of essential genes in cultured mammalian cells using small interfering RNAs", Journal of Cell Science, 114(24):4557-4565.
Harfe et al., "Analysis of a Caenorhabditis elegans twist homolog identifies conserved and divergent aspects of mesodermal patterning" Genes & Development 12:2623-2635 (1998).
Harris et al., "The Eu-myc Transgenic Mouse A Model for High-incidence Spontaneous Lymphoma and Leukemia of Early B Cells" J. Exp. Med. 167(2)353-371, 1988.
Hedges, "The Origin and Evolution of Model Organisms," Nature Reviews, 3:838-849 (2002).
Hoke, GD et al.; Nucleic Acids Res Oct. 25, 1991; 19(20):5743-8.
Holen, T. et al., (2002), "Positional effects of short interfering RNAs targeting the human coagulation trigger Tissue Factor", Nucleic Acids Research, 30(8):1757-1766.
Horn, T et al.; Nucleic Acids Research, 1997, vol. 25, No. 23 : 4842-4849.
Hornung et al., "Sequence-specific potent induction of IFN-α by short interfering RNA in plasmacytoid dendritic cells through TLR7,"Nature Medicine, 11(3):263-270 (2005).
Hsu et al., "Immunogencity of Recombinant Adenovirus-Respiratory Syncytial Virus Vaccines with Adenovirus Types 4, 5, and 7Vectors in Dogs and a Chimpanzee" J. Infectious Disease 166:769-775, 1992.
Huber et al., "Retroviral-mediated gene therapy for the treatment of hepatocellular carcinoma. An innovative approach for cancer therapy" Proc. Natl Acad. Sci USA 88:8039-8043, 1991.
Hu-Lieskovan et al., "Sequence-Specific Knockdown of EWS-FLI1 by Targeted, Nonviral Delivery of Small Interfering RNA Inhibits Tumor Growth in a Murine Model of Metastatic Ewing's Sarcoma" Cancer Res., 65(19):8984-8992 (2005).
Hung, C., et al., "A novel siRNA validation system for functional screening and identification of effective RNAi probes in mammalian cells," Biochemical and Biophysical Research Communications, 2006, pp. 707-720, vol. 346.
Hunter et aL, "The characteristics of inhibition of protein synthesis by double stranded ribonucleic acid in reticulocyte lysates," J. Biol. Chem., 250(2):409-417 (1975).
Hunter et al., "Genetics: A touch of elegance with RNAi" Curr. Biol. 9:R440-R442 (1999).
Hunter, Jun. 17, 1999, A touch of elegance with RNAi, Curr Biolo, 9: R440-R442.
Hwu et al., "Functional and Molecular Characterization of Tumor-Infiltrating Lymphocytes Transduced with Tumor Necrosis Factor-alpha cDNA for the Gene Therapy of Cancer in Humans" J. Immunol. 150:4104-4115, 1993.
Interlocutory Decision in opposition proceedings for European Patent No. 1144623 (Sep. 25, 2006), 72 pages.
International Preliminary Examination Report from PCT/DE00/00244.
International Search Report of International Application No. PCT/DE2000/00244, Jun. 20, 2000, 6 pages.
International Search Report of International Application No. PCT/EP2002/00151, Jan. 27, 2003, 7 pages.
Iwase, R et al.; Nucleic Acids Symp Ser 1997; (37);203-4.
Izant et al., "Constitutive and Conditional Suppression of Exogenous and Endogenous Genes by Anti-Sense RNA" Science 229:345-352, 1985.
Jackson, A. L. et al., "Widespread siRNA "off-target" transcript silencing mediated by seed region sequence complementarity," RNA Journal, 12(7): 1179-1187 (2007).
Jacobs, B.L., and Langland, J.O., 1996, When two stands are better than one: The mediators and modulators of the cellular responses to double-stranded RNA. Virology 219: 339-349.
James D. Thompson, Dec. 1999, Shortcuts from gene sequence to function, Nature Biotechnology, vol. 17, pp. 1158-1159.
James et al., "The Therapeutic Potential of Ribozymes" Blood 91:371-382, 1998.
Jaschke et al., "Synthesis and analytical characterization of RNA polyethylene glycol conjugates" Nucleosides & Nucleotides, 15:1519-1529, 1996.
Jen et al. Suppresion of Gene Expression by Targeted Disruption of Messenger RNA: Available Options and Current Strategies. Stem Cells 2000, vol. 18: 307-319. AlphaMed Press. *
Jennings et al., "Inhibition of SV40 Replicon Function by Engineered Antisense RNA Transcribed by RNA Polymerase III" EMBO Journal 6:3043-3047, 1987.
Jiang, A., et al., "In vivo cell type-specific gene delivery with retroviral vectors that display single chain antibodies," Gene Therapy, 1999, pp. 1982-1987, vol. 6.
Jorgensen et al., "Silencing of Plant Genes by Homologous Transgenes" AgBiotech News and Information 4:265-273, 1992.
Judge A.D., et al., "Design of Noninflammatory Synthetic siRNA Mediating Potent Gene Silencing in Vivo," Molecular Therapy (2006), 13(3): 494-505.
Judge et al., "Sequence-dependent stimulation of the mammalian innate immune response by synthetic siRNA," Nat. Biotechnol., pp. 1-6 (2005) (8 pages of supplementary content included).
Kabanov et al., "A new class of antivirals: antisense oligonucleotides combined with a hydrophobic substituent effectively inhibit influenze virus reproduction and synthesis of virus-specific proteins in MDCK cells" FEBS Lett. 259 (2):327-330,1990.
Kamio et al., "Nucleotide Sequence of an Incompatibility Region of Mini-Rts1 That Contains Five Direct Repeats" Journal of Bacteriology 155:1185-1191, 1983.
Kaufman et al., "Double-stranded RNA-activated protein kinase mediates virus-induced apoptosis: A new role for an old actor." PNAS USA, 96:11693-11695, 1999.
Kay et al., "Hepatic Gene Therapy: Persistent Expression of Human alphal-Antitrypsin in Mice after Direct Gene Delivery In Vivo" Human Gene Therapy 3:641-647, 1992.
Kelly, J. "Superagonist Trial Hit by Cytokine Storm," Muscoskeletal Report, Aug. 17, 2006, 3 Pages.
Kennerdell et al., "Use of dsRNA-Mediated Genetic Interference to Demonstrate that frizzled and frizzled 2 Act in the Wingless Pathway" Cell 95(7):1017-1026 (1998).
Kennerdell et al.; Cell, vol. 95, S. 1017-1026; "Use of dsRNA-Mediated Genetic Interference to Demonstrate that frizzled and frizzled 2 Act in the Wingless Pathway" Dec. 23, 1998.
Kim et al., "Stable Reduction of Thymidine Kinase Activity in Cells Expressing High Levels of Anti-Sense RNA" Cell 42:129-138, 1985.
Kitabwalla et al., "RNA-Interference—A New Weapon Against HIV and Beyond," N. Engl. J. Med., 347(17):1364-1367 (2002).
Klemens, et al.(1999), The 2 Å Structure of helix 6 of the human signal recognition particle RNA., Structure 7(11): 1345-1352.
Koshkin et al., "LNA (Locked Nucleic Acids) Synthesis of the Adenine, Cytosine, Guanine, 5-Methylcytosine, Thymine and Uracil Biclonucleoside Monomors, Oligomerisation and Unprecendented Nucleic Acid Recognition," Tetrahedron 54:3507-3630, 1998.
Kovalchuk et al., "Burkitt Lymphoma in the Mouse" J. Exp. Med. 192:1183-1190, 2000.
Krepela, "Cysteine proteinases in tumor cell growth and apoptosis" Neoplasma 48:332-349, 2001.
Kreutzer et al (1999) Gesellschaft fur Biochemie und Molekularbiologie S169, Abstract Only.
Krieger et al., "The Flavr Savr Tomato, an Early Example of RNAi Technology" HortScience 43:962-964, 2008.
Kumar et al., "Antisense RNA: function and fate of duplex RNA in cells of higher eukaryotes" Microbiology and Molecular Biology Reviews, 62(4):1415-1434, 1998.
Lamond, A., et al., "Antisense oligonucleotides made of 2′-O-alky1RNA: their properties and applications in RNA biochemistry," FEBS Letters (1993), 325(1-2): 123-127.
Lee et al., "The C. elegans Herochronic Gene lin-4 Encodes Small RNAs with Antisense Complementary to lin-14" Cell 75:843-854 (1993).
Lee, et al.; Cell, vol. 88; S. 637-646; Mar. 7, 1997; The Cold Shock Domain Protein LIN-28 Controls Developmental Timing in C. elegans and Is Regulated by the lin-4 RNA.
Letsinger et al., "Cholesteryl-conjugated oligonucleotides: Synthesis, properties, and activity as inhibitors of replication of human immunodeficiency virus in cell culture" PNAS USA 86:6553-6556, 1989.
Letter to the International Examining Authority from Gassner & Partner in the prosecution of PCT/DE00/00244 (WO 00/44895), 5 pages (Mar. 28, 2001) (in German).
Lewis, D.L. et al., (2002), "Efficient delivery of siRNA for inhibition of gene expression in postnatal mice", Nature Genetics, 32:107-108.
Li et al. , Dev. Biology vol. 210, 1999, p. 238 abstract 346, Abstract Only.
Li et al., "Folate-Mediated Targeting of Antisense Oligodeoxynucleotides to Ovarian Cancer Cells" Pharm. Res. 15(10):1540-1545, 1998.
Lin et al.; Nature, vol. 402:128-129, "Policing rogue genes" Nov. 11, 1999.
Lipardi, C. et al., (2001), "RNAi as Random Degradative PCR: siRNA Primers Convert mRNA into dsRNAs that Are Degraded to Generate New siRNAs", Cell, 107:297-307.
Lipinski, et al. (1997) Adv. Drug Delivery Review 23:3-25.
Lipson et al., "Psoralen cross-linking of ribosomal RNA" Methods in Enzymology, 164:330-341, 1998.
List of Documents in Opposition to German Application No. DE 10066235, filed by Silence Therapeutics AG, Sanofi Aventis Deutschland GmbH, and Pfizer Inc., 4 pages.
Liu et al., "Detection of a novel ATP-dependent cross-linked protein at the 5′ splice site-U1 small nuclear RNA duplex by methylene blue-mediated photo-cross-linking" Molecular Cell Biology, 18:6910-6920, 1998.
Livache et al., "Detection of HIV1 DNA in Biological Samples by an Homogenous Assay: Fluorescence Measurement of Double-Stranded RNA Synthesized from Amplified DNA" Analytical Biochemistry, 217:248-254, 1994.
Lopez-Fraga, M., et al., "RNA Interference-Based Therapeutics: New Strategies to Fight Infectious Disease," Infectious Disorders Drug Targets (2008), 8:262-273.
Lowy, D.R. et al., (1993), "Function and Regulation of RAS", Annu. Rev. Biochem., 62:851-891.
Lubberts, E., et al., "Adenoviral Vector-Mediated Overexpression of IL-4 in the Knee Joint of Mice with Collagen-Induced Arthritis Prevents Cartilage Destruction," The Journal of Immunology, 1999, pp. 4546-4556.
Luo et al., "The Gene-Silencing Efficiency of SiRNA is Strongly Dependent on the Local Structure of mRNA at the Targeted Region" Biochemical and Biophysical Research Communications, vol. 318(1):303-10, 2004.
Ma MY (1993) Biochem. 32(7):1751-8.
Madhur Kumar et al., "Antisense RNA: Function and Fate of Duplex RNA in Cells of Higher Eukaryotes" Microbiology and Molecular Biology Reviews, vol. 62, Dec. 1998, pp. 1415-1434.
Maitra et al., "HIV-1 TAR RNA Has an Intrinsic Ability to Activate Interferon-Inducible Enzymes" Virology 204:823-827, 1994.
Maiumdar, A et al.; Nat Genet Oct. 1998; 20(2):212-4.
Malone, R.W. et al., "Cationic liposome-mediated RNA transfection," Proc. Natl. Acad. Sci. USA (1989), 86: 6077-6081.
Manche et al. Molecular and Cellular Biology 1992, vol. 12, pp. 5238-5248.
Manche, L. et al., (1992), "Interactions between Double-Stranded RNA Regulators and the Protein Kinase DAI", Molecular and Cellular Biology, 12(11):5238-5248.
Manoharan et al., "Chemical Modifications to Improve Uptake and Bioavailability of Antisense Oligonucleotides" Ann. NY Acad. Sci. 660-306-309, 1992.
Manoharan et al., "Cholic Acid-Oligonucleotide Conjugates for Antisense Applications" Bioorg. Med. Chem. Lett. 4(8):1053-1060, 1994.
Manoharan et al., "Introduction of a Lipophilic Thioether Tether in the Minor Groove of Nucleic Acids for Antisense Applications" Bioorg. Med. Chem. Lett. 3(12):2765-2770, 1993.
Manoharan et al., "Lipidic Nucleic Acids" Tetrahedron 36:3651-3654, 1995.
Manoharan et al., "Oligonucleotide Conjugates Alteration of the Pharmacokinetic Properties of Antisense Agents" Nucleosides & Nucleotides 14:969-973, 1995.
Manoharan, M., "RNA interference and chemically modified small interfering RNAs," Current Opinion in Chemical Biology (2004), 8: 570-579.
Manoharan, Oligonucleotide Conjugates as Potential Antisense Drugs with Improved Uptake, Biodistribution, Targeted Delivery and Mechanism of Action: Antisense and Nucleic Acid Drug Development 12:103-128, 2002.
Marques et al., "A Structural Basis for Discriminating Between Self and Non-Self Double-Stranded RNAs In Mammalian Cells" Nature Biotechnology 24:559-65, 2006.
Marques et al., "Activation of the mammalian immune system by siRNAs," Nat. Biotechnol., 23(11):1399-1405 (2005).
Martinez et al., "Single stranded antisense siRNAs guide target RNA cleavage in RNAi," Cell, 110:563-574 (2002).
Martinez et al., "Single-Stranded Antisense siRNAs Guide Target RNA Cleavage in RNAi," Cell, 110:563-574 (2002).
Maru, "Molecular Biology of Chronic Myeloid Leukemia" Int. J. Hematol. 73:308-322, 2001.
Matrisian, "Cancer biology: Extracellular proteinases in malignancy" Curr. Biol. 9(20)R776-778, 1999.
McCaffrey, A.P. et al., (2002), "RNA interference in adult mice", Nature, 418:38-39.
McManus et al., "Gene Silencing in Mammals by Small Interfering RNAs," Nat. Rev. Genet., 3:737-747 (2002).
Meister, "RNA Interference in the Nucleus" Science 321:496-497, 2008.
Mendelsohn et al., "The EGF receptor family as target for cancer therapy" Oncogene 19(56):6550-6565, 2000.
Micura, "Cyclic oligoribonucleotides (RNA) by solid-phase synthesis" Chem. Eur. J. 5:207702082, 1999.
Mignatti et al., "Biology and Biochemistry of proteinases in Tumor Invasion" Physiol. Rev. 73:161-195,1993.
Milhaud et al., Journal of Interferon Research, 1991, vol. 11, 261-265.
Milligan et al., "Synthesis of Small RNAs Using T7 RNA Polymerase" Methods in Enzymology, 180:51-62, 1989.
Minks et al. Journal of Biological Chemistry 1979, vol. 254, pp. 10180-10183.
Minks, M. A. et al., The Journal of Biological Chemistry (1979), 254, (20):10180-10183.
Minutes of oral proceedings for European Patent EP 1214945, May 19, 2010, 13 pages.
Minutes of oral proceedings regarding opposition against German Patent DE 10066235.8, Feb. 5, 2010, 14 Pages.
Minutes of the Oral Proceedings held on Jan. 14, 2010 in Opposition to German Patent DE 10066235.8, issued by the German Patent and Trademark Office, 55 Pages.
Minutes of the Oral Proceedings in opposition proceedings for European Patent No. 1144623 (Jun. 22, 2006).
Mishra et al., "Improved leishmanicidal effect of phosphorotioate antisense oligonucleotides by LDL-mediated delivery" Biochem. Biophys. Acta. 264:229-237, 1995.
Misquitta et al., "Targeted disruption of gene function in Drosophila by RNA interference (RNA-i): A role for nautilus in embryonic somatic muscle fromation," PNAS USA, 96:1451-1456 (1999).
Misquitta, L. and Paterson, B.M., 1999, Targeted disruption of gene function in Drosophila by RNA interference (RNA-i): A role for nautilus in embryonic somatic muscle formation, Proc. Natl. Acad. Sci. 96: 1451-1456.
Mizuno et al., "Regulation of Gene Expression by a Small RNA Transcript (micRNA) in Escherichia coli K-12)" Proc. Japan Acad. 59:335-338, 1983.
Monia, B.P. et al., "Evaluation of 2′-Modified Oligonucleotides Containing 2′-Deoxy Gaps as Antisense Inhibitors of Gene Expression," The Journal of Biological Chemistry (1993), 268(19): 14514-14522.
Montgomery M.K., et al., 1998, RNA as a target of double-stranded RNA-mediated genetic interference in Caenorhabditis elegan, Proc. Natl. Acad. Sci. 95: 15502-15507.
Montgomery, et al., Jul. 1998, Double-stranded RNA as a mediator in sequence-specific genetic silencing and co-suppression, TIG, vol. 14, No. 7., pp. 255-258.
Montgomery, M., and Fire, 1998, Analysis of a Caenorhabditis elegans twist homolog identifies conserved and divergent aspects of mesodermal patterning, Genes and Development, 12: 2623-2635.
Morita et al., "RNAi Provides a New Tool for Functional Analyses of Mammalian Genes", Proteins, Nucleic Acids and Enzymes, vol. 47, No. 14, 2002, pp. 1939-1945, with English Abstract.
Moss et al., "The Cold Shock Domain Protein LIN-28 Controls Developmental Timing in C. elegans and Is Regulated by the lin-4 RNA," Cell, 88:637-646 (1997).
Mullauer et al., "Mutations in apoptosis genes: a pathogenetic factor for human disease" Mutat. Res.488:211-231, 2001.
Muzyczka, "Use of Adeno-Associated Virus as a General Transduction Vector for Mammalian Cells" Curr. Topics Micro. Immunol. 158:97-129, 1992.
Nakamura et al., "How Does RNase H recognize a DNA-RNA Hybrid?" Proc. Natl. Acad. Sci. 88:11535-11539 (1991).
Nakamura et al., "How does RNAseH recognize a DNA-RNA Hybrid?" Proc. Natl. Acad. Sci. 88:11535-11539, 1991.
Napoli et al., "Introduction of a chimeric Chalcone Synthase Gene into Petunia Results in Reversible Co-Suppression of Homologous Genes in trans" The Plant Cell 2:279-289, 1990.
Neilsen et al. (1997) Chem. Comm. 825-826.
Ngo, H., et al., 1998, Double-stranded RNA induces mRNA degradation in Trypanosoma brucei, Proc. Natl. Acad. Sci. 95: 14687-14692.
Nikiforov, et al. (1992) Nucleic Acids Research 20(6):1209-1214.
Nishi, T., et al., "High-Efficiency in Vivo Gene Transfer Using Intraarterial Plasmid DNA Injection following in Vivo Electroporation1," Cancer Research, Mar. 1, 1996, pp. 1050-1055, vol. 56.
Niu, G., et al., "Gene Therapy with Dominant-negative Stat3 Suppresses Growth of the Murine Melanoma B16 Tumor in Vivo1," Cancer Research, Oct. 15, 1999, pp. 5059-5063, vol. 59.
Normanno et al., "The role of EGF-Related Peptides in Tumor Growth" Front. Biosci. 6:D685-707, 2001.
Notice of Acceptance for Australian patent application No. AU 2008202208, Oct. 19, 2009, 3 pages.
Notice of opposition by Abbott Laboratories against European Patent No. 1 214 945 (Mar. 8, 2006).
Notice of Opposition by Alexandra Oppl against DE 10080167.6 (Jun. 20, 2008), 49 pages.
Notice of Opposition by AstraZeneca against European Patent No. 11 44 623 (May 28, 2003).
Notice of Opposition by Atugen AG against European Patent No. 11 44 623 (May 28, 2003).
Notice of opposition by Atugen against European Patent No. 1 214 945 (Mar. 8, 2006).
Notice of Opposition by Aventis against European Patent No. 11 44 623 (May 28, 2003).
Notice of Opposition by Dr. Martin Grund against European Patent No. 11 44 623 (May 28, 2003).
Notice of Opposition by Isis Pharmaceuticals against European Patent No. 11 44 623 (May 28, 2003).
Notice of Opposition by Jenssen Pharmaceuticals against European Patent No. 11 44 623 (May 28, 2003).
Notice of Opposition by Novartis against European Patent No. 11 44 623 (May 28, 2003).
Notice of Opposition by Pfizer against DE 10080167.6 (Jun. 19, 2008), 29 Pages.
Notice of opposition by Quark Biotech against European Patent No. 1 214 945 (Mar. 7, 2006).
Notice of Opposition by Sanofi Aventis against DE 10080167.6 (Jun. 16, 2008), 44 Pages. (Erroneously dated Jun. 16, 2007).
Notice of Opposition by Silence Therapeutics against DE 10080167.6 (Jun. 20, 2008), 53 pages.
Notice of opposition by Sima Therapeutics against European Patent No. 1 214 945 (Mar. 7, 2006).
Notice of Opposition by Sirna against DE 10080167.6 (Jun. 20, 2008), 76 pages.
Notice of Opposition by Sirna Therapeutics against European Patent No. 11 44 623 (May 19, 2003).
Notice of Opposition to Australian patent application No. AU 2008202208 filed by Sirna Therapeutics, Inc., filed on Jan. 29, 2010, 1 page.
Notice of Opposition to European Patent Application No. EP 05002454.6, filed by SIRNA Therapeutics, filed on Sep. 21, 2009, 42 Pages.
Notice of Opposition to European Patent EP 1550719 filed by Pfizer Limited, filed Sep. 23, 2009, 21 pages.
Notice of Opposition to European Patent EP 1550719 filed by Sanofi-Aventis Deutschland GmbH, filed Sep. 23, 2009, 46 pages.
Notice of Opposition to European Patent EP 1550719 filed by Sarah Elizabeth Rogues, filed Sep. 23, 2009, 24 pages.
Notice of Opposition to European Patent EP 1550719 filed by Silence Therapeutics AG, filed Sep. 24, 2009, 35 pages.
Notice of Opposition to German Application No. DE 100 66 235, filed by Pfizer Inc. on Jul. 9, 2008.
Notice of Opposition to German Application No. DE 10066235, filed by Sanofi Aventis Deutschland GmbH on Jul. 10, 2008, 42 pages.
Notice of Opposition to German Application No. DE 10066235, filed by Silence Therapeutics, AG on Jul. 10, 2008, 34 pages.
Notice of Reasons for Rejection for Japan Patent Application No. 2009-002824, Jun. 16, 2009, 15 Pages.
Notice of Reasons for Rejection for Japan Patent Application No. 2009-002826, Jun. 16, 2009, 15 Pages.
Notice of Reasons for Rejection, mailed on Nov. 1, 2011, Japanese Patent Application No. JP 2009-002825, 9 pages.
Novina, et al. The RNAi revolution. Nature (2004), vol. 430: 161-164. Nature Publishing Group. *
Oates et al., "Too Much Interference: Injection of Double-Stranded RNA Has Non-Specific Effects in the Zebrafish Embryo" Developmental Biology 24:20-28, 2000.
Oberhauser et al., "Effective incorporation of 2′-O-methyl-oligoribonucleotides into liposomes and enhanced cell association through modification with thiocholesterol" Nucl. Acids Res. 20:533-538, 1992.
Obika et al., "Stability and structural features of the duplexes containing nucleoside analogues with a fixed N-type conformation, 2′-O, 4′-C-mehtyleneribonucleosides" Tetrahedron 39:5401-5404, 1998.
Office Action Communication by the German Patent and Trademark Office dated Apr. 11, 2011 for German Divisional Patent Application No. 10066344.3-41, 7 pages.
Office Action Communication pursuant to Article 94(3) EPC dated Jul. 8, 2011, for European Patent Application No. EP 06025389.5, 8 pages.
Office Action dated Jun. 17, 2011, for U.S. Appl. No. 10/612,179, 11 Pages.
Office Action for U.S. Appl. No. 10/382,768, Feb. 5, 2010, 12 Pages.
Office Action for U.S. Appl. No. 10/382,768, Nov. 26, 2010, 7 pages.
Office Action for U.S. Appl. No. 10/383,099, Dec. 17, 2009, 9 Pages.
Office Action for U.S. Appl. No. 10/612,179 Dec. 17, 2009, 9 Pages.
Office Action for U.S. Appl. No. 10/612,179, Oct. 20, 2010, 24 pages.
Office Action for U.S. Appl. No. 11/982,305, Feb. 11, 2011, 13 pages.
Office Action for U.S. Appl. No. 11/982,305, Sep. 3, 2010, 10 pages.
Office Action for U.S. Appl. No. 11/982,325, Mar. 18, 2011, 12 pages.
Office Action for U.S. Appl. No. 11/982,328, Oct. 6, 2010, 11 pages.
Office Action for U.S. Appl. No. 11/982,345, Mar. 18, 2011, 14 pages.
Office Action for U.S. Appl. No. 11/982,345, Oct. 6, 2010, 11 pages.
Office Action for U.S. Appl. No. 11/982,411, Oct. 6, 2010, 12 pages.
Office Action for U.S. Appl. No. 11/982,425, Feb. 11, 2011, 13 pages.
Office Action for U.S. Appl. No. 11/982,425, Sep. 3, 2010, 10 pages.
Office Action for U.S. Appl. No. 11/982,434, Mar. 18, 2011, 12 pages.
Office Action for U.S. Appl. No. 11/982,434, Oct. 6, 2010, 11 pages.
Office Action for U.S. Appl. No. 11/982,441, Mar. 18, 2011, 12 pages.
Official Inquiry dated May 17, 2011, for Japanese Patent Application No. 2007-186339 (Appeal No. 2009-11870), 10 pages.
Official Inquiry dated May 17, 2011, for Japanese Patent Application No. 2007-186340 (Appeal No. 2009-11715), 11 pages.
Official Inquiry dated May 17, 2011, for Japanese Patent Application No. 2007-186341 (Appeal No. 2009-11871), 6 pages.
Opalinska et al., "Nucleic acid therapeutics: basic principles and recent applications", Nature Review 2002, vol. 1, pp. 503-514.
Ouchi et al., "Synthesis and Antitumor Activity of Poly(Ethylene Glycol)s Linked to 5-Flurouracil via Urethane or Urea Bond" Drug Design and Discovery 9:93-105, 1992.
Overview, http://arthritis-research.com/content/figures/ar1168-1.jpg, Jan. 12, 2010.
Oxford Advanced Learner's Dictionary of Current English, p. 253.
Paddison, P.J. et al., (2002), "Short hairpin RNAs (shRNAs) induce sequence-specific silencing in mammalian cells", Genes & Development, 16:948-958.
Pandolfi, "In vivo analysis of the molecular genetics of acute promyelocytic leukemia"Oncogene 20:5726-5735, 2001.
Paroo et al. Challenges for RNAi in vivo. Trends in Biotechnology (2004), vol. 22(8) 390-394. Elsevier. *
Parrish et al., "Functional anatomy of a dsRNA trigger: differential requirement for the two trigger strands in RNA interference" Molecular Cell, 6:1077-1087, 2000.
Paul et al., "Effective expression of small interfering RNA in human cells", Nature Biotechnology 2002, vol. 29, pp. 505-508.
PCT/GB00/04404 as filed (Nov. 19, 1999).
Pegram, MD et al., J. Clin Oncol Aug. 1998; 16(8):2659-71.
Pei et al., "On the Art of Identifying Effective and Specific siRNAs" Nature Methods 3: 670-676, 2006.
Perler, "InBase: the Intein Database," Nucleic Acids Res., 30(1):383-384 (2002).
Petition by Pfizer Inc. in opposition proceedings for German Patent No. 10066235.8 (May 25, 2009), 19 pages.
Petition by Sanofi-Aventis et al. in opposition proceedings for German Patent No. 10066235.8 (May 22, 2009).
Petition by Silence Therapeutics in opposition proceedings for German Patent No. 10066235.8 (May 25, 2009), 28 pages.
Petition regarding German Patent No. DE 10080167 filed by Silence Therapeutics AG, Mar. 17, 2009, 20 pages.
Petition submitted by Alnylam Europe AG against DE 10080167.6, including claims as filed and list of documents cited (Dec. 18, 2008), 80 pages.
Phillips et al., "The NZB Mouse as a Model for Chronic Lymphocyte Leukemia" Cancer Res. 52:437-443, 2000.
Phillips, M., "Antisense Inhibition and Adeno-Associated Viral Vector Delivery for Reducing Hypertension," Hypertension, Journal of the American Heart Association, 1997, pp. 177-187, vol. 29.
PiIs et al. (Nucleic Acids Research 2000, vol. 28: No. 9: 1859-1863). *
Pils, W. et al., "Flexible non-nucleotide linkers as loop replacements in short double helical RNAs," Nucleic Acids Research, 28(9): 1869-1963 (2000).
Pollock et al., "Mouse models of acute promyelocytic leukemia" Curr. Opin. Hematol. 8:206-211, 2001.
Polushin et al., "Synthesis of Oligonucleotides Containing 2′-Azido- and 2′-Amnio-2′-deoxyuridine Using Phosphtriester Chemistry" Tetrahedron 37: 3227-3230, 1996.
Prakash et al., "Positional effect of chemical modifications on short interference RNA activity in mammalian cells," J. Med. Chem. 48:4247-4253 (2005).
Pschyrembel Klinisches Worterbuch, 259., neu bearbeitete Auflage, Pschyrembel Clinical Dictionary 259th, Revised Edition, 2002, 1 page, with English summary.
Psychremebel Klinisches Worterbuch, 259, neu bearbeitete Auflage.
Pusch et al., "Nucleotide Sequence Homology Requirements of HIV-1 Specific Short Hairpin RNA" Nucleic Acids Research 31:6444-6449, 2003.
Randall, G. et al., (2003), "Clearance of replicating hepatitis C virus replicon RNAs in cell culture by small interfering RNAs", PNAS, 100(1):235-240.
Ravasio, "Selective Hydrogenations Promoted by Copper Catalysts. 1. Chemoselectivity, Regioselectivity, and Stereoselectivity in the Hydrogenation of 3-Substituted Steroids" J. Org. Chem. 56:4329-4333, 1991.
Record for the Oral proceedings before the Opposition Division from European Patent Office, in opposition of European Patent No. 1214945, Mar. 21, 2009, 92 Pages.
Reed, "Mechanisms of Apoptosis" Am. J. Pathol. 157:1415-1430, 2000.
Regalado, "Turning Off Genes Sheds New Light On How They Work," The Wall Street Journal, 4 pages (Aug. 6, 2002).
Rego et al., "Analysis of the Molecular Genetics of Acute Promyelocytic Leukemia in Mouse Models" Semin. In Hemat. 38:54-70, 2001.
Reply to notice of opposition by Alnylam Europe in the opposition proceedings of European Patent No. 1214945 (Dec. 28, 2006), 81 Pages.
Reply to Office Action per article 94 (3) EPC of Jul. 8, 2011, filed on Nov. 17, 2011, European Patent Application No. EP 06025389.5, 5 pages.
Request that patent be revoked in its entirety, in Opposition against European Patent 1214945, filed with European Patent Office Opposition Division, filed by Opponent 1, SIRNA Therapeutics on Aug. 16, 2011, 49 pages.
Response to Notice of Opposition filed against German Patent No. EP 1407044, filed by Max-Plank—Gesellschaft zur Forderung der Wissenschaften e.V., Mar. 26, 2009, 4 pages.
Response to Notice of Opposition to European Patent EP 1550719 filed by Alnylam Europe AG, filed Mar. 15, 2010, 40 pages.
Response to Official Action filed for Australian Application No. 32713/00 (Oct. 19, 2004).
Response to patentee's Grounds of Appeal filed by Quark Biotech, Inc. for European Patent EP 1214945, filed Dec. 28, 2009, 12 pages.
Response to patentee's Grounds of Appeal filed by Sirna Therapeutics AG for European Patent EP 1214945, filed Dec. 23, 2009, 60 pages.
Response to Preliminary Opinion of the Board of Appeal for European Patent EP 1214945, filed by Sirna Therapeutics, Inc., filed on Apr. 16, 2010, 15 pages.
Response to Summons for oral proceedings in Opposition against EP 1214945 filed by Silence Therapeutics AG, filed on Apr. 19, 2010, 5 pages.
Response to Summons to Attend Oral proceedings issued by the German Patent and Trademark office on Dec. 9, 2009 regarding opposition against German Patent DE 10066235.8, filed by Alnylam Europe AG and Jan. 4, 2010, 36 Pages.
Response to the Submission of Opponent 1, filed by Alnylam Europe AG on Nov. 17, 2011, Opposition against European Patent EP 1550719, 17 pages.
Response to three Notices of Opposition submitted by Alnylam Europe AG in German Patent No. 100 66 235.8-41 (Feb. 4, 2009), including list of documents cited (translation enclosed).
Reynolds et al., "Rational siRNA design for RNA interference" Nature Biotechnology 22:326-330, 2004.
Robbins et al., "Sensing the danger in RNA," Nat. Med., 11(3):250-251 (2005).
Rosenfeld et al., "Adenovirus-Mediated Transfer of a Recombinant a-Antitrypsin Gene to the Lung Epithelium in Vivo" Science 252:431-434, 1991.
Rosenfeld et al., "In Vivo Transfer to the Human Cystic Fibrosis Transmembrane Conductance Regulator Gene to the Airway Epithelium" Cell 68:143-155, 1992.
Rumney, S., et al., "Structural Optimization of Non-Nucleotide Loop Replacements for Duplex and Triplex DNAs," J. Am. Chem. Soc., 1995, pp. 5635-5646, vol. 117.
Saison-Behmoaras et al., "Short modified antisense oligonucleotdies directed again st Ha-ras point mutation induce selective cleavage of the mRNA and inhibit T24 cells proliferation" EMBO J. 10:111-118, 1991.
Scheffer et al., "The drug resistance-related protein LRP is the human major vault protein" Nat. Med. 1:578-582, 1995.
Scherr et al., "Quantitative Determination of Lentiviral Vector Particle Nos. by Real-time PCR" BioTechniques 31: 520-526, 2001.
Schlingensiepen et al., Antisense—From Technology to Therapy. Blackwell Science Ltd.,1997, vol. 6.
Schwarz et al., "Asymmetry in the assembly of the RNAi complex" Cell 115:199-208, 2003.
Schwarz et al., "Evidence that siRNAs Function as Guides, Not Primers, in the Drosophila and Human RNAi Pathways," Mol. Cell, 10:537-548 (2002).
Secrist et al., Abstract 21, Program & Abstracts, Tenth International Roundtable, Nucleotides, Nucleotides and their Biological Applications, Park City, Utah, Sep. 16-20, 1992.
Sedlik, C. et al., "Recombinant parvovirus-like particles as an antigen carrier: A novel nonreplicative exogenous antigen to elicit protective antiviral cytotoxic T cells," Proc. Natl. Acad. Sci. USA (1997) 94: 7503-7508.
Sen, G., et al., "A Brief History of RNAi: The Silence of the Genes," FASEB J., vol. 20, pp. 1293-1299, 2006.
Seow, Y., et al., "Biological Gene Delivery Vehicles: Beyond Viral Vectors," Molecular Therapy (2009), 17(5): 767-777.
Seydoux et al., "Repression of gene expression in the embryonic germ lineage of C. elegans" Nature 382: 713-716 (1996).
Shannon et al., "Modelling myeloid leukemia tumors suppressor gene inactivation in the mouse" Semin. Cancer Biol. 1:191-199, 2001.
Sharp, P.A., (2001), "RNA interference-2001", Genes & Development, 15:485-490.
Sharp, P.A., 1999, RNAi and double-stranded RNA. Gene and Development 13: 139-141.
Shea et al., "Synthesis, hybridization properties and antiviral activity of lipid-oligodeoxynucleotide conjugates" Nucl. Acids Res. 18:377703783, 1990.
Shi et al., "A CBP/p300 homolog specifics multiple differentiation pathways in Caenorhabditis elegans" Genes & Development 12(7):943-955 (1998).
Shiota et al., "I want to Know the RNAi Protocol of that Animal!—Effective RNAi in Mammal Cells", Cell Engineering, vol. 22, No. 3, 2003, pp. 310-315, with English summary.
Sijen, T. et al., (2001), "On the Role of RNA Amplification in dsRNA-Triggered Gene Silencing", Cell, 107:465-476.
Simons et al., "Translational Control of IS10 Transposition" Cell 34:683-691, 1983.
Sinha, "Large-scale Synthesis. Approaches to Large-scale Synthesis of Oligodeoxynucleotides and their Analogs," Antisense—From Technology to Therapy, vol. 6, Edited by Reimar Schlingensiepen et al., pp. 29-58 (1997).
Skorski et al., "Suppression of Philadelphia Leukemia cell growth in mice by BCR-ABL antisense oligodeoxynucleotide" Proc. Natl. Acad. Sci. USA 91:4504-4508, 1994.
Skripkin et al., "Psoralen crosslinking between human immunodeficiency virus type 1 RNA and primer tRNA3Lys," Nucleic Acids Res., 24(3):509-514 (1996).
Sledz et al., "Activation of the interferon system by short-interfering RNAs," Nat. Cell Biol., 5(9):834-839 (2003).
Sledz et al., "RNA Interference and Double-Stranded RNA Activated Pathways" Biochemical Society Transactions 32:956-956, 2004.
Soeda, E., et al., "Enhancement by polylysine of transient, but not stable, expression of genes carried into cells by polyoma VP1 pseudocapsids," Gene Therapy (1998), 5: 1410-1419.
Soutschek et al., "Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAs," Nature, 432:173-178 (2004).
Sporlein, B., et al., "Lipofectin: direct gene transfer to higher plants using cationic liposomes," Theoretical and Applied Genetics (1991), 83: 1-5.
Sproat, B., "Chapter 18: 2-O-Alkyloligoribonucleotides," Antisense Research and Applications, CRC Press, 351-362, 1993.
Sproat, B., "Chapter 6: Synthesis of 2'-O-Alkyloligoribonucleotides," Methods in Molecular Biology 20, Humana Press, NJ: 115-142, 1993.
Statement of Grounds & Particulars of Opposition filed by Sirna Therapeutics, Inc., on Aug. 23, 2011, for Australian Patent Application No. AU 778474, 9 pages.
Statement of Grounds & Particulars of Opposition to Australian patent application No. AU 2008202208 filed by Sirna Therapeutics, Inc., filed on Apr. 29, 2010, 28 pages.
Statement of Grounds and Particulars of Opposition to Australian Application No. 778474 filed by Sima Therapeutics, Inc. (Jun. 1, 2009).
Statement of Grounds and Particulars of Opposition to Australian Patent Application No. 2005201044, filed by Sirna Therapeutics (Dec. 1, 2008).
Statement of Grounds and Particulars of Opposition to Australian Patent No. 778474, filed by Sirna Therapeutics, Inc. on Jun. 9, 2005, 22 Pages.
Statutory Declaration by David Keith Myers dated Aug. 2, 2010, filed by Sirna Therapeutics, Inc., in opposition to Australia Patent No. AU 778474, 3 pages.
Statutory Declaration by David Keith Myers dated Nov. 7, 2008, filed by Sirna Therapeutics, Inc., in opposition to Australia Patent No. AU 778474, 16 pages, list of journals published before the end of 1999 which cite a journal article authored by Andrew Fire and co-workers, and published in the journal Nature on Feb. 19, 1998.
Statutory Declaration by David Keith Myers dated Nov. 7, 2008, filed by Sirna Therapeutics, Inc., in opposition to Australia Patent No. AU 778474, 3 pages, list of patent publications having an earliest claimed priority date of Nov. 24, 1999 or earlier, which cite Fire, A., et al., (1998), Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans, Nature 391: 806-811.
Statutory Declaration by Martin Edward O'Brien of Spruson and Ferguson in the matter of Opposition to Australian Patent No. 778474, filed by SIRNA Therapeutics, Inc. on Sep. 9, 2005.
Statutory Declaration dated Aug. 17 , 2010 by David M. Stalker with Exhibits DMS-A to DMS-C and Exhibits DMS-41 to DMS-74 thereto in respect of opposition to accepted Australian Patent Application No. 2005201044, 30 pages
Stetler-Stevenson et al., "Tumor Cell Interactions with the Extracellular Matrix During Invasion and Metastasis" Annu. Rev. Cell Biol. 9:541-573, 1993.
Strasser et al., "Apoptosis Signaling" Annu. Rev. Biochem. 69:217-245, 2000.
Strauss; Science, vol. 286:886; "Candidate 'Gene Silencers' Found" Oct. 29, 1999.
Stryer, L., Biochemistry, Part 1 Molecular Design of Life, Chapter 4 DNA and RNA: Molecules of Heredity, 1988, pp. 80-82.
Submission by Abbott Laboratories in the opposition proceedings of European Patent No. 1 214 945 (Nov. 20, 2008). English translation only.
Submission by Abbott Laboratories in the opposition proceedings of European Patent No. 1 214 945 (Oct. 30, 2007).
Submission by Alexandra Oppl against DE 10080167.6 on Mar. 4, 2009, 14 pages.
Submission by Alnylam Europe AG in opposition to DE 10080167.6 on Mar. 4, 2009, 21 pages.
Submission by Alnylam Europe in opposition proceedings for European Patent No. 1144623 (Apr. 21, 2006), 63 pages.
Submission by Alnylam Europe in opposition proceedings for European Patent No. 1144623 (Dec. 7, 2004), 140 pages.
Submission by Alnylam Europe in opposition proceedings for European Patent No. 1144623 (Jun. 25, 2007), 110 pages.
Submission by Alnylam Europe in opposition proceedings for European Patent No. 1144623 (Jun. 7, 2006) 247 pages.
Submission by Alnylam Pharmaceuticals in the opposition proceedings of European Patent No. 1 144 623 (Nov. 7, 2008). (translation attached).
Submission by Alnylam Pharmaceuticals in the opposition proceedings of European Patent No. 1214945 (Nov. 20, 2008), 35 Pages.
Submission by Atugen AG opposition to European Patent No. 1 144 623 (Nov. 7, 2008), pp. 1-22 only.
Submission by Pfizer against DE 10080167.6 on Feb. 27, 2009, 8 pages.
Submission by Silence Therapeutics in the opposition proceedings of DE 10080167.6 on Feb. 20, 2009, 3 pages.
Submission by Silence Therapeutics in the opposition proceedings of European Patent No. 1 214 945 (Nov. 20, 2008).
Submission by Sima Therapeutics in opposition to European Patent No. 1 144 623 (Nov. 6, 2008).
Submission by Sima Therapeutics in the opposition proceedings of European Patent No. 1 214 945 (Jan. 4, 2008).
Submission by Sima Therapeutics in the opposition proceedings of European Patent No. 1 214 945 (Nov. 20, 2008). English translation only.
Submission by Sirna Therapeutics against DE 10080167.6 on Mar. 4, 2009, 62 pages.
Submission by Sirna Therapeutics in opposition proceedings for European Patent No. 11 44 623 (Apr. 20, 2006—Uexkull & Stolberg), (Nov. 20, 2008).
Submission by Sirna Therapeutics in opposition proceedings for European Patent No. 1144623 (Apr. 20, 2006—Isenbruck, Bosl, Horschler, Wichmann, Huhn), 20 pages.
Sui, G., et al., "A DNA vector-based RNAI technology to suppress gene expression in mammalian cells," Proc. Natl. Acad. Sci. USA, Apr. 16, 2002, pp. 5515-5520, vol. 99, No. 8.
Summons to Attend Oral Hearing regarding opposition against European Patent EP 1214945, Feb. 26, 2010, 15 pages.
Summons to attend oral proceedings in the opposition proceedings of European Patent No. 1214945 (May 6, 2008), 18 pages.
Summons to attend oral proceedings pursuant to Rule 115(1) EPC issued by the European Patent Office on Nov. 25, 2011, for Opposition against European Patent No. EP 1550719, 50 pages.
Suntharalingam, G., et al., "Cytokine Storm in a Phase 1 Trial of the Anti-CD28 Monoclonal Antibody TGN1412," New England Journal of Medicine (2006), 355(10): 1018-1028.
Svinarchuk et a1., "Inhibition of HIV proliferation in MT-4 cells by antisense oligonucleotie conjugated to lipophilic groups" Biochimie 75:49-54, 1993.
Takayama et al., "Antisense RNA" Critical Reviews in Biochemistry and Molecular Biology 25:155-184, 1991.
Thomson et al. Activity of hammerhead ribozymes containing non-nucleotide linkers. Nucleic Acids Research 1993, vol. 21:5600-5603. Oxford University Press. *
Thomson et al., "Synthesis and Properties of Diuridine Phosphate Analogues Containing Thio and Amino Modifications" J. Org.Chem. 61:6273-6281, 1996.
Tijsterman, M. et al., (2002), "The Genetics of RNA Silencing", Annu. Rev. Genet., 36:489-519.
Timmons et al., "Specific interference by ingested dsRNA" Nature, 395:854, 1998.
Timmons et al.; Nature, 395(6705:854); "Specific Interference by Ingested dsRNA" Oct. 29, 1998.
Tolun et al., "Direct Repeats of the F Plasmid incC Region Express F Incompatibility" Cell 24: 687-694 (1981).
Touze, A., et al., "In vitro gene transfer using human papillomavirus-like particles," Nucleic Acids Res. (1998) 26(5): 1317-1323.
Tsutsui et al., "Role of Nine Repeating Sequences of the Mini-F Genome for Expression of F-Specific Incompatibility Phenotype and Copy Number Control" Journal of Bacteriology 155:337-344, 1983.
Tuschl et al. (Dec. 1999) Genes and Dev. 13:3191-7.
U.S. Appl. No. 60/117,635, filed Jan. 28, 1999.
U.S. Appl. No. 60/117,635, Li et al. (filed Jan. 28, 1999).
U.S. Appl. No. 60/130,377, Pachuk et al. (filed Apr. 21, 1999).
U.S. Appl. No. 60/175,440, filed Jan. I I, 2000.
Uhlenbeck, "A Small Catalytic Oligoribonucleotide" Nature 325:596-600, 1987.
Uhlmann, E. et al., "Antisense Nucleotides: A New Therapeutic Principal" Chemical Reviews, American Chemical Society, Easton, US vol. 90, No. 4, Jun. 1, 1990, pp. 543-584, ISSN:0009-2665.
Van Beusechem et al., "Long-term expression of human adenosine deaminase in rhesus monkeys transplanted with retrovirus-infected bone-marrow cells" Proc. Natl. Acad. Sci. USA 89:7640-7644, 1992.
Van Etten, "Pathogenesis and treatment of Ph leukemia: recent insights from mouse models" Curr. Opin. Hematol. 8:224-230, 2001.
Various, "Nature Insight: RNA Interference" Nature, 431:337-378, 2004.
Verma et al., "Gene therapy—promises, problems, and prospects," Nature, 389:239-242, 1997.
Vickers et al., "Efficient Reduction of Target RNAs by Small Interfering RNA and RNase H-dependent Antisense Agents. A Compartive Analysis" J. Biol. Chem. 278:7108-7118, 2003.
Voinnet, O. and Baulcombe, D. C., Nature (1997), 398:553.
Wacheck et al., "Small Interfering RNA Targeting Bcl-2 Sensitizers Malignant Melanoma" Oligonucleotides, vol. 13 (5):393-400,2003.
Wagner, "The state of the art in antisense research" Nat. Med. 1:1116-1118, 1995.
Wagner, et al., Feb. 19, 1998, Double-stranded RNA poses puzzle, Nature, 391: 744-745.
Wang et al., "Circular RNA oligonucleotides. Synthesis, nucleic acid binding properties, and a comparison with circular DNAs" Nucleic Acids Research, 22:2326-2333, 1994.
Wang et al., "RNA conformation in the Tat-TAR complex determined by site-specific photo-cross-linking," Biochem 35:6491:6499 (1996).
Wang, S., et al., "Delivery of antisense oligodeoxyribonucleotides against the human epidermal growth factor receptor into cultured KB cells with liposomes conjugated to folate via polyethylene glycol," Proc. Nat. Acad. Sci., Biochemistry, Apr. 1995, pp. 3318-3322.
Wargelius, et al., 1999, Double-stranded RNA induces specific developmental defects in zebrafish embryos, Biochem Biophys Res Com., 263: 156-161.
Waterhouse et al.; PNAS, vol. 95:13959-13964, "Virus resistance and gene silencing in plants can be induced by simultaneous expression of sense and antisense RNA"Nov. 1998.
Watkins et al., "In vivo UV cross-linking of U snRNAs that participate in trypanosome trans-splicing" Genes & Development, 5:1859-1869,1991.
Wengel, "Synthesis of 3′-C and 4′-C-branched oligodeoxynucleotides and the development of locked nucleic acid (LNA)" Acc. Chem, Res. 32:301-310, 1999.
Wess et al., "Early days for RNAi,"BioCentury, 11(12):A1-A8 (2003).
Wianny et al. Nature Cell Biology Feb. 2000: 70-75. *
Wianny, et al. (2000) Nature Cell Biology 2:70-75.
Wild, K. et al., (1999), "The 2 Å structure of helix 6 of the human signal recognition particle RNA", Structure, 7(11):1345-1352.
Williams et al., "Thermodynamic Comparison of the Salt Dependence of Natural RNA Hairpins and RNA Hairpins with Non-Nucleotide Spacers" Biochemistry 35:14665-14670, 1996.
Wilson et al., "Retrovirus-mediated transduction of adult hepatocytes" Proc. Natl. Acad. Sci. USA 85:3014-3018, 1998.
Wink, M., "Gene Therapy: Strategies and Vectors" Molekulare Biotechnologie, 2004, pp. 557-577, Wiley-VCH, with English summary.
Wong et al., "Modeling Philadelphia chromosome positive leukemias" Oncogene 20:5644-5659, 2001.
Written Reply filed on Oct. 17, 2011, Japanese Patent Application No. JP 2007-186339, 77 pages.
Written Reply filed on Oct. 17, 2011, Japanese Patent Application No. JP 2007-186340, 76 pages.
Written Reply filed on Oct. 17, 2011, Japanese Patent Application No. JP 2007-186341, 70 pages.
Written Submission by Alnylam Europe AG in Opposition proceedings for DE 100 80 167.6 (Mar. 4, 2009) (translation attached).
Xie, Y., et al., "Efficacy of Adenovirus-mediated CD/5-FC and HSV-I Thymidine Kinase/Ganciclovir Suicide Gene Therapies Concomitant with p53 Gene Therapy1," Clinical Cancer Research, Dec. 1999, pp. 4224-4232, vol. 5.
Yang, D. et al., (2000), "Evidence that processed small dsRNAs may mediate sequence-specific mRNA degradation during RNAi in Drosophila embryos", Current Biology, 10:1191-1200.
Yokota, "Tumor progression and metastasis" Carcinogenesis 21:497-503, 2000.
Yu, J. et al., (2002), "RNA interference by expression of short-interfering RNAs and hairpin RNAs in mammalian cells", PNAS, 99(9):6047-6052.
Zamecnik, P.C., et al., "Inhibition of Rous sarcoma virus replication and cell transformation by a specific oligodeoxynucleotide," Proc. Natl. Acad. Sci. USA (1978), 75(1): 280-284.
Zamore et al., "Evidence that siRNAs function as guides not primers in the Drosophila and human RNAi pathways," Mol. Cell, 10:537-48 (2002).
Zamore, et al. (2000) Cell 101:25-33.
Zelphati, O., et al., "Antisense oligonucleotides in solution of encapsulated in immunoliposomes inhibit replication of HIV-1 by several different mechanisms," Nucleic Acids Research, 1994, pp. 4307-4314, vol. 22, No. 20.
Zeng et al., "RNA Interference in human cells is restricted to the cytoplasm" RNA 8:855-860, (2002).
Zeng et al., "RNA interference in human cells is restricted to the cytoplasm," RNA, 8:855-860 (2002).
Zeng et al., "The Fetal Origin of B-Precursor Leukemia in the Eu-ret Mouse" Blood 92:3529-3536, 1988.
Zhang et al. Current Pharmaceutical Biotechnology 2004, vol. 5, pp. 1-7.
Zhang et al. Single processing center models for human dicer and bacterial Rnase III. Cell, 2004, vol. 118, pp. 57-68. *
Zhao et al., "Double-Stranded RNA Injection Produces Nonspecific Defects in Zebrafish," Dev. Biol., 229:215-223 (2001).
Zheng et al., "Activation of the protein kinase PKR by short double-stranded RNAs with single-stranded tails," RNA, 10:1934-1945 (2004).
Zheng, L., et al., "An approach to genomewide screens of expressed small interfering RNAs in mammalian cells," Proc. Natl. Acad. Sci. USA, Jan. 6, 2004, pp. 135-140, vol. 101, No. 1.
Zwieb et al., "Evidence of RNA-RNA cross-linked formation in Escherichia coli ribsomes" Nucleic Acids Research, 5:2705-2720, 1978.

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US8877726B2 (en)	1999-01-30	2014-11-04	Alnylam Pharmaceuticals, Inc.	Method and medicament for inhibiting the expression of a given gene
US9133454B2 (en)	1999-01-30	2015-09-15	Alnylam Pharmaceuticals, Inc.	Method and medicament for inhibiting the expression of a given gene
US9902955B2 (en)	1999-01-30	2018-02-27	Alnylam Pharmaceuticals, Inc.	Method and medicament for inhibiting the expression of a given gene
US9902954B2 (en)	1999-01-30	2018-02-27	Alynylam Pharmaceuticals, Inc.	Method and medicament for inhibiting the expression of a given gene
US9592250B2 (en)	2002-02-01	2017-03-14	Life Technologies Corporation	Double-stranded oligonucleotides
US9796978B1 (en)	2002-02-01	2017-10-24	Life Technologies Corporation	Oligonucleotide compositions with enhanced efficiency
US10036025B2 (en)	2002-02-01	2018-07-31	Life Technologies Corporation	Oligonucleotide compositions with enhanced efficiency
US10106793B2 (en)	2002-02-01	2018-10-23	Life Technologies Corporation	Double-stranded oligonucleotides
US10196640B1 (en)	2002-02-01	2019-02-05	Life Technologies Corporation	Oligonucleotide compositions with enhanced efficiency
US10626398B2 (en)	2002-02-01	2020-04-21	Life Technologies Corporation	Oligonucleotide compositions with enhanced efficiency
US20100184039A1 (en) *	2002-06-12	2010-07-22	Life Technologies Corporation	Methods and compositions relating to labeled rna molecules that reduce gene expression

Also Published As

Publication number	Publication date
JP2010057514A (ja)	2010-03-18
JP2006340732A (ja)	2006-12-21
US20080171861A1 (en)	2008-07-17
JP6471901B2 (ja)	2019-02-20
JP2019017390A (ja)	2019-02-07
DE50000414D1 (de)	2002-10-02
EP1214945A3 (de)	2002-09-04
US20050100907A1 (en)	2005-05-12
JP2008005844A (ja)	2008-01-17
DE19956568A1 (de)	2000-08-17
JP2003502012A (ja)	2003-01-21
US20130177631A1 (en)	2013-07-11
US9133454B2 (en)	2015-09-15
US20080171862A1 (en)	2008-07-17
US20130164366A1 (en)	2013-06-27
DE20023125U1 (de)	2003-05-15
EP1144623A1 (de)	2001-10-17
JP2010057515A (ja)	2010-03-18
US20130164843A1 (en)	2013-06-27
JP2007312784A (ja)	2007-12-06
EP1214945B1 (de)	2005-06-08
EP1214945A2 (de)	2002-06-19
US8729037B2 (en)	2014-05-20
DE10066235B4 (de)	2008-04-10
DE10080167B4 (de)	2008-03-20
PT1798285T (pt)	2017-06-26
US20080166800A1 (en)	2008-07-10
CY1119221T1 (el)	2018-02-14
EP1144623B9 (de)	2003-03-05
US9902955B2 (en)	2018-02-27
AU2005201044A1 (en)	2005-04-07
EP1798285A1 (de)	2007-06-20
ES2243608T5 (es)	2019-03-21
US20140220113A1 (en)	2014-08-07
US8168776B2 (en)	2012-05-01
JP2009100758A (ja)	2009-05-14
US8114981B2 (en)	2012-02-14
EP1144623B1 (de)	2002-08-28
ATE222953T1 (de)	2002-09-15
US20080233651A1 (en)	2008-09-25
WO2000044895A1 (de)	2000-08-03
DK2363479T3 (en)	2016-10-31
ZA200105909B (en)	2002-07-24
CA2359180A1 (en)	2000-08-03
ES2243608T3 (es)	2005-12-01
JP2007314555A (ja)	2007-12-06
US8114851B2 (en)	2012-02-14
US9902954B2 (en)	2018-02-27
EP1214945B2 (de)	2018-10-10
PT1214945E (pt)	2005-10-31
US8101742B2 (en)	2012-01-24
DK1214945T3 (da)	2005-09-26
US8101584B2 (en)	2012-01-24
ATE297463T1 (de)	2005-06-15
AU778474B2 (en)	2004-12-09
EP3018207A1 (de)	2016-05-11
HK1160487A1 (zh)	2012-08-17
US20180179526A1 (en)	2018-06-28
EP2363479B1 (de)	2016-07-13
EP1798285B1 (de)	2017-03-15
ES2321409T3 (es)	2009-06-05
DE20023125U8 (de)	2005-01-20
US20040072779A1 (en)	2004-04-15
ATE418610T1 (de)	2009-01-15
DK1550719T3 (da)	2009-04-27
JP2007031443A (ja)	2007-02-08
JP5990468B2 (ja)	2016-09-14
JP2013074901A (ja)	2013-04-25
DK1798285T3 (en)	2017-07-03
DE50015501D1 (de)	2009-02-05
US20080261303A1 (en)	2008-10-23
CY1108896T1 (el)	2014-07-02
US20040053875A1 (en)	2004-03-18
US8202980B2 (en)	2012-06-19
US20040102408A1 (en)	2004-05-27
ES2628535T3 (es)	2017-08-03
PT2363479T (pt)	2016-10-18
US20080182981A1 (en)	2008-07-31
US20140051166A1 (en)	2014-02-20
EP1550719A1 (de)	2005-07-06
CY1118264T1 (el)	2017-06-28
DE10080167D2 (de)	2002-02-28
DE10066235C5 (de)	2014-08-21
JP2015146823A (ja)	2015-08-20
AU3271300A (en)	2000-08-18
JP2009102380A (ja)	2009-05-14
EP2363479A1 (de)	2011-09-07
DE50010528D1 (de)	2005-07-14
ES2597953T3 (es)	2017-01-24
CA2359180C (en)	2007-06-12
DK1214945T4 (da)	2018-11-05
US20140220676A1 (en)	2014-08-07
US8877726B2 (en)	2014-11-04
ES2182791T3 (es)	2003-03-16
US8183362B2 (en)	2012-05-22
EP1550719B1 (de)	2008-12-24
AU2005201044B2 (en)	2008-05-29
JP2009100757A (ja)	2009-05-14
PT1550719E (pt)	2009-03-13

Publication	Publication Date	Title
US8119608B2 (en)	2012-02-21	Method and medicament for inhibiting the expression of a given gene
AU2008202208C1 (en)	2014-04-24	Method and medicament for inhibiting the expression of a defined gene
AU2017276342A1 (en)	2018-01-18	Method and medicament for inhibiting the expression of a defined gene

Legal Events

Date	Code	Title	Description
2003-10-27	AS	Assignment	Owner name: RIBOPHARMA AG, GERMANY Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:KREUTZER, ROLAND;LIMMER, STEFAN;REEL/FRAME:014621/0958;SIGNING DATES FROM 20030801 TO 20030825 Owner name: RIBOPHARMA AG, GERMANY Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:KREUTZER, ROLAND;LIMMER, STEFAN;SIGNING DATES FROM 20030801 TO 20030825;REEL/FRAME:014621/0958
2004-06-22	AS	Assignment	Owner name: ALNYLAM EUROPE AG, GERMANY Free format text: CHANGE OF NAME;ASSIGNOR:RIBOPHARMA AG;REEL/FRAME:015488/0614 Effective date: 20040527
2004-08-30	AS	Assignment	Owner name: RIBOPHARMA AG, GERMANY Free format text: CORRECTIVE ASSIGNMENT TO CORRECT RECEIVING PARTY ADDRESS, PREVIOUSLY RECORDED AT REEL 014621, FRAME 0958;ASSIGNORS:KREUTZER, ROLAND;LIMMER, STEFAN;REEL/FRAME:015733/0897;SIGNING DATES FROM 20030801 TO 20030825 Owner name: RIBOPHARMA AG, GERMANY Free format text: CORRECTIVE ASSIGNMENT TO CORRECT RECEIVING PARTY ADDRESS, PREVIOUSLY RECORDED AT REEL 014621, FRAME 0958;ASSIGNORS:KREUTZER, ROLAND;LIMMER, STEFAN;SIGNING DATES FROM 20030801 TO 20030825;REEL/FRAME:015733/0897
2009-08-07	AS	Assignment	Owner name: ALNYLAM PHARMACEUTICALS, INC., MASSACHUSETTS Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:ALNYLAM EUROPE AG;REEL/FRAME:023070/0300 Effective date: 20090805 Owner name: ALNYLAM PHARMACEUTICALS, INC.,MASSACHUSETTS Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:ALNYLAM EUROPE AG;REEL/FRAME:023070/0300 Effective date: 20090805
2011-10-27	ZAAA	Notice of allowance and fees due	Free format text: ORIGINAL CODE: NOA
2011-10-28	ZAAB	Notice of allowance mailed	Free format text: ORIGINAL CODE: MN/=.
2012-02-01	STCF	Information on status: patent grant	Free format text: PATENTED CASE
2012-04-17	CC	Certificate of correction
2015-08-21	FPAY	Fee payment	Year of fee payment: 4
2019-08-21	MAFP	Maintenance fee payment	Free format text: PAYMENT OF MAINTENANCE FEE, 8TH YEAR, LARGE ENTITY (ORIGINAL EVENT CODE: M1552); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY Year of fee payment: 8
2023-10-09	FEPP	Fee payment procedure	Free format text: MAINTENANCE FEE REMINDER MAILED (ORIGINAL EVENT CODE: REM.); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY
2024-03-25	LAPS	Lapse for failure to pay maintenance fees	Free format text: PATENT EXPIRED FOR FAILURE TO PAY MAINTENANCE FEES (ORIGINAL EVENT CODE: EXP.); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY
2024-03-25	STCH	Information on status: patent discontinuation	Free format text: PATENT EXPIRED DUE TO NONPAYMENT OF MAINTENANCE FEES UNDER 37 CFR 1.362
2024-04-16	FP	Lapsed due to failure to pay maintenance fee	Effective date: 20240221